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ABSTRACT 
Objective:  To assess quality of care provided to Medicaid beneficiaries using medication 
use-related quality indicators.  
Methods: This study is a retrospective analysis of 2006 & 2007 Medicaid administrative 
claims data from 45 states and DC. Eleven medication use-related measures 
(adherence/persistence and standard of care) from the AHRQ initial core set were included. A 
composite measure of medication use-related quality was also created. Patient case-mix adjusted 
measure scores were computed using hierarchical logistic regression models. States were ranked 
on both case-mix adjusted and unadjusted scores and categorized into top (~20%), medium 
(60%) and bottom (~20%) performers.  Agreement in rankings and groups based on adjusted and 
unadjusted scores were determined using Kendall’s b and Cohen’s κ. Cross-state variations in 
measure scores were described using coefficient of variation and choropleth maps. Multi-level 
models were used to assess the amount of variation in measures explained by the state level. 
Results:  National benchmarks on medication use-related measures for Medicaid for 2007 
ranged from 31.5% for the AD chronic measure to 66.8% for the ICS measure. There was 
substantial variation in the 13 measures being studied with coefficient of variation ranging from 
6.7 for the ICS measure to 20.5 for the MI1 measure. The best performing state Medicaid 
programs also had significant room for improvement across all measures. There was a lack of 
agreement in grouping based on crude and case-mix adjusted methods for majority of the 
 iii 
measures (κ=0.22–0.74), except for the ICS measure (κ=0.91). A very small proportion of 
variation in the study measures (1.5 – 5.7%) was explained by the state level random effect. 
Conclusions:  This study highlights the need for including medication use-related 
measures in the Medicaid adult quality measure set, considering the substantial variation in 
scores across states and the considerable room for improvement. States could create a composite 
measure of medication use-related quality using the approach used in this study if they find it 
burdensome to report on multiple measures. The study showcased the lack of agreement in crude 
and case-mix adjusted scores. Medicaid programs should consider the study findings before 
publicly reporting on crude scores.   
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CHAPTER I - INTRODUCTION 
Quality improvement is an issue of fundamental importance in healthcare in the United 
States. The last two decades has seen an increase in quality measurement efforts, benchmarking 
and quality reporting initiatives at the provider, facility and healthcare system levels.
1-5
 An 
important target of quality improvement efforts is the management of chronic conditions.
5-9
 
Numerous quality indicators used to assess provider quality are related to medication safety and 
effectiveness in the management of chronic conditions.
3,5,10,11
 These quality indicators can be 
applied to state Medicaid programs to assess the quality of chronic care provided to 
beneficiaries. The overarching goal of this study is to assess the quality of chronic care provided 
by Medicaid using medication-related chronic care quality indicators proposed by the Agency for 
Healthcare Research and Quality (AHRQ).  
On January 1, 2011 AHRQ published an initial set of quality indicators that can be used 
by state Medicaid programs to assess healthcare quality, as required by the Affordable Care Act.
5
 
This study used chronic care quality indicators related to medication use compiled by AHRQ to 
assess the quality of state Medicaid programs. Since, state Medicaid programs will soon adopt 
these measures for quality reporting, this study aims to assess the feasibility of using Medicaid 
data to measure quality of chronic care provided to beneficiaries. This study will also provide 
national estimates of chronic care quality, adjusting for patient case-mix, which will enable 
benchmarking performance of individual state Medicaid programs against national averages.  
 2 
 
State Medicaid programs vary widely in terms of their eligibility requirements and 
program generosity.
12,13
 These differences across states policies may result in variation in 
chronic care quality. This study will provide insights into the geographic variation in chronic 
care quality across the state Medicaid programs. Additionally, a substantial amount of variation 
in chronic care quality should be attributed to the state Medicaid level to justify quality 
improvement efforts at this level. Therefore, this study will assess the proportion of variability in 
chronic care quality explained at the patient and the state Medicaid levels using multi-level 
models.  
The specific objectives of this study are: 
1. To assess the feasibility of using state Medicaid data to provide national estimates of 
chronic care quality on medication use-related metrics 
2. To estimate and compare crude and case-mix adjusted scores of chronic care quality on 
medication use-related indicators for state Medicaid programs 
3. To describe the distribution of state Medicaid performance scores of chronic care quality 
on medication use-related measures 
4. To illustrate cross-state variation in performance scores of chronic care quality on 
medication use-related measures 
5. To assess the variation in chronic care quality that may be attributed to the patient and 
state Medicaid levels 
There are no firm hypotheses for this study. Rather, this study should be viewed as 
hypotheses generating. Nevertheless, on the basis of prior research, this study anticipated that (a) 
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Medicaid data can be used to assess chronic care quality indicators for a majority of states, (b) 
case-mix adjusted scores will be different from crude estimates of chronic care quality, (c) 
chronic care quality scores will vary across states, and (d) patients will explain the most variance 
in chronic care quality scores, followed by Medicaid programs.  
This study is a retrospective analysis of Medicaid administrative claims data from 45 
states with at least 100,000 enrollees in 2007, and the District of Columbia. Eleven measures 
from the AHRQ initial core set of measures were used to assess chronic care quality. All quality 
scores were aggregated to the state level to provide crude estimates of chronic care quality. 
Additionally, a composite measure of medication use-related quality was created at the state 
level. Performance scores were adjusted for patient case-mix and the distribution of states on 
adjusted scores was reported. Cross-state variations in chronic care performance scores were 
described. Finally, multi-level models were used to explain which level (patient and state 
Medicaid) contributes the most to variation in chronic care quality. 
This is the first study to apply AHRQ measures to study chronic care quality. This study 
proposed to compute indicators for all 45 states and provide national benchmarks for chronic 
care quality. The results will provide insights into the quality of chronic care provided by the 45 
state Medicaid programs. This study will allow individual state Medicaid programs to compare 
directly with other states in terms of quality of chronic care. It will also give an assessment of the 
variation in chronic care quality within individual states. Additionally, this study will inform 
researchers and state Medicaid program officials about the extent to which they can assess 
chronic care quality using Medicaid datasets.   
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CHAPTER II – LITERATURE REVIEW 
This chapter contains a brief overview of the importance of quality measurement and 
existing quality metrics, followed by a review of the AHRQ chronic care quality measures 
related to medication use and empirical evidence to judge their usability as reliable quality 
indicators. This section also outlines the need for case-mix adjustment and provides a rationale 
for the selection of a case-mix adjustment tool. Finally, this chapter provides a summary of the 
patient and state Medicaid factors that could potentially affect the quality of chronic care. 
Quality Measurement 
Quality improvement has received considerable attention in U.S. health policy initiatives. 
As healthcare costs continue to rise, efficiently managing healthcare service delivery becomes 
paramount for all stakeholders of healthcare, especially payers. This notion, coupled with the 
national focus on quality healthcare and empirical evidence indicating gaps in existing healthcare 
quality, provides an impetus for quality improvement. A crucial element of quality improvement 
is the availability of valid measures of quality of care. In the last decade, several researchers and 
organizations have developed valid indicators for measurement of quality.
5,10,11,14,15
 Quality 
measurement and reporting at the levels of the patient, physician, payer, hospital and facility 
have received considerable attention.
1,2,3,6
 Most quality indicators developed to be used at these 
levels are related to medication safety and effectiveness. These measures can be readily used to 
 5 
 
assess performance of Medicaid programs on medication use-related metrics. Health plans are 
currently using technical quality indicators related to medications such as use of inappropriate 
medications in the elderly and adherence with chronic care medications to monitor quality at the 
plan level.
14
 Centers for Medicare & Medicaid Services (CMS) reports the quality of medication 
use in their Part D plans. Yet, quality monitoring at the Medicaid level has received less 
attention.  
Need for Quality Measurement 
The U.S. healthcare system is consistently ranked first globally in terms of total 
healthcare spending.
 16
 However, the U.S. population has poorer health outcomes compared to 
many other developed nations.
16
 As healthcare costs continue to grow, efficiently managing 
healthcare delivery becomes paramount for all healthcare stakeholders. Efficient management of 
healthcare entails the provision of good quality healthcare, while reducing costs. Quality 
improvement has been shown to reduce healthcare costs in the long-term, which explains the 
surge in healthcare quality improvement efforts in the US.
17
 To improve quality, it is important 
to first define and measure quality.  Once quality is measured, the information can be used to 
improve quality in the following ways: (1) healthcare organizations can use this data to identify 
opportunities for improvement, (2) healthcare organizations can also use the data to monitor the 
success of their quality improvement initiatives, (3) regulatory and accrediting bodies can use 
this data to retain accreditation, (4) provider payment can be adjusted based on the quality of 
care delivered, and (5) quality reports can be made publicly available, so that consumers can 
make informed choices.
17
 Similar strategies can be applied to state Medicaid programs to 
stimulate quality improvement.  
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Traditionally, managed care plans and other payers relied on structure components for 
regulation purposes. An emphasis on process and outcomes measures has the potential to 
improve quality of chronic care greatly. Pay-for-performance and public reporting are two other 
ways to influence chronic care quality provided by payers.
18
 These three strategies were 
successfully implemented in the context of physicians, hospitals, and long-term care facilities, 
demonstrating improvements in the quality of medical care provision.
19-21
  
Definition and Measurement of Quality of Medical Care 
A standard definition of healthcare quality is “the degree to which health services for 
individuals and populations increase the likelihood of desired health outcomes and are consistent 
with current professional knowledge”.22 While quality has been defined in numerous other ways, 
the main purpose of defining and measuring quality is the identification of opportunities for 
quality improvement.
17
  
Donabedian’s framework of quality is often used for healthcare quality measurement.23 
According to Donabedian, quality of care can be measured using three components: (1) structure, 
(2) process, and (3) outcome measures. Structural elements of medical care are necessary but not 
sufficient to ensure quality care. For example, structural components of care in the pharmacy 
setting would include computer systems for tracking patient information, patient counseling 
areas, and professional licensure. Process measures refer to the services and products provided 
by the pharmacist to the patient and include activities such as identifying and resolving drug-
related problems, providing patient counseling and developing a caring relationship with the 
customer. Outcomes are perceived to be the ideal indicator of quality of medical care provided to 
patients. Donabedian defined outcomes as “a change in a patient’s current and future health 
status that can be attributed to antecedent healthcare.”23 Outcomes can be broadly classified as 
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economic, clinical and humanistic outcomes.
24
 Examples of outcome measures include cost of 
care, emergency room visits, mortality, and health-related quality of life among others.  
Existing Quality Measures 
In the last two decades, this stream of research has moved from justifying the need for 
quality measurement to the development of appropriate measures of quality. Quality is 
monitored using quality indicators or performance indicators. While there is a difference 
between the terms performance and quality, most researchers use quality and performance 
interchangeably. The main difference between the two is that quality indicators infer judgment 
about the care provided whereas performance indicators are devices for monitoring care provided 
without any inferences about quality.
25
 
Quality measurement using administrative databases 
Historically, numerous sources of data have been used to construct quality indicators. The 
most common data sources are medical records, administrative claims, and patient reports. Using 
medical record abstractions and patient reports to construct quality indicators is often labor 
intensive, slow and expensive to obtain. Administrative claims, though not originally intended 
for quality assessment purposes, provide an attractive option to measure quality.
26
 
Administrative claims databases contain information on the patient, provider and facility 
and can be aggregated to measure quality at any of these levels. Claims data are routinely 
collected and are easily accessible due to their electronic format, but often remain underused in 
measuring quality of care. A major concern with this source of data is the lack of clinical 
information, which is necessary for calculating several existing quality indicators. Quality 
organizations are trying to develop quality/performance indicators that could be used solely with 
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administrative claims databases to improve the efficiency of quality measurement.
27,28 
State 
Medicaid programs have convenient access to this data, and could readily use it for quality 
measurement purposes. 
Technical Quality Indicators 
Most existing technical quality measures are based on the processes, intermediate 
outcomes or final outcomes of care. Quality improvement efforts are intended to improve health 
outcomes. Therefore, outcomes should be the ideal measure of quality. However, the most 
commonly used technical quality measures are related to the process of care.
29,30
 The advantage 
of process measures is that they are strongly influenced by provider behaviors rather than patient 
characteristics. Process measures that have an established link to health outcomes are very useful 
measures of quality of care.
7
 Health outcome measures are not typically used in quality 
measurement for the following reasons: (1) important outcomes are sometimes rare, requiring 
large sample sizes to make statistically valid conclusions, (2) outcomes are affected mainly by 
patient factors and not providers, and (3) outcomes are observed after a long periods of time 
(e.g., ESRD in diabetic patients). Intermediate outcomes are observed immediately after clinical 
interventions, but they are often not available in administrative claims databases (e.g., blood 
pressure control, HbA1c levels). However, outcomes are preferred over process measures in 
cases where the outcome has a strong link to the process and occurs in a timely, efficient, and 
reliable manner.
7
 Since this study focuses on chronic care quality where outcomes are observed 
after long periods of time, and because only two years of data will be used, process measures 
will be used to assess quality of chronic care. 
Technical quality measures and performance measures are commonly expressed as ratios 
at the provider level. The denominator in the ratio is the number of patients eligible for the 
 9 
 
measure and numerator is the number of patients who achieved a specified goal. For instance, if 
we were to construct an indicator for adherence with oral hypoglycemic medications at the state 
Medicaid level, the numerator would be the number of Medicaid beneficiaries adherent to oral 
hypoglycemics and the denominator would be all patients with diabetes using oral hypoglycemic 
enrolled in the state Medicaid program. 
AHRQ Technical Quality Measures for Medicaid-Eligible Adults 
In December 2010, AHRQ compiled a list of initial core set of health quality measures 
applicable to Medicaid-eligible adults for public comment as a part of section 2701 of the 
Affordable Care Act.
5
 AHRQ created a subcommittee to enable compilation of new measures, 
and the following criteria were used to select measures: (1) the scientific acceptability of the 
measure, (2) feasibility of use by Medicaid and (3) importance to Medicaid programs.
5
 Broadly, 
these measures fall in the areas of prevention and health promotion, management of acute 
conditions, management of chronic conditions, family experiences of care, and access. Several of 
the measures proposed by AHRQ for the management of chronic conditions are related to 
medication use, and they overlap with the quality indicators endorsed by the Pharmacy Quality 
Alliance (PQA) to assess community pharmacy quality.
10,11
 AHRQ chronic care quality 
measures include three additional measures related to beta-blocker use post-myocardial 
infarction, statin use in coronary artery disease patients and persistence with antidepressant 
therapy. While the technical specifications have not been developed for these measures, this 
study will borrow the specifications provided by PQA and NCQA, where appropriate. 
The Affordable Care Act mandates the Secretary of Health and Human Services (HHS) 
to establish a Medicaid quality measurement program by January 2012.
5
 All state Medicaid 
programs will start reporting these measures in 2013, and this study will test the feasibility of 
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using Medicaid data to assess performance on these measures. This study will also provide 
baseline estimates of quality on management of chronic conditions, forming the foundation for 
assessing changes in quality scores in the future. 
However, there is no existing evidence on the usability of Medicaid data to assess chronic 
care quality using the AHRQ proposed chronic care quality measures. As previously stated, data 
from 45 individual state Medicaid programs and the District of Columbia will be used in this 
study. Medicaid managed care penetration is variable across states, and some programs like 
Mississippi and North Carolina Medicaid were exclusively fee-for-service until 2011. The 
exhaustiveness of the data submitted by Medicaid managed care plans has not yet been studied, 
and the quality and quantity of Medicaid data across states available to researchers is variable. 
Therefore, the usability of Medicaid data in assessing chronic care quality may vary across states 
depending on the population size and managed care penetration.  
Rationale for Measure Selection 
It is important to assess the appropriateness of selected indicators before using them to 
assess quality. An ideal indicator should be clearly defined, quantitative, reliable, and tightly 
linked.
7,17
 An indicator that is clearly defined provides definitions for all variables and explicates 
the inclusion and exclusion criterion for selection of cases for the denominator and the 
numerator.
7
 Appropriate technical specifications are available for the AHRQ proposed measures 
that overlap with the existing PQA measures. For the three additional measures, a detailed 
methodology, including definitions, inclusion and exclusion criteria will be provided in this 
study. If an indicator is tightly linked, meaning the link between the process and outcome is 
clearly established, then the indicator becomes clinically meaningful and actionable. Indicator 
selection for this study was based on the aforementioned criteria. Additionally, an evidence of 
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sufficient variability in the quality indicator across Medicaid programs and a room for 
improvement in performance are required for justifying the measurement of quality indicators.
27
 
For instance, if existing research suggests that over 95% of the patients with coronary artery 
disease are using statins, it is not very meaningful to focus quality improvement efforts in that 
area. Though applicable to all quality indicators, the aforementioned criteria are particularly 
important while assessing chronic disease care quality indicators.  
Therefore, areas reported to have substantial suboptimal quality should be the focus of 
future research. Numerous studies have indicated a strong link between the AHRQ chronic care 
process measures and health outcomes.
31-76
 Existing literature provides sufficient evidence that 
there is a considerable room for improvement in the quality of medical care provided in these 
areas. The following section evaluates the AHRQ chronic care quality indicators on these 
criteria. 
Persistence of beta-blocker treatment after a heart attack 
Studies since the 1980s have reported that use of beta-blockers post myocardial infarction 
(MI) can improve survival and reduce the risk of secondary MI.
31-33
 However, multiple studies 
have also demonstrated that beta-blockers are underused in post MI patients.
34,35
 While there has 
been an increase in the prescribing of beta-blockers post-MI at hospital discharge from 63% in 
1996 to 93% by 2002, the long-term outpatient use of beta-blockers is reported to be 
suboptimal.
36-38
 Sustained used of beta-blockers has been shown to improve survival after MI in 
several randomized trials and observational studies. In a study examining the use of beta-
blockers for one year after acute MI, only 45% of patients were found to be adherent to beta-
blockers and the biggest drop in the percentage of patients adherent to beta-blockers was 
between 30 and 90 days.
36
 Ackincigil et al.
39
 found that only 50% of patients continued using 
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beta-blockers post MI. A recent study reported that adherence rates for beta-blockers have 
significantly improved over time but remain unsatisfactory.
40
  
Statin use in people with coronary artery disease 
The benefits of lipid lowering therapy using statins in patients with coronary artery 
disease are well documented.
41-44
 Significant reductions in cardiovascular morbidity and 
mortality have been demonstrated in patients with and without coronary artery disease (CAD) 
using statins across large randomized clinical trials. For example, the West of Scotland Coronary 
Prevention Study reported a 31% risk reduction of non-fatal MI or death in patients with 
coronary artery disease.
41
 The Scandinavian Simvastatin Survival Study (4S) demonstrated a 
34% risk reduction in coronary events in statin-using patients with CAD.
42
 Several other large 
cardiovascular outcome studies have shown significant reductions in death due to CAD with 
statin use.
43,44
 Despite the compelling evidence of the benefits and clinical guidelines 
recommending statin therapy, there are wide gaps in statin use among patients with CAD.
45
 In a 
survey conducted in nine European countries, only 32% of patients with coronary artery disease 
were found to be using a lipid-lowering drug.
46
 Whincup et al.
47
 reported that the prevalence of 
lipid lowering drug use was 29% among patients with a documented CAD. In a large study 
exploring treatment rates among 48,586 patients with CAD from 140 medical practices, only 
39% received a lipid-lowering medication.
48
 All these studies signify a considerable room for 
improvement. 
Use of appropriate medication in people with asthma 
The National Asthma Education and Prevention Program’s Expert Panel Report 3 (EPR 
3) on the diagnosis and management of asthma recommends the use of inhaled corticosteroids 
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(ICS) for the treatment of persistent asthma.
49
 If asthma is not controlled by the use of ICS alone, 
long-acting β2-adrenergic agonist (LABA) is added, but LABA should not be prescribed alone. 
Use of ICS is related to a decrease in asthma-related morbidity and mortality.
50
 Still, patients are 
reported to be overusing reliever medications and under using preventer medications.
51
 Kandane-
Rathnayake et al.
52
 explored guideline adherence for middle-aged adults with persistent asthma 
and found that only 29% of patients were prescribed ICS. 
Persistence with antidepressant medications 
Persistence with antidepressant therapy is crucial for consolidating treatment response 
and for reducing the risk of relapse. Clinical practice guidelines recommend that antidepressant 
medications should be used for at least four - nine months post remission of acute symptoms.
53-56
 
Suboptimal duration of antidepressant medication use is reported to increase the risk of 
relapse.
57,58
 However, growing evidence indicates that majority of patients discontinue 
antidepressant medications during the first few weeks of treatment. For example, between 29 - 
42% of patients prematurely discontinue medications after four weeks, and the discontinuation 
rate is between 63-76% after six months.
59-63
 A high rate of discontinuation was also reported in 
Medicaid patients, with 70% patients discontinuing therapy in the first six months. Patients who 
discontinued antidepressant therapy had a 77% higher risk of relapse than patients who 
continued to use their medications in this study.
64
  
Adherence with oral hypoglycemic, antihypertensive and antihyperlipidemic medications 
Medication adherence is a major concern across all therapeutic categories with estimates 
of nonadherence ranging between 30 – 60%.65 This finding was corroborated by another study 
reporting that the medication nonadherence averages 50% among chronic disease patients.
66
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Average adherence with prescribed therapy for type 2 diabetes patients was reported to be 
67.5%.
65
 A meta-analysis of studies exploring adherence to oral hypoglycemic medications 
reported that adherence ranges between 36-93%.
67
 Similar trends of non-adherence were 
reported with lipid lowering therapy.
68
 In another study, only 50% of patients were reported to be 
adherent to antihyperlipidemics six months after treatment initiation and the adherence rate 
dropped to 30-40% within one year.
69
 In case of antihypertensive medications, the adherence rate 
is also suboptimal, ranging between 50-70%.
70
  
Adherence to oral hypoglycemic medications has been linked to glycemic control and 
type 2 diabetes outcomes across several studies.
68,71
 Schectman et al.
71
 reported that for every 
10% increase in drug adherence, HbA1c significantly decreased by 0.16%. Adherence to 
antihypertensive and antihyperlipidemic medications is linked to reduction in risk of coronary 
heart disease, stroke and death across numerous clinical trials and meta-analyses.
72-76
 
Overall, there is sufficient variation in quality across patients for all the AHRQ measures 
included in this study. However, few studies explored if these variations in quality at the patient 
level translate to practice variations at the provider level or the payer level, or if it is mainly due 
to the patient case-mix. Also, there is a tight link between the AHRQ process measures and 
health outcomes, making these measures good indicators of quality. 
Case-Mix Adjustment 
It is important to report case-mix adjusted performance scores because Medicaid 
programs with a greater proportion of younger, sicker individuals, females or people from racial 
minorities are expected to perform poorly on these measures.
77-80
 Risk adjustment methods will 
help explain variation in chronic care quality related to patient factors, so that the remaining 
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differences in quality measures can be attributed to other factors, such as the physician, 
pharmacist or the payer. Patient selection bias is another factor to adjust for when providing 
performance scores. Greenfield et al.
78
 demonstrated that comparison of provider groups may be 
inaccurate if adjustment for patient case-mix and provider level clustering is not taken into 
account. Failure to control for payer level clustering by using techniques like multi-level 
regression analysis will cause standard errors of regression coefficients to be underestimated.
77
 
Case-mix adjustment has been used to adjust performance of providers, facilities, or 
healthcare systems for making comparisons on the dimensions of access, efficiency and quality 
of care.
81
 Several studies have found that adjusting for patient demographics, disease severity 
and comorbidity burden changes provider’s performance profile.78-80,81-83 Hofer et al.6 
demonstrated that physicians can improve their performance profile by preferential patient 
selection. A recent study found that adjusting for patient characteristics and treatment 
opportunities improved hospital rankings on indicators assessing adherence to treatment 
guidelines for acute MI.
80
 Importance of case-mix adjustment was also demonstrated in 
evaluating health plan performance on chronic care provided to Medicaid enrollees.
82
 Similarly, 
application of risk-adjustment methodologies to adjust for differences in patient’s case-mix will 
be important in assessing the quality provided by state Medicaid programs. 
A plethora of measures are available to adjust for patient case-mix in the outpatient care 
setting. Broadly, these measures can be classified into three components: (1) health status, (2) 
patient health behaviors and psychosocial factors and (3) contextual factors.
79
 Sociodemographic 
factors (e.g., age, gender, insurance type) and contextual factors (e.g., number of specialists 
available in a given area, median income in the county) are commonly used dimensions of risk in 
studies using administrative claims databases, because this information is readily available.
83
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Ideally, a comprehensive understanding of population’s health status using clinical assessment 
and a complete sociodemographic profile would provide an accurate assessment of risk. 
However, such methods are often cost prohibitive, and several alternative tools for risk 
assessment that use administrative claims are available to researchers.  
Diagnosis-based or pharmacy-based measures are widely accepted to classify patients 
into different risk categories.
84-87
 Adjusted clinical groups (ACG) and diagnostic cost 
groups/hierarchical condition categories (HCC) are the commonly used diagnosis-based 
measures.
86
 ACG classifies patients into 32 clinical groups called Ambulatory Diagnostic Codes 
(ADGs) based on disease duration and severity. Each person is further classified into mutually 
exclusive categories based on age, gender and total number of ADGs. DCG model assigns 
patients to Condition Categories (CCs), based on disease type grouped by cost and clinical 
relation.
81,88
 This model also includes several disease interaction terms and child-specific 
conditions are weighted. However, the completeness and reliability of ICD-9 codes could vary 
across providers, facilities and healthcare systems. Other measures like Charlson’s comorbidity 
index (CCI), and Elixhauser’s comorbidity index (EI) are more commonly used to adjust for 
comorbidity burden.
68,86
 The applicability of diagnosis-based risk-adjusters like ACG and HHC 
is mostly seen while modeling healthcare utilization and costs.
86
  
Alternate approaches to case-mix adjustment use pharmacy claims data. The most 
extensively used pharmacy-based case-mix adjustment measure is RxRisk.
87
 It is also used as a 
disease severity measure.
81
 Patients are classified into 42 non-mutually exclusive disease 
conditions based on the medications used to treat chronic conditions.
86
 Other measures like 
chronic disease score, pharmacy cost groups, and pediatric chronic disease score have been used 
to adjust for case-mix and disease severity.
89-91
 In its earlier applications, the RxRisk model was 
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predominantly used as a risk-adjustment tool when modeling cost and utilization data.
86
 More 
recently, the RxRisk measure was found to be a better predictor of adherence to diabetes 
medications compared to CCI, EI, and Health Related Quality of Life comorbidity index.
92,93
 
Chronic disease score and CCI index were mostly used in predicting medication use across 
several studies.
68,94
  
The RxRisk instrument coupled with demographics (age, sex, race) will be used to adjust 
for patient case-mix in this study. Pharmacy-based models are useful especially for populations 
with drug benefits like Medicaid. One main advantage of using pharmacy claims based risk 
adjuster is that stable chronic diseases are better captured using drug records than by using ICD-
9 codes. Patients with a stable chronic condition may not visit a physician because most health 
plans do not require a physician visit to fill or refill a prescription. The choice of pharmacy-based 
risk adjustment is also driven by the fact that this study will predominantly use pharmacy claims 
data (except for two measures) so that payers can use this tool to create quality scores related to 
medication use for most of the measures being studied, using limited data. 
Chronic Care Quality 
An estimated 144 million people in the United States had one or more chronic conditions 
in 2010. Approximately 20% of these individuals have multiple chronic conditions.
95
 The 
prevalence of chronic conditions is projected to increase in the near future. Cost of managing 
these conditions is estimated to be $1.8 trillion annually, which forms 75% of all healthcare 
spending.
96
 As the cost of chronic conditions continues to rise, it is important to ensure that the 
quality of care can be improved and expenditures controlled. Most chronic diseases such as 
diabetes, cardiovascular disease, asthma, and depression can be effectively managed using 
lifestyle changes and medications, thereby improving health outcomes and reducing overall 
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expenditures.
68,97
 For example, appropriate management of diabetes using oral hypoglycemic 
agents was shown to improve health outcomes and decreases expenditures.
68
 On the other hand, 
a lack of adherence to asthma medications has been implicated in costly procedures and 
hospitalizations.
97
  
Payers play an important role in the management of chronic conditions by providing 
better access to pharmaceutical care, disease management, and medication therapy management. 
Therefore, it is appropriate to measure quality of chronic care at the payer level. If there is an 
evidence of variation in chronic care quality provided by the various state Medicaid programs, it 
reflects a scope for quality improvement. There is also a paucity of studies examining variation 
in chronic care quality across state Medicaid programs. Evaluating variation across state 
Medicaid programs can provide insights into healthcare quality issues relative to resource 
allocation and access to care.  
Variation in quality of care as measured by medication adherence or persistence and use 
of inappropriate medications provided to patients with chronic conditions across provider, 
facility and health system level have been reported.
9,98,99
 For instance, multilevel modeling 
studies assessing variation in diabetes care contributed by the patient, provider and facility have 
found that a large proportion of variation was explained by patients, with less but substantial 
variation explained by clinician and facility.
100,101
 Most studies using multi-level data only report 
the amount of variation in quality that is attributable to each of the levels of analysis, typically 
the patient, provider and facility.
102
 A wide range of studies also assessed patient characteristics 
associated with quality of care, including chronic care.
68,97
 However, characteristics of the payer 
associated with suboptimal quality are rarely reported. 
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Factors affecting quality of care  
There is a paucity of studies investigating the provider, facility and payer/program 
characteristics as determinants of variation in quality of care, in general. Fewer studies explored 
factors associated with chronic care quality using measures related to medication use. Factors 
like physician age and specialty at the physician level, and number of providers at the state level 
were some of the factors assessed in previous studies.
98-101
 The conceptual framework for 
understanding the factors explaining chronic care quality is provided in Figure A-1 
(APPENDIX). The choice of patient and state characteristics presented in the model are based on 
prior research in this area and data availability.  
Patient Characteristics 
The Aday-Andersen model for healthcare utilization is widely used to understand patient 
characteristics explaining a particular medication behavior, like medication adherence.
103
 This 
model categorizes the determinants of healthcare utilization behavior into three components: 
predisposing, enabling, and need-related factors (APPENDIX - Figure A-2). Predisposing factors 
such as age, gender or race are indicative of a person’s propensity to utilize healthcare. Enabling 
factors are related to the person’s ability to gain access to services, such as income, insurance, 
and other access variables. Need-related factors are defined as the disease severity or 
comorbidity burden. Since, this study population is only comprised of Medicaid beneficiaries, 
people enrolled in a state Medicaid program may not have meaningful differences in enabling 
factors like access and income. Few access variables (e.g., proximity to the pharmacy/physician, 
rural or urban residence) may still be useful in understanding medication use in the Medicaid 
population. However, only predisposing (age, sex, and race) and the need-related (RxRisk score) 
patient characteristics will be included in this study to adjust for patient case-mix. 
 20 
 
State Medicaid Characteristics 
State Medicaid policies affect beneficiary’s access to and use of healthcare services, so 
there are likely to be differences in chronic care quality across states. In a study examining if 
adult healthcare access and use varied across state Medicaid programs, case load per state, 
physician reimbursement, co-payments, and limits on number of physician visits or hospital days 
were some of the factors found to affect use.
13
 Tang et al.
104
 also used 50 state Medicaid data to 
assess state level factors (such as, state managed care penetration, primary care and mental health 
providers and Medicaid reimbursement rate) related to unmet mental healthcare need for 
Medicaid children and reported that none of the state-level variables were significant in 
predicting unmet need. Additionally, physician supply is a factor to consider when assessing 
quality of care provided to Medicaid patients because fewer physicians accept Medicaid patients 
relative to Medicare and privately insured patients, mainly because of low reimbursement rates.
12
 
Since chronic care quality often depends on access to care, primary care physician 
supply, specialist supply, pharmacy benefits, presence of medication therapy management 
programs, and managed care penetration are some of the factors that may affect quality measures 
being used in the study.  
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CHAPTER III – RESEARCH METHODOLOGY 
Data Source 
Medicaid is a federal aided, state-operated program providing healthcare coverage for 
certain indigent or low-income individuals and families. Under broad federal guidelines, states 
devise their own programs by establishing eligibility standards, determining the scope of services 
provided, setting payment rates and administering their own programs.
105
 Therefore, each state’s 
Medicaid program is unique. Medicaid data is made available for research purposes through the 
Research Data Assistance Center (ResDAC).
106
 States submit provider claims and payments 
electronically to the Centers for Medicaid & Medicare Services (CMS) through Medicaid 
Management Information Systems (MSIS). ResDAC is a CMS contractor that provides de-
identified data in the form of Medicaid Analytic Extract (MAX) files which are extracted from 
the MSIS system. The MAX files contain beneficiary level enrollment, utilization and 
expenditure data. Medicaid MAX data files from 45 states (except Alaska, Montana, North 
Dakota, South Dakota, and Wyoming) with over 100,000 enrollees and the District of Columbia 
for the years 2006 and 2007 were requested from ResDAC for the purpose of this project. 
Medicaid eligibility, pharmacy claims, medical claims and inpatient claims files were used in 
this study. The components of each of the files are enlisted below:  
1. Person summary file: Person-level file with demographic information and eligibility 
periods for the beneficiaries.  
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2. Pharmacy claims file: Event level file with information on prescription dispensed, 
amount paid, quantity dispensed, prescription date, and prescribing physician.  
3. Other services file: Event level file with information on the outpatient facility visits 
(outpatient hospital, physician office, ER), diagnoses, amount paid, and provider type.  
4. Inpatient services file: Event level file with information on the admission and discharge 
dates, diagnoses, and amount paid.  
Study Design  
This study was a retrospective analysis of administrative claims data from Medicaid 
programs for 45 states and the District of Columbia for the years 2006 and 2007. Eleven 
measures from the AHRQ initial core set related to management of chronic conditions using 
medications were studied, including – (1) persistence with beta-blocker medications post-MI 
(MI), (2) statin use in people with CAD (CAD), (3) use of ICS or similar medications in 
individuals with persistent asthma (ICS), (4) persistence with antidepressant medications, acute 
and chronic (AD), (5) adherence to ACEI/ARBs (ACEI), (6) adherence to beta-blockers (BB), 
(7) adherence to calcium-channel blockers (CCB), (8) adherence to statins (STAT), (9) 
adherence to biguanides (BIGU), (10) adherence to sulfonylureas (SU), and (11) adherence to 
thiazolidinediones (TZD). An additional measure not included in the AHRQ core set, assessing 
beta-blocker use in people with MI (MI1) was also computed. Medicaid data for the year 2006 
were used for computing the MI and AD measure scores. Detailed definitions of the 11 selected 
measures are provided in Table A-1 (APPENDIX). Medicaid beneficiaries for whom at least one 
of the measures can be assessed were identified using a combination of drug claims data and 
diagnosis codes using the patient selection criteria (see Eligibility Criteria).  
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Eligibility Criteria 
Medicaid beneficiaries between 18-65 years of age by the end of 2007 and with 
continuous enrollment in the particular state Medicaid program during the measurement period 
were included if they met the indicator specific eligibility criteria. To be considered continuously 
enrolled, a Medicaid beneficiary should not have a gap of more than one month during each 
study year. Additionally, dual-eligible patients that are enrolled simultaneously in Medicaid and 
Medicare were excluded from this study. A combination of National Drug Codes (NDCs) and 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9- CM) codes 
were used to identify beneficiaries eligible for each measure. NDCs for the list of medications in 
Table A-2 were compiled from Multum drug database and matched to drug claims in the 
pharmacy claims file to flag medication use. Similarly, ICD-9-CM codes were matched to 
diagnosis claims in the inpatient and medical claims files to identify cases for MI and CAD 
measures. Additional criteria for patients to be eligible for each measure are listed below: 
 MI – A primary or non-primary diagnosis code for myocardial infarction (ICD-9 code: 
410;412) in the inpatient claims file between April 1, 2006 and March 31, 2007. Since, 
beta-blockers have multiple indications, persistence with beta-blockers were observed 
post identification of patients with MI. Patients filling a prescription for a beta-blocker 
within one month after discharge from the hospital were included in the denominator.  
 CAD – A primary or non-primary diagnosis code for coronary artery disease (ICD-9 
codes: 410.X0, 410.X1, 410.X2 where X=0-9; 412;413;413.10;413.90;414;414.0X where 
X=1-7;414.80;414.9;v45.81;v454.82 ) in 2007.  
  ICS – At least two prescriptions for asthma medications (Asthma – A, included in Table 
A-2 (APPENDIX)) within four months of one another. Patients who filled at least one 
 24 
 
prescription for a COPD medication, pulmozyme or a nasal steroid medication (Asthma – 
B, included in Table A-2) were excluded from this measure. 
 AD – At least two prescriptions for an antidepressant medication (included in Table A-2) 
filled on two unique service dates, with the first prescription filled between May 1, 2006 
and April 30, 2007 and no prior use of antidepressants for at least three months. 
 ACEI – At least two prescriptions for ACEI/ARB or ACEI/ARB combination 
medications (included in Table A-2) filled on two unique dates of service at any time in 
2007. 
 BB – At least two prescriptions for beta-blocker or beta-blocker combination medications 
(included in Table A-2) filled on two unique dates of service at any time in 2007. 
 CCB – At least two prescriptions for calcium channel blocker or calcium channel blocker 
combination medications (included in Table A-2) filled on two unique dates of service at 
any time in 2007. 
 STAT – At least two prescriptions for statin or statin combination medications (included 
in Table A-2) filled on two unique dates of service at any time in 2007. 
 BIGU – At least two prescriptions for biguanide or biguanide combination medications 
(included in Table A-2) filled on two unique dates of service at any time in 2007. 
 SU – At least two prescriptions for sulfonylurea or sulfonylurea combination medications 
(included in Table A-2) filled on two unique dates of service at any time in 2007. 
 TZD – At least two prescriptions for thiazolidinedione or thiazolidinedione combination 
medications (included in Table A-2) filled on two unique dates of service at any time in 
2007. 
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Medications dispensed in key therapeutic classes were used instead of diagnosis claims 
for identifying eligible patients for all except two measures, MI and CAD. There are two reasons 
for this approach: (1) a person with a stable chronic disease is better captured from their drug 
records than using ICD-9 codes with only one year of data. Patients with a stable chronic 
condition may not visit a physician because most health plans do not require a physician visit to 
fill or refill a prescription. (2) We used pharmacy claims only for those measures wherein 
confirming the diagnosis is not germane to questions about the validity of the measures.
27
 The 
majority of these measures were related to persistence/adherence with medications and did not 
require a diagnosis, except MI and CAD. For instance, MI measures the persistence of beta-
blockers post myocardial infarction, but beta-blockers are used for managing multiple 
cardiovascular conditions. Patient post an acute MI might be more persistent with their beta-
blocker therapy compared to those with mild hypertension. Therefore, we could be 
overestimating or underestimating the performance measure without the inclusion of a MI 
diagnosis. Also, if it can be shown that a majority of these indicators can be constructed using 
pharmacy claims alone, Medicaid can request community pharmacies to report on these 
measures.  
Patients with non-acute stays anytime during the measurement year were excluded from 
the analysis. Patients with at least one claim in the long term care services file were excluded. 
Non-acute stays were identified from the other services file using UB revenue codes related to 
hospice, skilled nursing facility, rehabilitation, respite, residential substance abuse treatment 
facility and psychiatric residential treatment center.  
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A list of UB revenue codes is provided in Table A-3 (APPENDIX). Patient in non-acute 
care facilities listed above are a select population that is sicker and may demonstrate different 
medication use behavior as they are under constant supervision. 
Study Variables 
Measures 
The numerator and denominators for the 11 selected measured are provided in Table A-1 
(APPENDIX). Medication adherence (ACEI, BB, CCB, LLD, BU, SU, TZD) were measured as 
proportion of days covered (PDC). PDC is one of the most common methods of adherence 
measurement with increasing use in literature.
107
 PDC is calculated as the total number of days 
with medications on hand divided by the specified time interval. The denominator for the PDC 
measure is the patient’s measurement period, defined as the index prescription date to the end of 
the calendar year. PDC is multiplied by 100 to yield a percentage and ranges between 0 and 
100%. Typically, a PDC measure is adjusted for hospitalizations by subtracting the number of 
days spent in a hospital from the numerator and the denominator. However, since use of non-
pharmacy data is limited in this study, hospitalization stay adjusted PDC was not computed.  
PDC were measured for all seven therapeutic classes for each eligible patient. Switching 
between medications within the same therapeutic class during the measurement period were 
treated as continuous use of that class of medication, to reduce the complexity of adherence 
measurement. Concomitant use of medications from different therapeutics classes and switching 
across therapeutics classes is common in individuals using oral hypoglycemic and 
antihypertensive medications. Therefore, PDC measure scores for oral hypoglycemic and 
antihypertensive medication classes were reported. PDC less than 80% was considered 
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nonadherent, a common threshold used in adherence research for the therapeutic classes in 
question.
108
 Implicit to this approach is an assumption that patients who initiate a particular class 
of medication will maintain the therapy throughout the measurement period. A limitation to this 
approach is that it is difficult with claims data to determine whether or not a patient was advised 
by their physician to discontinue or switch therapy. 
Persistence represents the time over which a prescription is filled by the patient. For 
persistence measures (MI and AD), treatment was considered continuous if the total gap without 
medications was less than 51 days over a period 6 months. Persistence with medications was 
measured as a dichotomous variable, with a total gap in medication therapy of 51 or more days 
(AD) during the 6 month measurement period considered non-persistent. A limitation of using 
claims data to capture persistence is that it is not possible to determine if the medication was 
discontinued as per physician recommendation. An additional measure related to effectiveness of 
antidepressant therapy during an acute phase was computed. For the AD acute measure, total gap 
in medication therapy of 30 or more days (AD) during a 12 week measurement period was 
considered non-persistent. 
For the ICS measure, patients were included in the numerator if they have at least one 
prescription for inhaled corticosteroids, nedocromil, cromolyn sodium, leukotriene modifiers or 
methylxanthines during the measurement year. Patients were included in the numerator for the 
CAD measure if they had at least one prescription for a statin during the measurement year. 
Additionally, a summary composite measure of chronic care, defined as the total number of 
measures for which the individual received good care (i.e., adherent, persistent or used the 
recommended therapy) divided by the total number of measures the subject is eligible for were 
calculated for all Medicaid adults meeting the eligibility criteria. 
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State Medicaid performance on each measure were calculated as the number of patients 
who received good quality care (i.e., adherent, persistent, received or used the recommended 
therapy) divided by the number of patients eligible for the measure. A state-level measure was 
also created for oral hypoglycemic and antihypertensive medications. Additionally, the 
composite score developed at the patient level as a summary measure of chronic care was 
aggregated to the state Medicaid level. 
Patient Characteristics 
Information on patient demographic variables was obtained from the personal summary 
file.  
Age: Age was calculated as the difference between the beneficiary’s date of birth field 
‘DOB07’ and the end of the measurement year ‘31st December 2007’.  It was treated as a 
continuous variable. 
Gender: Male or female. The field ‘SEX07’ was utilized to identify patient’s gender. 
Race/ethnicity: Four major racial and ethnic groups were considered: Non-Hispanic 
Whites, African Americans, Hispanics, and Other races. Based on the racial distribution of the 
population across the eligible states, we collapsed groups with a small representation into “other 
races”. The field ‘RACE107’ was used to identify race/ethnicity. 
RxRisk: RxRisk was used as the comorbidity burden measure. RxRisk, which is an 
extension of the chronic disease score, uses pharmacy claims to quantify patient’s comorbidity 
burden. RxRisk system includes 42 chronic disease categories related to adults. A list of the 
chronic disease categories related to adults and all the medication classes that belong to each 
category is provided in Table A-4 (APPENDIX).  
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To construct the RxRisk score, indicators were created for the different chronic disease 
categories. Each individual is flagged as having a chronic condition by matching the NDC codes 
(for medications related to the chronic disease categories) to their prescription records anytime 
during the measurement period. These indicators were summed to create the unweighted RxRisk 
score for the individual. Additionally, a weighted RxRisk score was created using empirical 
weights based on the predictive validity of the chronic conditions for mortality obtained from 
Johnson et al.
109
  
Data Management 
MAX data files are fully de-identified with encrypted beneficiary identification numbers. 
MAX data files were made available to the researcher in SAS format. Beneficiaries without a 
single claim in the study period and beneficiaries with missing prescription service date or 
product service date in pharmacy claims were excluded. The data were checked for duplicate 
claims and only the first record was retained in the case of duplication. Data management was 
conducted using SAS software version 9.2.
110
 Research and analytical procedures were approved 
by the University of Mississippi Institutional Review Board. 
 
Statistical Analysis 
Objective 1: To assess the feasibility of using state Medicaid data to provide national estimates 
of chronic care quality on medication use-related metrics. 
Each state is required to have a sample size of 30 or more patients in the denominator to 
be considered for a measure.
27
 Performance rates on each measure were computed only for those 
states meeting this criterion. Additionally, at least 10 states should meet the minimum sample 
size criterion for reporting the performance rate on each measure at the national level. 
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Objective 2: To estimate crude and case-mix adjusted scores of chronic care quality on 
medication use-related indicators for state Medicaid programs. 
For the 11 measures, the crude performance score at the state level was calculated as the 
number of patients in the numerator divided by the number of patients in the denominator for the 
particular measure. Additionally, a summary composite measure of chronic care (expressed as a 
proportion), defined as the total number of care opportunities in which a beneficiary received 
good care (i.e., adherent, persistent or used the recommended therapy) divided by the total 
number of care opportunities in the state. This measure provides a summary of the proportion of 
care opportunities fulfilled in each state. 
The study uses statistical risk-adjustment, also known as case-mix adjustment, to control 
effects of confounding variables seen in patients. A hierarchical multivariable logistic regression 
analysis was performed to adjust performance scores (on the composite measure and the 11 
AHRQ process measures) for patient case-mix, similar to the method proposed by Mehta et al.
80
 
Multilevel models are appropriate for this data, considering the hierarchical structuring of the 
data, where patients are clustered within states. Performance on each measure was adjusted for 
patient case-mix by including patient characteristics in the model. These characteristics include 
age, sex, race/ethnicity, and RxRisk score. The hierarchical approach treats states as random 
effects and allows adjustment for within-state correlation in the process measures. 
Adjusted scores reflect the predicted mean scores for each state if they all had the same 
case-mix. For computing adjusted scores for the composite measure, opportunity-based data was 
used, meaning each measure for which patient is eligible will contribute an observation to the 
dataset. For instance, if a patient is eligible for the CAD, BB, MI measures and is eligible for the 
numerator (referred to as adherent hereafter) for BB and MI, the patient then has three 
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observations in the dataset, with two positive events. First, state-specific estimates of observed 
adherence rates were calculated as the mean of the predicted probability of adherence from the 
hierarchical model across all patients attributed to the state. Second, the expected adherence 
score in a given state was calculated as the mean of the predicted probabilities of adherence from 
the model with patient characteristics, without incorporating state as a random effect. To 
compute the adjusted performance score on the measure, state-specific observed adherence rate 
was multiplied by the overall observed adherence rate and divided by the state’s estimated 
expected adherence rate.
80
 Adjusted scores were computed similarly for the 11 measures, except 
each patient had one observation in the dataset. 
To assess the difference between the adjusted and unadjusted scores, states were grouped 
into three categories: (1) low quality (if unadjusted score is less than the average unadjusted 
score and 95% CI of the unadjusted score does not contain the average unadjusted score; if case-
mix adjusted score is less than 1 and the 95% CI of the case-mix adjusted score does not contain 
1), (2) medium quality (if the 95% CI of the unadjusted score contains the average unadjusted 
score; if the 95% CI of the case-mix adjusted score contains 1), and (3) high quality (if 
unadjusted score is higher than the average unadjusted score and 95% CI of the unadjusted score 
does not contain the average unadjusted score; if case-mix adjusted score is higher than 1 and the 
95% CI of the case-mix adjusted score does not contain 1). The agreement in classification based 
on unadjusted and adjusted performance scores was evaluated using Cohen’s Kappa     
coefficient.  
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Additionally, the agreement in classification across the various measures was also 
evaluated using Cohen’s Kappa     coefficient by classifying states into low (bottom 20%), 
medium (middle 60%), and high (top 20%) performing states on the 11 measures. If the 
percentage of states whose classification would be changed by case-mix adjustment is 
substantial, then adjusted scores were used to describe the distribution of states for Objective 3. 
Objective 3: To describe the distribution of Medicaid performance scores of chronic care quality 
on medication use-related measures. 
Univariate statistics and coefficient of variation were used to describe the distribution of 
the performance scores across states. Median, mean, 10
th
 and 90
th
 percentiles were reported for 
each measure individually and for the composite measure. The median score is representative of 
the room for improvement in performance scores and the 10
th
 and 90
th
 percentiles identify the 
spread of scores across the states. The 90
th
 percentile represents the top performing Medicaid 
programs in the nation. The coefficient of variation is a frequently computed statistic in studies 
of practice variation and is calculated as the standard deviation divided by the mean and 
multiplied by 100, so that the result can be expressed as a percentage. Coefficient of variation 
provides an indication of the spread of data and is sensitive to outliers. Additionally, to 
determine if performance on one indicator influenced the performance on another indicator, 
states were ranked independently on all 11 measures and, Kendall’s τ rank order correlations was 
estimated among indicators using state as the unit of analysis.  
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Objective 4: To illustrate cross-state variation in performance scores of chronic care quality on 
medication use-related measures.  
Variation across states was described by generating state-level US maps to depict cross-
state variations in performance scores on the 11 measures and the composite measure.  
Objective 5: To assess the variation in chronic care quality that may be attributed to the patient 
and state Medicaid levels. 
For the 11 measures, hierarchical logistic regression models were used to assess the 
variation in chronic care quality attributable to each level. The composite measure was fitted 
using a three-level hierarchical logistic regression models. Hierarchical models were used to 
account for the clustering of patients within states. Using ordinary least squares with nested data 
can yield biased parameter estimates and inefficient standard errors. Multilevel models, on the 
other hand, allow errors to be dependent within contexts.
43
  
An intercept-only model, without any covariates, was constructed for each measure and 
Medicaid identifiers were entered for each patient as a random effect. ICC was estimated for the 
state level based on the formula given by Snijders and Bosker (1999)
112
. The coefficients reflect 
the proportion of the total variance in the dependent variable that is attributable to the state 
level.
43
 In addition, residual ICC was computed from the models with patient level variables 
included in the model and state variable entered as a random effect. The multilevel analysis was 
performed using the PROC GLIMMIX procedure in SAS version 9.3.
110
 
The standard cut-off point of a p-value of 0.05 was used in all analyses. 
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CHAPTER IV - RESULTS 
 
Feasibility of using Medicaid data to provide national benchmarks of medication use-
related quality measures  
Medicaid data was obtained for 45 states and the District of Columbia for the years 2006 
and 2007. States with less than 100,000 Medicaid beneficiaries including Alaska, Montana, 
North Dakota, South Dakota and Wyoming were excluded from this study. All states met the 
eligibility criteria of having at least 30 eligible patients in the denominator for all measures 
except MI1 and MI. Seven and thirteen states had less than 30 beneficiaries eligible for the MI1 
and MI measures respectively. Also, most measures could not be generated for Michigan and 
Ohio due to incompleteness of the day supply field. In addition, AD, CAD and MI measures 
could not be computed for Maine because of missing inpatient hospital and other services claims. 
Inpatient and other services claims are not required for computing PDC and ICS measures, but 
are used in identifying patients with non-acute stays.  
Overall, MI measure could be generated for 30 states, MI1 measure for 36 states, AD 
measures could be computed for 43 states, PDC for 44 states, CAD for 45 states and the ICS 
measure could be calculated for 46 states. All measures could be estimated for at least 10 states, 
thereby meeting the minimum sample size criterion for reporting the performance rate on each 
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measure at the national level. A summary of the usability of data obtained from ResDAC in 
computing medication use-related quality measures is presented in Table 1. 
Table 1: Data Quality Summary 
State\Measure 
Measure Eligibility 
Reason 
PDC AD CAD ICS MI 
# eligible states 44 43 45 46 30  
Alabama       
Alaska - - - - - Data not requested 
Arizona        
Arkansas       
California       
Colorado       
Connecticut       
Delaware       
District of Columbia       
Florida       
Georgia       
Hawaii       
Idaho       
Illinois        
Indiana       
Iowa       
Kansas       
Kentucky       
Louisiana       
Maine      
40.7% missing claims (IP and OT 
files unavailable) 
Maryland       
Massachusetts       
Michigan      
36% claims with missing day 
supply field  
Minnesota       
Mississippi        
Missouri       
Montana - - - - - Data not requested 
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Table 1: Data Quality Summary (continued) 
State\Measure 
Measure Eligibility 
Reason 
PDC AD CAD ICS MI 
# eligible states 44 43 45 46 30  
 
Nebraska        
Nevada       
New Hampshire       
New Jersey       
New Mexico       
New York       
North Carolina       
North Dakota - - - - - Data not requested 
Ohio      
100% claims with missing day 
supply field 
Oklahoma       
Oregon       
Pennsylvania       
Rhode Island       
South Carolina       
South Dakota - - - - - Data not requested 
Tennessee      
 
Texas      
 
Utah      26.5% with no claims* 
Vermont        
Virginia       
Washington       
West Virginia        
Wisconsin       
Wyoming - - - - - Data not requested 
*Data anomaly obtained from annual Medicaid Analytic Extract Claims Anomaly Tables generated by 
Mathematica Policy Research. 
 
Overall, 1,538,448 Medicaid beneficiaries were eligible for at least one of the study 
measures. Demographic characteristics and co-morbidity indices of this patient pool are 
described in Table 2. The average age of Medicaid beneficiaries included in the study was 46.2 
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years (SD: 11.9) and 68.0% were female. A total of 45.1% of the study population was white, 
25.0% black, and 16.8% Hispanic.  Co-morbidities were assessed using weighted and 
unweighted RxRisk and Charlson’s comorbidity indices.  
Table 2: Baseline characteristics of the study population 
 
The number of patients eligible for the 11 measures varied considerably from 4,140 
patients in the denominator for the MI measure compared to 706,849 patients for the ACEI/ARB 
PDC measure. Table 3 provides a detailed overview of the number of patients in the numerator 
and denominator for all study measures.  
 
  
Baseline Characteristics  
Prevalence(%) or 
Mean ± SD 
N 1,538,448 
Age  46.19 (11.94) 
Sex  
 Female 67.99% 
 Male 32.01% 
Race  
 White 45.06% 
 Black 25.04% 
 Hispanic 16.76% 
 Other 13.14% 
RxRisk 5.96 (3.01) 
RxRisk (Weighted) 7.88 (5.13) 
Charlson’s Comorbidity Index (Unweighted) 1.00 (1.14) 
Charlson’s Comorbidity Index  1.57 (1.87) 
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Table 3: Overview of patient eligibility by measure type 
Measure Description 
2007  
# patients in the denominator % patients in the numerator 
PDC 
(Proportion of Medicaid patients 18-65 years who met PDC threshold of 80 percent) 
ACEI/ARBs 706,849 52.34 
Betablockers 458,852 49.54 
Calcium Channel Blockers 324,536 50.94 
Biguanides 317,670 44.23 
Sulfonylureas 200,182 46.56 
Thiazolidinediones 154,969 41.76 
Statins 557,765 48.32 
Antihypertensives 1,025,359 54.85 
Oralhypoglycemics 410,126 50.16 
AD Acute 
(Proportion of Medicaid patients 18-65 years newly diagnosed with MDD and prescribed antidepressant therapy 
persistent with the therapy for at least 3 months) 
AD-Acute 93,960 52.88 
AD Chronic 
(Proportion of Medicaid patients 18-65 years newly diagnosed with MDD and prescribed antidepressant therapy 
persistent with the therapy for at least 6 months) 
AD-Chronic 93,960 31.28 
CAD 
(Proportion of Medicaid patients 18-65 years diagnosed with CAD that received at least one prescription for a statin 
medication) 
CAD 145,391 62.50 
ICS 
(Proportion of Medicaid patient 18-65 years with persistent asthma that received at least one prescription for an 
inhaled corticosteroid or similar medication) 
ICS 262,043 68.12 
MI1 
(Proportion of Medicaid patients 18-65 years with MI that filled a beta-blocker prescription within 30 days of 
discharge) 
MI1 8,293 49.13 
MI 
(Proportion of Medicaid patients 18-65 years with MI that filled a beta-blocker prescription within 30 days of 
discharge persistent with therapy for at least 6 months) 
MI 3,945 59.15 
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Crude and case-mix adjusted scores on medication use-related quality measures 
Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker (ACEI/ARB) 
The PDC measure for ACEI/ARBs could be computed for 42 states and the District of 
Columbia. The number of patients eligible for the measure in each state and the proportion of 
patients meeting the 80% adherence threshold are shown in Table 4. The number of patients in 
the denominator ranged from 1,109 for New Hampshire to 136,018 for New York. The average 
adherence rate for the ACEI/ARB measure was 52.3% across all states, ranging from 42.1% of 
Medicaid patients being adherent in Mississippi to 69.0% in Vermont. States with scores above 
the national benchmark are highlighted in bold.  
Table 4: Patients meeting the ACEI/ARB measure criteria by state 
State 
ACEI/ARB 
#patients in the denominator %patients in the numerator 
Alabama 16,818 52.52 
Alaska - - 
Arizona  18,680 46.93 
Arkansas 5,931 52.72 
California 102,520 47.91 
Colorado 4,143 45.84 
Connecticut 4,998 61.42 
Delaware 3,620 51.35 
District of Columbia 2,814 49.08 
Florida 23,544 55.16 
Georgia 21,082 45.43 
Hawaii 2,679 48.82 
Idaho 1,457 68.36 
Illinois  30,267 52.35 
Indiana 9,463 50.27 
Iowa 4,019 60.74 
Kansas 3,392 58.70 
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Table 4: Patients meeting the ACEI/ARB measure criteria by state (continued) 
State 
ACEI/ARB 
#patients in the denominator %patients in the numerator 
Kentucky 22,459 61.05 
Louisiana 18,748 49.79 
Maine - - 
Maryland 13,333 49.00 
Massachusetts 17,058 54.24 
Michigan - - 
Minnesota 6,671 51.46 
Mississippi  12,254 42.10 
Missouri 15,198 57.97 
Montana - - 
Nebraska  1,843 58.87 
Nevada 2,085 58.13 
New Hampshire 1,109 63.21 
New Jersey 16,062 52.09 
New Mexico 5,636 53.00 
New York 13,6018 53.40 
North Carolina 26,544 52.20 
North Dakota - - 
Ohio - - 
Oklahoma 7,106 50.86 
Oregon 1,541 62.88 
Pennsylvania 8,960 64.53 
Rhode Island 3,608 57.59 
South Carolina 13,217 48.38 
South Dakota - - 
Tennessee 30,672 47.38 
Texas 36,830 53.73 
Utah 2,677 53.16 
Vermont  2,410 68.96 
Virginia 12,682 58.07 
Washington 13,011 59.93 
West Virginia  11,090 60.72 
Wisconsin 12,600 53.77 
Wyoming - - 
Total 706,849 52.34 
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Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 5. Approximately 64% of the patients were women, and the 
mean age (± SD) was 50 (± 10) years. Non-adherent patients were slightly younger and a greater 
proportion of non-adherent patients were Black and Hispanic compared to the adherent patients. 
The mean co-morbidity scores were higher in the adherent group compared to Medicaid 
beneficiaries who were nonadherent to ACEI/ARBs. 
Table 5: Characteristics of Medicaid patients eligible for the ACEI/ARB measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  50.00 ± 9.89 51.38 ± 9.31 48.48 ± 10.27 
Sex    
 Female 64.42 63.11 65.87 
 Male 35.58 36.89 34.13 
Race    
 White 40.53 45.36 35.21 
 Black 29.02 24.82 33.63 
 Hispanic 17.06 15.58 18.67 
 Other 13.40 14.23 12.48 
RxRisk 6.69 ± 3.00 6.95 ± 3.01 6.39 ± 2.95 
RxRisk (Weighted) 8.47 ± 5.17 8.68 ± 5.22 8.25 ± 5.16 
CCI 1.21 (1.23) 1.23 ± 1.20 1.18 ± 1.25 
CCI (Weighted) 1.94 (1.98) 1.98 ± 1.94 1.89 ± 2.02 
 
The results of the risk-adjusted analyses predicting adherence to ACEI/ARBs are 
presented in Table 6. The odds ratio estimates from the classical logistic regression model and 
the hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were significant 
predictors of adherence with ACEI/ARBs. Models including weighted RxRisk score, CCI, and 
unweighted CCI instead of RxRisk were estimated and the c-statistic was comparable across the 
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four models. An additional model with the 42 RxRisk categories in place of the RxRisk index 
was analyzed, and the c-statistic was slightly higher at 0.63 compared to 0.61 for the RxRisk 
index and CCI models. However, 42 covariates cannot be fitted in the hierarchical regression 
model where the random effect only has 43 levels. Therefore, models with the RxRisk index 
were used for case-mix adjustment of all measures in the study. The c-statistic was 0.613 for 
both the classical logistic and hierarchical logistic regression models, showing modest 
discriminative ability for both models.  
The race/ethnicity variable was found to be a strong predictor of adherence behavior in 
both models, with Blacks being 38% less likely to adhere to ACEI/ARB medications compared 
to Whites. Hispanics and other racial/ethnic groups were also less likely to adherence to 
ACEI/ARB medications compared to Whites. Females were 11% less likely to adhere to 
ACEI/ARB medications compared to males. Age and RxRisk were significant predictors, but 
with modest association with adherence behavior.  
Table 6: Odds ratio estimates for the ACEI/ARB measure 
*significant at p < 0.0001 
  
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.028 1.029 
Sex 
  
 Female vs. Male 0.880 0.883 
Race 
  
 Black vs. White 0.607 0.618 
 Hispanic vs. White 0.654 0.677 
 Other vs. White 0.842 0.879 
RxRisk 1.044 1.040 
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In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.03669 (SE: 0.008275). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 3123.82 (p<0.0001) indicating the presence of a random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 7. The residual intra class correlation coefficient (ρ) for the random intercept 
model was estimated to be 0.01103 which indicates that 1.1% of the unexplained variation after 
controlling for patient level variables could be attributed to variation between states.   
Table 7 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted ACEI/ARB measure scores ranged from 45.5% to 65.24%, a decrease in range 
compared to unadjusted scores. Case-mix adjustment ranked the states differently with 12% (5) 
states ranked the same, 12% (5) of states changing one position in the ranking order and 77% 
(33) changing more than two positions. There was moderate agreement in rankings based on the 
crude scores and case-mix adjusted scores based on the hierarchical logistic regression model 
with a random intercept (Kendall’s b=0.80). 
Table 7: Agreement in ranks: Crude and case-mix adjusted ACEI/ARB measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates 
Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 52.52 25 53.84 25 -1.32 0 
Alaska - - - - - - 
Arizona  46.93 40 48.12 39 -1.19 1 
Arkansas 52.72 24 54.99 21 -2.27 3 
California 47.91 38 49.28 37 -1.36 1 
Colorado 45.84 41 45.54 43 0.30 -2 
Connecticut 61.42 6 60.54 4 0.89 2 
Delaware 51.35 30 55.02 19 -3.67 11 
 44 
 
Table 7: Agreement in ranks: Crude and case-mix adjusted ACEI/ARB measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
District of Columbia 49.08 34 53.53 28 -4.45 6 
Florida 55.16 17 54.88 22 0.29 -5 
Georgia 45.43 42 46.51 42 -1.09 0 
Hawaii 48.82 36 46.72 41 2.11 -5 
Idaho 68.36 2 63.45 2 4.91 0 
Illinois  52.35 26 55.66 16 -3.31 10 
Indiana 50.27 32 48.98 38 1.29 -6 
Iowa 60.74 8 58.90 7 1.84 1 
Kansas 58.70 12 57.27 11 1.42 1 
Kentucky 61.05 7 56.89 12 4.16 -5 
Louisiana 49.79 33 52.98 29 -3.19 4 
Maine - - - - - - 
Maryland 49.00 35 52.31 31 -3.31 4 
Massachusetts 54.24 18 51.70 32 2.55 -14 
Michigan - - - - - - 
Minnesota 51.46 29 51.66 33 -0.20 -4 
Mississippi  42.10 43 47.01 40 -4.91 3 
Missouri 57.97 15 56.78 13 1.20 2 
Montana - - - - - - 
Nebraska  58.87 11 58.32 9 0.55 2 
Nevada 58.13 13 55.89 15 2.23 -2 
New Hampshire 63.21 4 58.40 8 4.81 -4 
New Jersey 52.09 28 53.61 26 -1.52 2 
New Mexico 53.00 23 53.55 27 -0.55 -4 
New York 53.40 21 54.65 23 -1.24 -2 
North Carolina 52.20 27 54.52 24 -2.32 3 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 50.86 31 49.52 36 1.34 -5 
Oregon 62.88 5 57.68 10 5.20 -5 
Pennsylvania 64.53 3 60.76 3 3.77 0 
Rhode Island 57.59 16 59.40 6 -1.81 10 
South Carolina 48.38 37 52.49 30 -4.10 7 
South Dakota - - - - - - 
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Table 7: Agreement in ranks: Crude and case-mix adjusted ACEI/ARB measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Tennessee 47.38 39 49.64 35 -2.27 4 
Texas 53.73 20 55.43 18 -1.70 2 
Utah 53.16 22 51.23 34 1.93 -12 
Vermont  68.96 1 65.24 1 3.73 0 
Virginia 58.07 14 59.78 5 -1.71 9 
Washington 59.93 10 56.51 14 3.42 -4 
West Virginia  60.72 9 55.45 17 5.27 -8 
Wisconsin 53.77 19 55.00 20 -1.23 -1 
Wyoming - - - - - - 
bKendall’s b 0.80   
a
ACEI/ARB
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43.
  
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores. 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 8a and Table 
8b. Results based on the two risk adjustment models showed strong agreement in grouping 
(κ=0.91). However, there was moderate agreement in classification of the states based on the 
crude and case-mix adjusted models when case-mix adjustment was conducted using both 
classical logistic regression (κ=0.57) and random intercept models (κ=0.65).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in Table A-5 (APPENDIX). Choropleth maps depicting the top, medium and bottom 
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performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 1. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in Figure A-3 (APPENDIX).  
Table 8a: Agreement in groups: Crude and case-mix adjusted ACEI/ARB scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 6 2 0 
Medium (60%) 2 22 3 2 23 2 
Top (~20%) 0 3 5 0 2 6 
Percentage 
misclassified
a
 
25.0% 18.5% 37.5% 25.0% 14.8% 25.0% 
Cohen’s κb  0.57 0.65 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
 
Table 8b: Agreement in groups: Case-mix adjusted ACEI/ARB scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 26 1 
Top 0 1 7 
Percentage misclassified
a
 0.0% 3.7% 12.5% 
Cohen’s κb  0.91 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 1. Interstate variations in ACEI/ARB adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
A 
B 
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Beta Blockers (BB) 
The PDC measure for this class of medications was computed for 42 states and the 
District of Columbia. The number of patients eligible for the measure in each state and the 
proportion of patients meeting the 80% adherence threshold are shown in Table 9. The number 
of patients in the denominator ranged from 969 for Idaho to 83,365 for New York. The average 
adherence rate for the beta blocker measure was 49.5% across all states, ranging from 34.4% of 
Medicaid patients adherent in Arkansas to 64.1% in Vermont. States with scores above the 
national benchmark are highlighted in bold.  
Table 9: Patients meeting the BB measure criteria by state 
State 
BB 
#patients in the denominator %patients in the numerator 
Alabama 10,715 48.81 
Alaska - - 
Arizona  12,500 44.52 
Arkansas 3,774 34.42 
California 63,042 46.36 
Colorado 2,902 45.55 
Connecticut 3,363 59.29 
Delaware 2,030 48.23 
District of Columbia 1,487 43.58 
Florida 15,868 52.19 
Georgia 12,626 43.36 
Hawaii 1,514 50.00 
Idaho 969 62.33 
Illinois  20,108 51.09 
Indiana 7,546 48.57 
Iowa 3,341 58.58 
Kansas 2,286 55.25 
Kentucky 17,589 56.35 
Louisiana 11,154 45.94 
Maine - - 
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Table 9: Patients meeting the BB measure criteria by state (continued) 
State 
BB 
#patients in the denominator %patients in the numerator 
Maryland 8,542 46.46 
Massachusetts 15,274 53.19 
Michigan - - 
Minnesota 5,639 50.20 
Mississippi  6,230 34.57 
Missouri 10,993 52.28 
Montana - - 
Nebraska  1,464 56.63 
Nevada 1,268 56.31 
New Hampshire 1,039 58.71 
New Jersey 9,455 49.59 
New Mexico 3,384 49.59 
New York 83,365 50.47 
North Carolina 16,585 49.64 
North Dakota - - 
Ohio - - 
Oklahoma 5,088 43.93 
Oregon 1,210 57.93 
Pennsylvania 7,521 59.17 
Rhode Island 2,450 50.45 
South Carolina 7,062 41.91 
South Dakota - - 
Tennessee 19,029 43.64 
Texas 21,038 49.73 
Utah 1,411 49.33 
Vermont  2,077 64.08 
Virginia 8,400 54.18 
Washington 10,531 54.48 
West Virginia  7,720 59.65 
Wisconsin 9,263 51.99 
Wyoming - - 
Total 458,852 49.54 
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Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 10. Approximately 64% of the patients were women, and the 
mean age (± SD) was 49 (± 11) years. Non-adherent patients were slightly younger and a greater 
proportion of non-adherent patients were Black and Hispanic compared to the adherent patients. 
The mean co-morbidity scores were higher in the adherent group compared to Medicaid 
beneficiaries who were nonadherent to beta-blockers. 
Table 10: Characteristics of Medicaid patients eligible for BB measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  49.12 ± 10.79 50.78 ± 10.08 47.49 ± 11.20 
Sex    
 Female 64.33 61.97 66.65 
 Male 35.67 38.03 33.35 
Race    
 White 47.30 52.00 42.68 
 Black 24.96 20.52 29.31 
 Hispanic 14.32 13.09 15.53 
 Other 13.43 14.39 12.48 
RxRisk 6.97 ± 3.10 7.23 ± 3.12 6.72 ± 3.05 
RxRisk (Weighted) 8.17 ± 5.46 8.38 ± 5.51 7.97 ± 5.41 
CCI 1.20 ± 1.36 1.22 ± 1.32 1.18 ± 1.39 
CCI (Weighted) 1.86 ± 2.18 1.89 ± 2.12 1.82 ± 2.24 
 
The results of the risk-adjusted analyses predicting adherence to BBs are presented in 
Table 11. The odds ratio estimates from the classical logistic regression model and the 
hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of adherence with beta-blockers. The c-statistic was 0.614 for both 
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classical logistic and hierarchical logistic regression models, showing modest discriminative 
ability for both models.  
Race/ethnicity variable was a strong predictor of adherence behavior in both models, with 
Blacks being 40% less likely to adhere to beta-blocker medications compared to Whites. 
Hispanics and other racial/ethnic groups were also less likely to be adherent to beta-blocker 
medications compared to Whites. Females were 14% less likely to adhere to beta-blocker 
medications compared to males. Age and RxRisk were found to be significant predictors, but 
with modest association with adherence behavior.  
Table 11: Odds ratio estimates for the BB measure 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.04534 (SE: 0.01021). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 2324.92 (p<0.0001) indicating the presence of random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 12. The residual intra class correlation coefficient (ρ) for the random intercept 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.028 1.028 
Sex 
  
 Female vs. Male 0.855 0.860 
Race 
  
 Black vs. White 0.582 0.598 
 Hispanic vs. White 0.675 0.691 
 Other vs. White 0.878 0.904 
RxRisk 1.032 1.027 
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model was estimated to be 0.01359 which indicates that 1.36% of the unexplained variation after 
controlling for patient level variables could be attributed to variation between states.   
Table 12 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted BB measure scores ranged from 38.53% to 60.62%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 24% (10) states 
ranked the same, 12% (5) of states changing one position in the ranking order and 65% (28) 
changing more than two positions. There was moderate agreement in rankings based on the 
crude scores and case-mix adjusted scores based on the hierarchical logistic regression model 
with a random intercept (Kendall’s b=0.80). 
Table 12: Agreement in ranks: Crude and case-mix adjusted BB measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 48.81 29 50.00 28 -1.19 1 
Alaska - - - - - - 
Arizona  44.52 36 44.94 38 -0.42 -2 
Arkansas 34.42 43 35.82 43 -1.40 0 
California 46.36 33 46.89 35 -0.53 -2 
Colorado 45.55 35 45.32 37 0.24 -2 
Connecticut 59.29 4 58.49 3 0.81 1 
Delaware 48.23 31 51.18 21 -2.95 10 
District of Columbia 43.58 39 47.90 32 -4.32 7 
Florida 52.19 17 51.85 17 0.34 0 
Georgia 43.36 40 44.19 40 -0.83 0 
Hawaii 50.00 23 46.95 34 3.05 -11 
Idaho 62.33 2 58.60 2 3.74 0 
Illinois  51.09 19 54.27 11 -3.18 8 
Indiana 48.57 30 47.78 33 0.78 -3 
Iowa 58.58 7 57.91 4 0.66 3 
Kansas 55.25 12 54.52 9 0.73 3 
Kentucky 56.35 10 52.72 15 3.63 -5 
Louisiana 45.94 34 48.75 30 -2.82 4 
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Table 12: Agreement in ranks: Crude and case-mix adjusted BB measure scores
a
 (cont.) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Maine - - - - - - 
Maryland 46.46 32 49.27 29 -2.81 3 
Massachusetts 53.19 15 50.66 26 2.53 -11 
Michigan - - - - - - 
Minnesota 50.20 22 50.99 22 -0.79 0 
Mississippi  34.57 42 38.53 42 -3.96 0 
Missouri 52.28 16 51.72 19 0.56 -3 
Montana - - - - - - 
Nebraska  56.63 9 56.81 5 -0.18 4 
Nevada 56.31 11 54.00 12 2.31 -1 
New Hampshire 58.71 6 55.49 8 3.22 -2 
New Jersey 49.76 24 50.92 24 -1.16 0 
New Mexico 49.59 27 50.22 27 -0.63 0 
New York 50.47 20 50.98 23 -0.52 -3 
North Carolina 49.64 26 51.79 18 -2.15 8 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 43.93 37 43.20 41 0.72 -4 
Oregon 57.93 8 53.44 14 4.50 -6 
Pennsylvania 59.17 5 56.20 6 2.96 -1 
Rhode Island 50.45 21 51.71 20 -1.26 1 
South Carolina 41.91 41 44.85 39 -2.93 2 
South Dakota - - - - - - 
Tennessee 43.64 38 45.44 36 -1.80 2 
Texas 49.73 25 50.86 25 -1.12 0 
Utah 49.33 28 48.08 31 1.25 -3 
Vermont  64.08 1 60.62 1 3.46 0 
Virginia 54.18 14 55.75 7 -1.57 7 
Washington 54.48 13 52.46 16 2.02 -3 
West Virginia  59.65 3 54.27 10 5.38 -7 
Wisconsin 51.99 18 53.47 13 -1.48 5 
Wyoming - - - - - - 
bKendall’s b 0.80   
a
BB
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43.
  
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
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Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 13a and Table 
13b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was good agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.74) and random intercept 
models (κ=0.74).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in Table A-6 (APPENDIX). Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 2. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in Figure A-4 (APPENDIX).  
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Table 13a: Agreement in groups: Crude and case-mix adjusted BB measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 7 1 0 7 1 0 
Medium (60%) 1 24 2 1 24 2 
Top (~20%) 0 2 6 0 2 6 
Percentage 
misclassified
a
 
12.5% 11.1% 25% 12.5% 11.1% 25% 
Cohen’s κb  0.74 0.74 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 13b: Agreement in groups: Case-mix adjusted BB measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 2. Interstate variations in BB adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
  
A 
B 
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Calcium Channel Blockers (CCB) 
The PDC measure for this class of medications was computed for 42 states and the 
District of Columbia. The number of patients eligible for the measure in each state and the 
proportion of patients meeting the 80% adherence threshold are shown in Table 14. The number 
of patients in the denominator ranged from 399 in New Hampshire to 67,257 in New York. The 
average adherence rate for the beta blocker measure was 49.5% across all states, ranging from 
37.3% of Medicaid patients being adherent in Maryland to 69.7% in Vermont. States with scores 
above the national benchmark are highlighted in bold.  
Table 14: Patients meeting the CCB measure criteria by state 
State 
CCB 
#patients in the denominator %patients in the numerator 
Alabama 7,251 52.54 
Alaska - - 
Arizona  5,865 48.85 
Arkansas 2,771 48.97 
California 44,641 48.57 
Colorado 1,507 45.99 
Connecticut 2,207 58.99 
Delaware 1,434 45.89 
District of Columbia 1,750 49.71 
Florida 12,381 51.17 
Georgia 11,321 44.22 
Hawaii 896 52.79 
Idaho 506 65.61 
Illinois  15,142 51.01 
Indiana 4,640 47.91 
Iowa 1,680 58.45 
Kansas 1,503 58.42 
Kentucky 9,563 60.40 
Louisiana 9,712 48.93 
Maine - - 
Maryland 6,942 37.32 
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Table 14: Patients meeting the CCB measure criteria by state (continued) 
State 
CCB 
#patients in the denominator %patients in the numerator 
Massachusetts 5,984 55.26 
Michigan - - 
Minnesota 2,568 48.48 
Mississippi  7,027 44.51 
Missouri 6,808 52.85 
Montana - - 
Nebraska  803 57.04 
Nevada 1,029 58.02 
New Hampshire 399 64.41 
New Jersey 8,283 49.28 
New Mexico 1,818 54.79 
New York 67,257 51.40 
North Carolina 12,962 52.71 
North Dakota - - 
Ohio - - 
Oklahoma 2,527 53.94 
Oregon 463 60.91 
Pennsylvania 3,425 60.79 
Rhode Island 1,616 56.31 
South Carolina 7,159 46.04 
South Dakota - - 
Tennessee 14,004 46.87 
Texas 17,109 54.57 
Utah 873 53.04 
Vermont  763 69.72 
Virginia 6,179 55.74 
Washington 4,675 58.63 
West Virginia  3,750 60.45 
Wisconsin 5,343 49.82 
Wyoming - - 
Total 324,536 50.94 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 15. Approximately 67% of the patients were women, and the 
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mean age (± SD) was 51 ± 10 years. Non-adherent patients were slightly younger and a greater 
proportion of non-adherent patients were Black and Hispanic compared to adherent patients. The 
mean co-morbidity scores were higher in the adherent group compared to Medicaid 
beneficiaries’ nonadherent to calcium channel blockers. 
Table 15: Characteristics of Medicaid patients eligible for CCB adherence measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  50.71 ± 9.87 52.29 ± 9.03 49.06 ± 10.42 
Sex    
 Female 66.90 65.01 68.86 
 Male 33.10 34.99 31.14 
Race    
 White 33.97 38.81 28.95 
 Black 38.41 33.11 43.91 
 Hispanic 14.07 13.41 14.75 
 Other 13.55 14.66 12.40 
RxRisk 6.86 ± 3.08 7.11 ± 3.07 6.60 ± 3.06 
RxRisk (Weighted) 8.12 ± 5.50 8.34 ± 5.52 7.90 ± 5.47 
CCI 1.20 ± 1.31 1.22 ± 1.27 1.18 ± 1.36 
CCI (Weighted) 1.89 ± 2.13 1.93 ± 2.07 1.84 ± 2.19 
 
The results of the risk-adjusted analyses predicting adherence to CCBs are presented in 
Table 16. The odds ratio estimates from the classical logistic regression model and the 
hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of adherence with calcium channel blockers. The c-statistic was 0.618 for 
both classical logistic and hierarchical logistic regression models, showing modest discriminative 
ability for both models.  
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Race/ethnicity variable was found to be a strong predictor of adherence behavior in both 
models, with Blacks being 40% less likely to adhere to calcium channel blocker medications 
compared to Whites. Hispanics and other racial/ethnic groups were also less likely to adherence 
to calcium channel blocker medications compared to Whites. Females were 14% less likely to 
adhere to calcium channel blocker medications compared to males. Age and RxRisk were 
significant predictors, but with modest association with adherence behavior.  
Table 16: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.03238 (SE: 0.007708). Testing the null hypothesis of 
no random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo-likelihood yielded a chi-square of 1298.33 (p<0.0001) indicating the 
presence of random effect. Therefore, case-mix adjusted scores based on hierarchical logistic 
regression model with a random intercept are presented in Table 17. The residual intra class 
correlation coefficient (ρ) for the random intercept model was estimated to be 0.00974 which 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.032 1.032 
Sex 
  
 Female vs. Male 0.862 0.861 
Race 
  
 Black vs. White 0.602 0.616 
 Hispanic vs. White 0.674 0.689 
 Other vs. White 0.833 0.871 
RxRisk 1.032 1.030 
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indicates that 0.97% of the unexplained variation after controlling for patient level variables 
could be attributed to variation between states.   
Table 17 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted CCB measure scores ranged from 40.46% to 65.43%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 16% (7) states 
ranked the same and 81% (35) changing more than two positions. There was modest agreement 
in rankings based on the crude scores and case-mix adjusted scores based on the hierarchical 
logistic regression model with a random intercept (Kendall’s b=0.67). 
Table 17: Agreement in ranks: Crude and case-mix adjusted CCB adherence scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 52.54 24 54.66 18 -2.11 6 
Alaska - - - - - - 
Arizona 48.85 33 48.59 39 0.26 -6 
Arkansas 48.97 31 51.97 27 -3.00 4 
California 48.57 34 48.91 38 -0.34 -4 
Colorado 45.99 39 45.72 41 0.26 -2 
Connecticut 58.99 8 58.30 4 0.70 4 
Delaware 45.89 40 49.99 35 -4.10 5 
District of Columbia 49.71 29 53.89 21 -4.18 8 
Florida 51.17 26 51.51 28 -0.34 -2 
Georgia 44.22 42 45.52 42 -1.30 0 
Hawaii 52.79 22 49.40 36 3.39 -14 
Idaho 65.61 2 60.65 2 4.96 0 
Illinois 51.01 27 54.92 17 -3.91 10 
Indiana 47.91 36 48.18 40 -0.27 -4 
Iowa 58.45 10 56.67 10 1.78 0 
Kansas 58.42 11 56.71 9 1.71 2 
Kentucky 60.40 7 55.95 13 4.45 -6 
Louisiana 48.93 32 52.75 24 -3.83 8 
Maine - - - - - - 
Maryland 37.32 43 40.46 43 -3.13 0 
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Table 17: Agreement in ranks: Crude and case-mix adjusted CCB adherence scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Massachusetts 55.26 16 52.24 26 3.02 -10 
Michigan - - - - - - 
Minnesota 48.48 35 49.19 37 -0.71 -2 
Mississippi 44.51 41 50.33 34 -5.81 7 
Missouri 52.85 21 52.71 25 0.14 -4 
Montana - - - - - - 
Nebraska 57.04 13 57.44 7 -0.41 6 
Nevada 58.02 12 56.03 12 1.99 0 
New Hampshire 64.41 3 58.68 3 5.73 0 
New Jersey 49.28 30 51.48 29 -2.20 1 
New Mexico 54.79 17 54.10 20 0.69 -3 
New York 51.40 25 52.81 22 -1.41 3 
North Carolina 52.71 23 56.12 11 -3.42 12 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 53.94 19 52.76 23 1.17 -4 
Oregon 60.91 4 55.58 15 5.33 -11 
Pennsylvania 60.79 5 57.07 8 3.72 -3 
Rhode Island 56.31 14 57.58 6 -1.26 8 
South Carolina 46.04 38 50.76 31 -4.72 7 
South Dakota - - - - - - 
Tennessee 46.87 37 50.39 33 -3.53 4 
Texas 54.57 18 55.88 14 -1.32 4 
Utah 53.04 20 50.64 32 2.40 -12 
Vermont 69.72 1 65.43 1 4.30 0 
Virginia 55.74 15 58.05 5 -2.31 10 
Washington 58.63 9 55.02 16 3.61 -7 
West Virginia 60.45 6 54.40 19 6.05 -13 
Wisconsin 49.82 28 51.44 30 -1.62 -2 
Wyoming - - - - - - 
bKendall’s b 0.67   
a
CCB
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43.
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
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Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 18a and Table 
18b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was poor agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.39) and random intercept 
models (κ=0.39). CCB measure performed poorer compared to other PDC measures on how the 
crude and case-mix adjusted groupings compare. 
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-7. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 3. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-5.  
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Table 18a: Agreement in groups: Crude and case-mix adjusted CCB adherence scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 4 4 0 4 4 0 
Medium (60%) 4 20 3 4 20 3 
Top (~20%) 0 3 5 0 3 5 
Percentage 
misclassified
a
 
50.0% 25.9% 37.5% 50.0% 25.9% 37.5% 
Cohen’s κb  0.39 0.39 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 18b: Agreement in groups: Case-mix adjusted CCB adherence scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 3. Interstate variations in CCB adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Biguanides (BIGU) 
The PDC measure for this class of medications was computed for 42 states and the 
District of Columbia. The number of patients eligible for the measure in each state and the 
proportion of patients meeting the 80% adherence threshold are tabulated in Table 19. The 
number of patients in the denominator ranged from 549 in New Hampshire to 65,501 in New 
York. The average adherence rate for the biguanide measure was 44.2% across all states, ranging 
from 34.1% of Medicaid patients being adherent in Mississippi to 58.3% in Vermont. Adherence 
rates are lower for biguanide medications compared to the antihypertensive medications included 
in the study. States with scores above the national benchmark are highlighted in bold.  
Table 19: Patients meeting the BIGU measure criteria by state 
State 
BIGU 
#patients in the denominator %patients in the numerator 
Alabama 6,316 44.16 
Alaska - - 
Arizona  10,246 38.59 
Arkansas 2,380 40.25 
California 54,942 38.03 
Colorado 2,268 38.62 
Connecticut 2,488 50.36 
Delaware 1,269 42.79 
District of Columbia 1,005 44.58 
Florida 9,495 49.83 
Georgia 7,310 39.66 
Hawaii 983 47.41 
Idaho 989 51.67 
Illinois  12,335 45.30 
Indiana 4,080 40.96 
Iowa 1,967 52.26 
Kansas 1,531 47.94 
Kentucky 9,477 52.11 
Louisiana 6,184 39.68 
Maine - - 
Maryland 5,127 43.30 
Massachusetts 7,957 46.02 
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Table 19: Patients meeting the BIGU measure criteria by state (continued) 
State 
BIGU 
#patients in the denominator %patients in the numerator 
Michigan - - 
Minnesota 3,362 42.00 
Mississippi  4,201 34.11 
Missouri 6,497 49.25 
Montana - - 
Nebraska  824 46.97 
Nevada 855 50.06 
New Hampshire 549 55.74 
New Jersey 7,043 45.41 
New Mexico 3,175 44.16 
New York 65,501 47.88 
North Carolina 10,204 43.49 
North Dakota - - 
Ohio - - 
Oklahoma 2,949 37.20 
Oregon 737 55.36 
Pennsylvania 4,069 53.45 
Rhode Island 1,415 42.69 
South Carolina 4,740 40.11 
South Dakota - - 
Tennessee 12,492 38.98 
Texas 16,685 43.36 
Utah 1,396 40.97 
Vermont  998 58.32 
Virginia 5,010 50.08 
Washington 6,676 52.50 
West Virginia  4,328 51.83 
Wisconsin 5,615 46.59 
Wyoming - - 
Total 317,670 44.23 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 20. Approximately 69% of the patients were women, and the 
mean age (± SD) was 49 ± 11 years. Non-adherent patients were slightly younger and a greater 
proportion of non-adherent patients were Black and Hispanic compared to adherent patients. The 
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mean co-morbidity scores were higher in the adherent group compared to Medicaid 
beneficiaries’ nonadherent to biguanides. 
Table 20: Characteristics of Medicaid patients eligible for BIGU adherence measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  49.04 ± 10.50 50.92 ± 9.62 47.54 ± 10.92 
Sex    
 Female 68.79 66.99 70.22 
 Male 31.21 33.01 29.78 
Race    
 White 38.32 43.68 34.07 
 Black 23.40 19.63 26.38 
 Hispanic 23.43 20.21 25.98 
 Other 14.85 16.47 13.56 
RxRisk 6.70 ± 3.09 7.10 ± 3.07 6.37 ± 3.06 
RxRisk (Weighted) 8.71 ± 5.03 9.03 ± 5.09 8.46 ± 4.96 
CCI 1.49 ± 1.02 1.52 ± 0.99 1.46 ± 1.05 
CCI (Weighted) 2.58 ± 1.59 2.63 ± 1.51 2.54 ± 1.64 
 
The results of the risk-adjusted analyses predicting adherence to biguanides are presented 
in Table 21. The odds ratio estimates from the classical logistic regression model and the 
hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of adherence with biguanides. The c-statistic was 0.624 for both classical 
logistic and hierarchical logistic regression models, showing modest discriminative ability for 
both models.  
Race/ethnicity variable was found to be a strong predictor of adherence behavior in both 
models, with Blacks being 40% less likely and Hispanics 36% less likely to adhere to biguanide 
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medications compared to Whites. Other racial/ethnic groups were also less likely to adhere to 
biguanides compared to Whites. Females were 14% less likely to adhere to biguanide 
medications compared to males. Age and RxRisk were found to be significant predictors, but 
with modest association with adherence behavior.  
Table 21: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.02988 (SE: 0.006952). Testing the null hypothesis of 
no random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo-likelihood yielded a chi-square of 1723.40 (p<0.0001) indicating the 
presence of random effect. Therefore, case-mix adjusted scores based on hierarchical logistic 
regression model with a random intercept are presented in Table 22. The residual intra class 
correlation coefficient (ρ) for the random intercept model was estimated to be 0.00900 which 
indicates that only 0.90% of the unexplained variation after controlling for patient level variables 
could be attributed to variation between states.   
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.029 1.029 
Sex 
  
 Female vs. Male 0.860 0.861 
Race 
  
 Black vs. White 0.606 0.602 
 Hispanic vs. White 0.636 0.641 
 Other vs. White 0.917 0.920 
RxRisk 1.052 1.048 
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Table 22 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted BIGU measure scores ranged from 36% to 54%, a decrease in range compared to 
the crude estimates. Case-mix adjustment ranked the states differently with 16% (7) states ranked 
the same and 81% (35) changing more than two positions. There was good agreement in 
rankings based on the crude scores and case-mix adjusted scores based on the hierarchical 
logistic regression model with a random intercept (Kendall’s b=0.72). 
Table 22: Agreement in ranks: Crude and case-mix adjusted BIGU adherence scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 44.16 24 44.38 29 -0.22 -5 
Alaska - - - - - - 
Arizona 38.59 40 41.59 35 -3.00 5 
Arkansas 40.25 34 41.86 33 -1.61 1 
California 38.03 41 41.07 37 -3.04 4 
Colorado 38.62 39 39.16 41 -0.53 -2 
Connecticut 50.36 10 50.40 7 -0.04 3 
Delaware 42.79 29 45.45 24 -2.66 5 
District of Columbia 44.58 23 49.28 11 -4.71 12 
Florida 49.83 13 48.96 12 0.87 1 
Georgia 39.66 37 40.12 39 -0.46 -2 
Hawaii 47.41 17 44.77 27 2.64 -10 
Idaho 51.67 9 51.25 3 0.42 6 
Illinois 45.30 22 48.85 13 -3.55 9 
Indiana 40.96 33 39.63 40 1.33 -7 
Iowa 52.26 6 50.52 6 1.74 0 
Kansas 47.94 15 47.17 18 0.78 -3 
Kentucky 52.11 7 47.06 19 5.04 -12 
Louisiana 39.68 36 41.70 34 -2.02 2 
Maine - - - - - - 
Maryland 43.30 28 46.74 20 -3.44 8 
Massachusetts 46.02 20 43.24 32 2.78 -12 
Michigan - - - - - - 
Minnesota 42.00 31 43.55 31 -1.55 0 
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Table 22: Agreement in ranks: Crude and case-mix adjusted BIGU adherence scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Mississippi 34.11 43 38.00 42 -3.89 1 
Missouri 49.25 14 47.39 17 1.86 -3 
Montana - - - - - - 
Nebraska 46.97 18 47.42 16 -0.45 2 
Nevada 50.06 12 47.46 15 2.59 -3 
New Hampshire 55.74 2 51.30 2 4.44 0 
New Jersey 45.41 21 46.00 22 -0.59 -1 
New Mexico 44.16 25 46.41 21 -2.25 4 
New York 47.88 16 49.73 9 -1.86 7 
North Carolina 43.49 26 45.23 26 -1.74 0 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 37.20 42 35.77 43 1.43 -1 
Oregon 55.36 3 50.63 5 4.73 -2 
Pennsylvania 53.45 4 49.70 10 3.75 -6 
Rhode Island 42.69 30 44.39 28 -1.70 2 
South Carolina 40.11 35 43.71 30 -3.60 5 
South Dakota - - - - - - 
Tennessee 38.98 38 41.07 36 -2.09 2 
Texas 43.36 27 45.72 23 -2.35 4 
Utah 40.97 32 40.85 38 0.12 -6 
Vermont 58.32 1 54.37 1 3.95 0 
Virginia 50.08 11 51.23 4 -1.15 7 
Washington 52.50 5 49.86 8 2.64 -3 
West Virginia 51.83 8 45.32 25 6.51 -17 
Wisconsin 46.59 19 47.65 14 -1.06 5 
Wyoming - - - - - - 
bKendall’s b 0.72   
a
BIGU
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43.
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
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grouping based on the unadjusted and risk-adjusted groupings are shown in Table 23a and Table 
23b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was moderate agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.57) and random intercept 
models (κ=0.57).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-8. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 4. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-6.  
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Table 23a: Agreement in groups: Crude and case-mix adjusted BIGU adherence scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 6 2 0 
Medium (60%) 2 22 3 2 22 3 
Top (~20%) 0 3 5 0 3 5 
Percentage 
misclassified
a
 
25% 18.5% 37.5% 25% 18.5% 37.5% 
Cohen’s κb  0.57 0.57 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 23b: Agreement in groups: Case-mix adjusted BIGU adherence scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 4. Interstate variations in BIGU adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Sulfonylureas (SU) 
The PDC measure for this class of medications was computed for 42 states and the 
District of Columbia. The number of patients eligible for the measure in each state and the 
proportion of patients meeting the 80% adherence threshold are shown in Table 24. The number 
of patients in the denominator ranged from 280 in New Hampshire to 40,599 in New York. The 
average adherence rate for the beta blocker measure was 46.6% across all states, ranging from 
34.9% of Medicaid patients being adherent in Mississippi to 61.0% in Idaho. States with scores 
above the national benchmark are highlighted in bold.  
Table 24: Patients meeting the SU measure criteria by state 
State 
SU 
#patients in the denominator %patients in the numerator 
Alabama 3,957 49.86 
Alaska - - 
Arizona  6,165 40.16 
Arkansas 1,694 43.51 
California 38,842 39.49 
Colorado 1,106 41.77 
Connecticut 1,389 55.08 
Delaware 720 48.33 
District of Columbia 630 46.67 
Florida 6,836 50.00 
Georgia 5,031 43.35 
Hawaii 739 48.17 
Idaho 349 61.03 
Illinois  8,477 49.75 
Indiana 2,348 45.87 
Iowa 1,088 52.21 
Kansas 721 47.99 
Kentucky 5,457 56.02 
Louisiana 3,987 45.55 
Maine - - 
Maryland 3,691 46.09 
Massachusetts 4,473 48.69 
Michigan - - 
Minnesota 1,834 44.22 
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Table 24: Patients meeting the SU measure criteria by state (continued) 
State 
SU 
#patients in the denominator %patients in the numerator 
Mississippi  2,961 34.89 
Missouri 3,467 53.99 
Montana - - 
Nebraska  514 52.53 
Nevada 517 58.41 
New Hampshire 280 55.00 
New Jersey 4,736 48.71 
New Mexico 2,050 45.90 
New York 40,599 49.55 
North Carolina 6,199 48.04 
North Dakota - - 
Ohio - - 
Oklahoma 1,826 41.68 
Oregon 390 54.36 
Pennsylvania 2,447 58.03 
Rhode Island 877 47.78 
South Carolina 2,833 43.35 
South Dakota - - 
Tennessee 6,462 43.59 
Texas 11,010 44.87 
Utah 620 45.00 
Vermont  498 60.64 
Virginia 3,177 54.36 
Washington 3,491 51.93 
West Virginia  2,700 55.33 
Wisconsin 2,994 49.80 
Wyoming - - 
Total 200,182 46.56 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 25. The majority of the study population comprised of women 
(65%) and the mean age (± SD) was 51 ± 10 years. A greater proportion of the study population 
is Black or Hispanic compared to the antihypertensive medication-related PDC measures. Non-
adherent patients were slightly younger and a greater proportion of non-adherent patients were 
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Black and Hispanic compared to adherent patients. The mean co-morbidity scores were slightly 
higher in the adherent group compared to Medicaid beneficiaries’ nonadherent to sulfonylureas. 
Table 25: Characteristics of Medicaid patients eligible for SU adherence measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  50.75 ± 9.54 52.38 ± 8.71 49.32± 9.99 
Sex    
 Female 65.00 63.47 66.33 
 Male 35.00 36.53 33.67 
Race    
 White 35.19 40.28 30.76 
 Black 24.25 21.37 26.77 
 Hispanic 24.31 20.55 27.58 
 Other 16.24 17.80 14.89 
RxRisk 6.71 ± 3.08 7.09 ± 3.06 6.38 ± 3.06 
RxRisk (Weighted) 8.72 ± 5.07 9.03 ± 5.13 8.45 ± 5.00 
CCI (Unweighted) 1.60 ± 1.11 1.63 ± 1.07 1.57 ± 1.13 
CCI  2.77 ± 1.73 2.82 ± 1.67 2.72 ± 1.78 
 
The results of the risk-adjusted analyses predicting adherence to sulfonylureas are 
presented in Table 26. The odds ratio estimates from the classical logistic regression model and 
the hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of adherence with sulfonylureas. The c-statistic was 0.620 for both 
classical logistic and hierarchical logistic regression models, showing modest discriminative 
ability for both models.  
Race/ethnicity variable was found to be a strong predictor of adherence behavior in both 
models, with Blacks being 35% less likely to adhere to sulfonylurea medications compared to 
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Whites. Hispanics were 38% less likely to meet the 0.80 adherence threshold for SU medications 
and other racial/ethnic groups were also less likely to adhere to SU medications compared to 
Whites. Females were 12% less likely to adhere to SUs compared to males. Age and RxRisk 
were found to be significant predictors, but with modest association with adherence behavior.  
Table 26: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.02901 (SE: 0.007068). Testing the null hypothesis of 
no random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo-likelihood yielded a chi-square of 996.01 (p<0.0001) indicating the 
presence of random effect. Therefore, case-mix adjusted scores based on hierarchical logistic 
regression model with a random intercept are presented in Table 27. The residual intra class 
correlation coefficient (ρ) for the random intercept model was estimated to be 0.00874 which 
indicates that 0.87% of the unexplained variation after controlling for patient level variables 
could be attributed to variation between states.   
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.031 1.031 
Sex 
  
 Female vs. Male 0.878 0.890 
Race 
  
 Black vs. White 0.650 0.646 
 Hispanic vs. White 0.624 0.655 
 Other vs. White 0.913 0.941 
RxRisk 1.050 1.045 
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Table 27 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted SU measure scores ranged from 40.46% to 65.43%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 16% (7) states 
ranked the same and 81% (35) changing more than two positions. There was good agreement in 
rankings based on the crude scores and case-mix adjusted scores based on the hierarchical 
logistic regression model with a random intercept (Kendall’s b=0.74). 
Table 27: Agreement in ranks: Crude and case-mix adjusted SU adherence scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 49.86 16 50.60 16 -0.74 0 
Alaska - - - - - - 
Arizona 40.16 41 43.91 38 -3.75 3 
Arkansas 43.51 36 45.47 33 -1.96 3 
California 39.49 42 43.19 40 -3.70 2 
Colorado 41.77 39 42.19 41 -0.42 -2 
Connecticut 55.08 7 55.69 4 -0.61 3 
Delaware 48.33 22 51.21 12 -2.87 10 
District of Columbia 46.67 27 50.31 19 -3.64 8 
Florida 50.00 15 49.93 20 0.07 -5 
Georgia 43.35 37 43.83 39 -0.48 -2 
Hawaii 48.17 23 45.59 32 2.58 -9 
Idaho 61.03 1 56.32 2 4.71 -1 
Illinois 49.75 18 53.00 7 -3.26 11 
Indiana 45.87 30 44.50 36 1.37 -6 
Iowa 52.21 13 50.93 14 1.28 -1 
Kansas 47.99 25 47.04 29 0.95 -4 
Kentucky 56.02 5 51.19 13 4.83 -8 
Louisiana 45.55 31 47.12 28 -1.57 3 
Maine - - - - - - 
Maryland 46.09 28 49.74 21 -3.66 7 
Massachusetts 48.69 21 46.42 31 2.27 -10 
Michigan - - - - - - 
Minnesota 44.22 34 45.40 34 -1.18 0 
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Table 27: Agreement in ranks: Crude and case-mix adjusted SU adherence scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Mississippi 34.89 43 38.68 43 -3.79 0 
Missouri 53.99 11 52.75 8 1.24 3 
Montana - - - - - - 
Nebraska 52.53 12 52.15 9 0.38 3 
Nevada 58.41 3 56.16 3 2.26 0 
New Hampshire 55.00 8 51.31 11 3.69 -3 
New Jersey 48.71 20 49.47 24 -0.76 -4 
New Mexico 45.90 29 47.52 26 -1.62 3 
New York 49.55 19 51.68 10 -2.13 9 
North Carolina 48.04 24 49.51 22 -1.47 2 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 41.68 40 40.60 42 1.07 -2 
Oregon 54.36 10 50.82 15 3.54 -5 
Pennsylvania 58.03 4 54.21 6 3.82 -2 
Rhode Island 47.78 26 49.18 25 -1.40 1 
South Carolina 43.35 38 46.76 30 -3.42 8 
South Dakota - - - - - - 
Tennessee 43.59 35 45.31 35 -1.72 0 
Texas 44.87 33 47.43 27 -2.56 6 
Utah 45.00 32 44.32 37 0.68 -5 
Vermont 60.64 2 57.36 1 3.29 1 
Virginia 54.36 9 55.34 5 -0.98 4 
Washington 51.93 14 50.34 18 1.59 -4 
West Virginia 55.33 6 49.51 23 5.82 -17 
Wisconsin 49.80 17 50.55 17 -0.75 0 
Wyoming - - - - - - 
bKendall’s b 0.74   
a
SU
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43.
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
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grouping based on the unadjusted and risk-adjusted groupings are shown in Table 28a and Table 
28b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was modest agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.57) and random intercept 
models (κ=0.57).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-9. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 5. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-7.  
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Table 28a: Agreement in groups: Crude and case-mix adjusted SU adherence scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 6 2 0 
Medium (60%) 2 22 3 2 22 3 
Top (~20%) 0 3 5 0 3 5 
Percentage 
misclassified
a
 
25.0% 18.5% 37.5% 25.0% 18.5% 37.5% 
Cohen’s κb  0.57 0.57 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 28b: Agreement in groups: Case-mix adjusted SU adherence scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 5. Interstate variations in SU adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Thiazolidinediones (TZD) 
The PDC measure for TZDs was computed for 42 states and the District of Columbia. 
The number of patients eligible for the measure in each state and the proportion of patients 
meeting the 80% adherence threshold are shown in Table 29. The number of patients in the 
denominator ranged from 242 in New Hampshire to 32,568 in New York. The average adherence 
rate for the beta blocker measure was 41.8% across all states, ranging from 29.7% of Medicaid 
patients being adherent in Mississippi to 58.8% in Vermont. States with scores above the 
national benchmark are highlighted in bold.  
Table 29: Patients meeting the TZD measure criteria by state 
State 
TZD 
#patients in the denominator %patients in the numerator 
Alabama 3,539 39.81 
Alaska - - 
Arizona  3,516 36.35 
Arkansas 1,177 44.86 
California 28,236 39.06 
Colorado 946 37.63 
Connecticut 1,332 48.20 
Delaware 674 41.39 
District of Columbia 360 34.72 
Florida 5,584 43.77 
Georgia 4,163 38.58 
Hawaii 592 47.47 
Idaho 509 55.60 
Illinois  6,296 42.44 
Indiana 1,923 40.41 
Iowa 944 52.97 
Kansas 801 49.31 
Kentucky 4,255 52.03 
Louisiana 3,515 41.14 
Maine 
- - 
Maryland 2,057 36.90 
Massachusetts 3,401 42.84 
Michigan - - 
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Table 29: Patients meeting the TZD measure criteria by state (continued) 
State 
TZD 
#patients in the denominator %patients in the numerator 
Minnesota 1,356 47.57 
Mississippi  2,118 29.70 
Missouri 2,902 49.04 
Montana - - 
Nebraska  538 49.63 
Nevada 415 49.16 
New Hampshire 242 52.48 
New Jersey 3,860 41.19 
New Mexico 1,263 38.24 
New York 32,568 39.65 
North Carolina 5,412 44.22 
North Dakota - - 
Ohio 
- - 
Oklahoma 1,572 45.17 
Oregon 307 49.51 
Pennsylvania 1,904 55.62 
Rhode Island 712 42.98 
South Carolina 2,493  
South Dakota - - 
Tennessee 4,316 36.17 
Texas 8,580 43.37 
Utah 582 43.47 
Vermont  400 58.75 
Virginia 2,290 47.55 
Washington 2,336 47.39 
West Virginia  2,625 50.93 
Wisconsin 2,358 43.04 
Wyoming - - 
Total 154,969 41.76 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 30. The majority of the study population comprised of women 
(67%) and the mean age (± SD) was 51 ± 10 years. A greater proportion of the study population 
is Black or Hispanic compared to the antihypertensive medication-related PDC measures. Non-
adherent patients were slightly younger, and a greater proportion of non-adherent patients were 
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female and of Black/Hispanic race/ethnicity compared to adherent patients. The mean RxRisk 
scores were slightly higher in the adherent group compared to Medicaid beneficiaries’ 
nonadherent to thiazolidinediones. CCI weighted and unweighted indices were the same across 
the two groups. 
Table 30: Characteristics of Medicaid patients eligible for TZD adherence measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  50.93 ± 9.28 52.14 ± 8.70 50.06 ± 9.59  
Sex    
 Female 67.14 64.51 69.02 
 Male 32.86 35.49 30.98 
Race    
 White 37.53 43.25 33.43 
 Black 22.86 19.48 25.28 
 Hispanic 23.72 20.12 26.29 
 Other 15.89 17.15 14.99 
RxRisk 7.06 ± 3.09 7.32 ± 3.06 6.89 ± 3.09 
RxRisk (Weighted) 9.00 ± 5.14 9.22 ± 5.18 8.84 ± 5.11 
CCI (Unweighted) 1.59 ± 1.05 1.59 ± 1.01 1.60 ± 1.08 
CCI  2.75 ± 1.60 2.76 ± 1.53 2.75 ± 1.64 
 
The results of the risk-adjusted analyses predicting adherence to thiazolidinediones are 
presented in Table 31. The odds ratio estimates from the classical logistic regression model and 
the hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of the TZD adherence measure. The c-statistic was 0.599 for both classical 
logistic and hierarchical logistic regression models, showing weak discriminative ability for both 
models, compared to the other measures included in the study.  
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Race/ethnicity and gender were strong predictors of adherence behavior in both models. 
Blacks were 37% less likely to adhere to TZDs compared to Whites in the classical logistic 
regression model. Hispanics were 39% less likely to meet the 0.80 adherence threshold for TZDs 
and other racial/ethnic groups were also less likely to be adherent compared to Whites. Females 
were 19% less likely to adhere to TZDs compared to males. Age and RxRisk were found to be 
significant predictors, but with modest association with adherence behavior. Similar results were 
observed using the hierarchical logistic regression model with state included as a random 
intercept. 
Table 31: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.03249 (SE: 0.008010). Testing the null hypothesis of 
no random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo-likelihood yielded a chi-square of 488.74 (p<0.0001) indicating the 
presence of random effect. Therefore, case-mix adjusted scores based on hierarchical logistic 
regression model with a random intercept are presented in Table 32. The residual intra class 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.023 1.023 
Sex 
  
 Female vs. Male 0.808 0.890 
Race 
  
 Black vs. White 0.629 0.655 
 Hispanic vs. White 0.614 0.643 
 Other vs. White 0.869 0.910 
RxRisk 1.031 1.027 
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correlation coefficient (ρ) for the random intercept model was estimated to be 0.00978 which 
indicates that 0.98% of the unexplained variation after controlling for patient level variables 
could be attributed to variation between states.   
Table 32 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted SU measure scores ranged from 40.46% to 65.43%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 16% (7) states 
ranked the same and 81% (35) changing more than two positions. There was good agreement in 
rankings based on the crude scores and case-mix adjusted scores based on the hierarchical 
logistic regression model with a random intercept (Kendall’s b=0.78). 
Table 32: Agreement in ranks: Crude and case-mix adjusted TZD adherence scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 39.81 33 40.98 33 -1.17 0 
Alaska - - - - - - 
Arizona 36.35 40 39.11 37 -2.76 3 
Arkansas 44.86 19 46.71 13 -1.85 6 
California 39.06 35 41.70 31 -2.64 4 
Colorado 37.63 38 38.18 40 -0.55 -2 
Connecticut 48.20 13 49.90 6 -1.70 7 
Delaware 41.39 28 44.45 23 -3.06 5 
District of Columbia 34.72 42 37.85 42 -3.13 0 
Florida 43.77 21 44.29 24 -0.52 -3 
Georgia 38.58 36 39.46 35 -0.88 1 
Hawaii 47.47 16 45.62 18 1.85 -2 
Idaho 55.60 3 53.77 2 1.83 1 
Illinois 42.44 27 44.97 20 -2.54 7 
Indiana 40.41 32 39.04 39 1.37 -7 
Iowa 52.97 4 51.70 3 1.27 1 
Kansas 49.31 10 48.51 8 0.80 2 
Kentucky 52.03 6 47.86 12 4.17 -6 
Louisiana 41.14 30 43.19 28 -2.06 2 
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Table 32: Agreement in ranks: Crude and case-mix adjusted TZD adherence scores
a
 (cont.) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Maine - - - - - - 
Maryland 36.90 39 39.11 38 -2.21 1 
Massachusetts 42.84 26 40.88 34 1.96 -8 
Michigan - - - - - - 
Minnesota 47.57 14 47.98 10 -0.41 4 
Mississippi 29.70 43 33.22 43 -3.52 0 
Missouri 49.04 12 46.68 14 2.36 -2 
Montana - - - - - - 
Nebraska 49.63 8 49.99 5 -0.36 3 
Nevada 49.16 11 47.96 11 1.20 0 
New Hampshire 52.48 5 48.43 9 4.05 -4 
New Jersey 41.19 29 42.05 30 -0.86 -1 
New Mexico 38.24 37 39.32 36 -1.08 1 
New York 39.65 34 41.35 32 -1.70 2 
North Carolina 44.22 20 46.26 16 -2.04 4 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 45.17 18 44.18 26 0.99 -8 
Oregon 49.51 9 44.92 21 4.59 -12 
Pennsylvania 55.62 2 51.65 4 3.97 -2 
Rhode Island 42.98 25 45.11 19 -2.13 6 
South Carolina 40.95 31 44.19 25 -3.24 6 
South Dakota - - - - - - 
Tennessee 36.17 41 37.94 41 -1.77 0 
Texas 43.37 23 46.65 15 -3.28 8 
Utah 43.47 22 42.41 29 1.06 -7 
Vermont 58.75 1 54.61 1 4.14 0 
Virginia 47.55 15 48.51 7 -0.96 8 
Washington 47.39 17 44.52 22 2.87 -5 
West Virginia 50.93 7 46.18 17 4.75 -10 
Wisconsin 43.04 24 43.63 27 -0.58 -3 
Wyoming - - - - - - 
bKendall’s b 0.78   
a
TZD
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
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Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 33a and Table 
33b. Results based on the two risk adjustment models showed close to perfect agreement in 
classification of states into top, medium and bottom groups (κ=0.91). There was modest 
agreement in classification of the states based on the crude and case-mix adjusted models when 
case-mix adjustment was conducted using both classical logistic regression (κ=0.65) and random 
intercept models (κ=0.65).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-10. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 6. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-8.  
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Table 33a: Agreement in groups: Crude and case-mix adjusted TZD adherence scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 7 1 0 7 1 0 
Medium (60%) 1 23 3 1 23 3 
Top (~20%) 0 3 5 0 3 5 
Percentage 
misclassified
a
 
12.5% 14.8% 37.5% 12.5% 14.8% 37.5% 
Cohen’s κb  0.65 0.65 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 33b: Agreement in groups: Case-mix adjusted TZD adherence scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 7 1 0 
Medium  1 26 0 
Top 0 0 8 
Percentage misclassified
a
 12.5% 3.7% 0% 
Cohen’s κb  0.91 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement. 
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Figure 6. Interstate variations in TZD adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Statins (STAT) 
The PDC measure for this class of medications was computed for 42 states and the 
District of Columbia. The number of patients eligible for the measure in each state and the 
proportion of patients meeting the 80% adherence threshold are shown in Table 34. The number 
of patients in the denominator ranged from 1,182 in Oregon to 121,522 in New York. The 
average adherence rate for the statin adherence measure was 48.3% across all states, ranging 
from 38.4% of Medicaid patients being adherent in Mississippi to 67.6% in Vermont. States with 
scores above the national benchmark are highlighted in bold.  
Table 34: Patients meeting the STAT measure criteria by state 
State 
STAT 
#patients in the denominator %patients in the numerator 
Alabama 11,258 51.02 
Alaska - - 
Arizona  14,405 41.66 
Arkansas 3,776 46.00 
California 84,254 42.78 
Colorado 3,437 44.57 
Connecticut 4,652 58.19 
Delaware 2,664 47.18 
District of Columbia 1,843 45.25 
Florida 19,897 51.19 
Georgia 13,710 44.35 
Hawaii 2,260 54.47 
Idaho 1,201 66.19 
Illinois  21,752 49.17 
Indiana 7,702 49.51 
Iowa 3,495 61.34 
Kansas 2,653 58.20 
Kentucky 20,199 56.84 
Louisiana 11,396 47.26 
Maine - - 
Maryland 9,277 47.03 
Massachusetts 16,860 46.79 
Michigan - - 
Minnesota 5,634 50.75 
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Table 34: Patients meeting the STAT measure criteria by state (continued) 
State 
STAT 
#patients in the denominator %patients in the numerator 
Mississippi  6,165 38.44 
Missouri 11,733 57.74 
Montana - - 
Nebraska  1,496 59.83 
Nevada 1,581 54.59 
New Hampshire 1,224 61.27 
New Jersey 12,877 45.25 
New Mexico 3,889 48.78 
New York 121,522 46.21 
North Carolina 18,879 51.70 
North Dakota - - 
Ohio - - 
Oklahoma 4,854 52.51 
Oregon 1,182 59.31 
Pennsylvania 8,559 58.11 
Rhode Island 3,242 43.58 
South Carolina 8,646 45.95 
South Dakota - - 
Tennessee 19,197 41.24 
Texas 25,742 50.91 
Utah 1,882 51.97 
Vermont  2,303 67.56 
Virginia 9,334 57.67 
Washington 11,460 57.23 
West Virginia  9,968 56.99 
Wisconsin 9,705 52.50 
Wyoming - - 
Total 557,765 48.32 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 35. The majority of the study population was comprised of 
women (64%) and the mean age (± SD) was 51 ± 9 years. A greater proportion of the study 
population is Black or Hispanic compared to the antihypertensive medication-related PDC 
measures. Non-adherent patients were slightly younger and a greater proportion of non-adherent 
patients were women, of Black and Hispanic race/ethnicity compared to adherent patients. The 
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mean comorbidity scores were slightly higher in the adherent group compared to Medicaid 
beneficiaries’ nonadherent to statins. 
Table 35: Characteristics of Medicaid patients eligible for STAT adherence measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Adherent Nonadherent 
Age  51.37 ± 8.98 52.39 ± 8.63 50.41 ± 9.20  
Sex    
 Female 64.12 62.48 65.66 
 Male 35.88 37.52 34.34 
Race    
 White 45.79 51.61 40.35 
 Black 20.07 17.32 22.64 
 Hispanic 18.08 14.49 21.42 
 Other 16.06 16.57 15.59 
RxRisk 6.95 ± 3.07 7.27 ± 3.07 6.65 ± 3.04 
RxRisk (Weighted) 7.65 ± 5.41 8.09 ± 5.45 7.23 ± 5.34 
CCI (Unweighted) 1.18 ± 1.21 1.21 ± 1.20 1.14 ± 1.22 
CCI  1.87 ± 1.90 1.93 ± 1.88 1.81 ± 1.92 
 
The results of the risk-adjusted analyses predicting adherence to statins are presented in 
Table 36. The odds ratio estimates from the classical logistic regression model and the 
hierarchical logistic regression model with a random intercept are similar. All parameters 
included in the models, including age, sex, race/ethnicity, and RxRisk score were found to be 
significant predictors of the STAT adherence measure. The c-statistic was 0.611 for both 
classical logistic and hierarchical logistic regression models, showing weak discriminative ability 
for both models, compared to the other measures included in the study.  
Race/ethnicity and gender were found to be strong predictors of adherence behavior in 
both models. Blacks were 40% less likely, Hispanics were 45% less likely, and other 
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racial/ethnic groups were 17% less likely to meet the 0.80 adherence threshold for statins. 
Females were 18% less likely to adhere to statins compared to males. Age and RxRisk were 
found to be significant predictors, but with modest association with adherence behavior.  
Table 36: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.04566 (SE: 0.01027). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 3095.49 (p<0.0001) indicating the presence of random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 37. The residual intra class correlation coefficient (ρ) for the random intercept 
model was estimated to be 0.01369 which indicates that 1.37% of the unexplained variation after 
controlling for patient level variables could be attributed to variation between states.   
Table 37 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted statin measure scores ranged from 42.10% to 64.05%, a decrease in range 
compared to the crude estimates. Case-mix adjustment ranked the states differently with 12% (5) 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.025 1.025 
Sex 
  
 Female vs. Male 0.819 0.820 
Race 
  
 Black vs. White 0.609 0.619 
 Hispanic vs. White 0.550 0.569 
 Other vs. White 0.832 0.864 
RxRisk 1.057 1.051 
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states ranked the same, 30% (13) states changing one position and 58% (25) changing more than 
two positions. There was good agreement in rankings based on the crude scores and case-mix 
adjusted scores based on the hierarchical logistic regression model with a random intercept 
(Kendall’s b=0.81). 
Table 37: Agreement in ranks: Crude and case-mix adjusted STAT adherence scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 51.02 22 50.98 23 0.04 -1 
Alaska - - - - - - 
Arizona 41.66 41 44.44 40 -2.79 1 
Arkansas 46.00 33 46.80 34 -0.80 -1 
California 42.78 40 45.84 37 -3.06 3 
Colorado 44.57 37 45.24 39 -0.66 -2 
Connecticut 58.19 8 60.47 3 -2.28 5 
Delaware 47.18 29 49.55 30 -2.37 -1 
District of Columbia 45.25 35 50.16 27 -4.91 8 
Florida 51.19 21 51.72 21 -0.52 0 
Georgia 44.35 38 44.38 41 -0.03 -3 
Hawaii 54.47 16 53.39 15 1.08 1 
Idaho 66.19 2 62.09 2 4.11 0 
Illinois 49.17 26 51.91 19 -2.74 7 
Indiana 49.51 25 47.12 33 2.39 -8 
Iowa 61.34 3 58.92 4 2.42 -1 
Kansas 58.20 7 56.30 8 1.90 -1 
Kentucky 56.84 14 52.49 17 4.36 -3 
Louisiana 47.26 28 48.43 32 -1.17 -4 
Maine - - - - - - 
Maryland 47.03 30 49.66 28 -2.63 2 
Massachusetts 46.79 31 45.36 38 1.43 -7 
Michigan - - - - - - 
Minnesota 50.75 24 50.84 24 -0.10 0 
Mississippi 38.44 43 42.18 42 -3.74 1 
Missouri 57.74 10 55.45 9 2.30 1 
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Table 37: Agreement in ranks: Crude and case-mix adjusted STAT adherence scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Montana - - - - - - 
Nebraska 59.83 5 58.88 5 0.95 0 
Nevada 54.59 15 52.92 16 1.66 -1 
New Hampshire 61.27 4 57.18 6 4.09 -2 
New Jersey 45.25 36 46.79 35 -1.54 1 
New Mexico 48.78 27 50.63 25 -1.85 2 
New York 46.21 32 49.56 29 -3.36 3 
North Carolina 51.70 20 52.22 18 -0.52 2 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 52.51 17 50.56 26 1.96 -9 
Oregon 59.31 6 54.69 10 4.61 -4 
Pennsylvania 58.11 9 54.66 11 3.45 -2 
Rhode Island 43.58 39 46.57 36 -2.99 3 
South Carolina 45.95 34 48.44 31 -2.48 3 
South Dakota - - - - - - 
Tennessee 41.24 42 42.10 43 -0.86 -1 
Texas 50.91 23 54.25 12 -3.34 11 
Utah 51.97 19 50.99 22 0.97 -3 
Vermont 67.56 1 64.05 1 3.52 0 
Virginia 57.67 11 57.14 7 0.53 4 
Washington 57.23 12 54.06 13 3.18 -1 
West Virginia 56.99 13 51.80 20 5.19 -7 
Wisconsin 52.50 18 53.46 14 -0.96 4 
Wyoming - - - - - - 
bKendall’s b 0.81   
a
STAT
 
adherence scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 38a and Table 
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38b. Results based on the two risk adjustment models showed close to perfect agreement in 
classification of states into top, medium and bottom groups (κ=0.91). There was good agreement 
in classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.74) and random intercept 
models (κ=0.83).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-11. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 7. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-9.  
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Table 38a: Agreement in groups: Crude and case-mix adjusted STAT adherence scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 7 1 0 
Medium (60%) 2 24 1 1 25 1 
Top (~20%) 0 1 7 0 1 7 
Percentage 
misclassified
a
 
25.0% 11.1% 12.5% 12.5% 7.4% 12.5% 
Cohen’s κb  0.74 0.83 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 38b: Agreement in groups: Case-mix adjusted STAT adherence scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 7 1 0 
Medium  1 26 0 
Top 0 0 8 
Percentage misclassified
a
 12.5% 3.7% 0% 
Cohen’s κb  0.91 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 7. Interstate variations in STAT adherence measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Persistence with Antidepressant Medications (AD) 
The AD measure was computed for 42 states and the District of Columbia. The number 
of patients eligible for the measure in each state and the proportion of patients with continuous 
use of antidepressant medications over an acute phase (12 weeks) and chronic phase (6 months) 
are shown in Table 39. The number of patients in the denominator ranged from 198 in District of 
Columbia to 12,401 in New York. The average proportion of patients with continuous use of 
antidepressants was 52.9% for acute phase measure and 31.3% for the chronic phase measure. 
The short term antidepressant use scores ranged from 44.7% in Mississippi to 61.9% in Vermont. 
Most states performed poorer than other measures on the chronic use of antidepressant measure, 
with scores ranging from 14.0% of Medicaid patients continuously using antidepressant 
medications over a period of six months in Hawaii to 40.6% in Vermont. States with scores 
above the national benchmark are highlighted in bold.  
Table 39: Patients meeting the AD measure criteria by state 
State 
AD Measure AD Acute AD Chronic 
#patients in the 
denominator 
%patients in the 
numerator 
%patients in the 
numerator 
Alabama 1318 50.76 33.08 
Alaska - - - 
Arizona  3337 57.12 34.85 
Arkansas 1032 50.68 28.59 
California 8059 53.96 30.30 
Colorado 1101 61.31 37.87 
Connecticut 526 52.09 35.55 
Delaware 489 53.99 32.31 
District of Columbia 198 44.44 24.75 
Florida 1641 52.35 31.32 
Georgia 1645 48.57 25.05 
Hawaii 314 40.76 14.01 
Idaho 533 58.54 34.90 
Illinois  3989 49.24 27.30 
Indiana 2150 51.72 30.56 
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Table 39: Patients meeting the AD measure criteria by state (continued) 
State 
AD Measure AD Acute AD Chronic 
#patients in the 
denominator 
%patients in the 
numerator 
%patients in the 
numerator 
Iowa 1481 56.85 37.41 
Kansas 630 52.38 32.22 
Kentucky 3112 52.41 30.17 
Louisiana 1744 47.13 25.63 
Maine - - - 
Maryland 1227 50.69 28.44 
Massachusetts 2744 51.53 30.61 
Michigan - - - 
Minnesota 3470 49.39 29.14 
Mississippi  1239 44.71 21.87 
Missouri 2689 52.77 32.35 
Montana - - - 
Nebraska  555 54.95 35.14 
Nevada 275 61.45 37.82 
New Hampshire 497 57.75 37.02 
New Jersey 1701 51.68 29.63 
New Mexico 879 49.15 29.47 
New York 12401 54.64 33.10 
North Carolina 4499 52.88 31.61 
North Dakota - - - 
Ohio - - - 
Oklahoma 1476 56.78 35.09 
Oregon 1174 55.71 32.28 
Pennsylvania 2112 56.96 36.46 
Rhode Island 838 49.28 28.40 
South Carolina 1624 49.57 26.35 
South Dakota - - - 
Tennessee 5277 47.49 24.60 
Texas 2462 58.81 37.08 
Utah 780 55.38 33.72 
Vermont  984 61.89 40.55 
Virginia 1965 50.33 29.72 
Washington 3422 55.38 35.42 
West Virginia  1165 54.94 35.11 
Wisconsin 5206 52.94 32.17 
Wyoming - - - 
Total 93960 52.88 31.28 
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Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 40. The majority of the study population was comprised of 
women (67%) and the mean age (± SD) was 51 ± 10 years. A greater proportion of AD measure 
eligible population is female and White compared to the study population eligible for other 
measures. Non-persistent patients were slightly younger and a greater proportion of these 
patients were Black and Hispanic compared to persistent patients. The mean RxRisk scores were 
slightly higher in the persistent group compared to Medicaid beneficiaries who were non-
persistent to antidepressants. Comorbidity burden measured using the CCI weighted and 
unweighted indices was lower in this population compared to Medicaid beneficiaries eligible for 
the PDC measures. 
Table 40: Characteristics of Medicaid patients eligible for AD measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
 Acute Chronic 
Overall Persistent 
Non-
persistent 
Persistent 
Non-
persistent 
Age  37.37 ± 11.31 38.06 ± 11.28 36.59 ± 11.28 39.47 ± 11.19 36.41 ± 11.23 
Sex      
 Female 81.46 80.66 82.36 79.12 82.53 
 Male 18.54 19.34 17.64 20.88 17.47 
Race      
 White 64.51 68.23 60.33 70.40 61.82 
 Black 14.88 12.15 17.94 10.67 16.79 
 Hispanic 12.35 11.46 13.36 10.69 13.11 
 Other 8.26 8.16 8.37 8.24 8.27 
RxRisk 6.17 ± 3.08 6.29 ± 3.15 6.03 ± 3.00 6.61 ± 3.22 5.97 ± 2.99 
RxRisk (Weighted) 9.14 ± 5.15 9.24 ± 5.22 9.03 ± 5.07 9.62 ± 5.34 8.93 ± 5.05 
CCI (Unweighted) 0.53 ± 0.94 0.56 ± 0.95 0.51 ± 0.93 0.62 ± 0.99 0.50 ± 0.91 
CCI  0.82 ± 1.54 0.85 ± 1.56 0.78 ± 1.52 0.95 ± 1.62 0.75 ± 1.50 
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The results of the risk-adjusted analyses predicting persistence to antidepressants are 
presented in Table 41. The odds ratio estimates from the classical logistic regression model and 
the hierarchical logistic regression model with a random intercept are fairly similar. All 
parameters included in the models, including age, sex, race/ethnicity, and RxRisk score were 
found to be significant predictors of the AD measure. In case of the AD acute measure, c-statistic 
was 0.572 for both classical logistic and 0.571 for the hierarchical logistic regression models, 
showing weak discriminative ability for both models, compared to the other measures included 
in the study. However, the model performed better while predicting chronic phase persistence, 
with the c-statistic being 0.613 for both classical logistic and hierarchical logistic regression 
models, showing modest discriminative ability. 
Race/ethnicity and gender were found to be strong predictors of antidepressant 
persistence in both models, with Blacks being 43% less likely to be persistent with the 
recommended antidepressant therapy over a 12-week time period compared to Whites in both 
regression models. Hispanics and other racial/ethnic groups were also less likely to be persistent 
compared to Whites. Age, sex and RxRisk were found to be significant predictors, but with 
modest association with persistence. Similar trends were observed in the model predicting 
chronic phase persistence. Blacks were 50% less likely to continue their medications over a 6-
month period compared to Whites. Hispanic, other racial groups, and females were also found to 
be less likely to be persistent with antidepressants over a six month period compared to Whites 
and males, respectively, in both models. 
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Table 41: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.001 
For the AD acute measure, in the hierarchical logistic regression model with a random-
intercept, the state-level variance component was estimated to be 0.02262 (SE: 0.005893). 
Testing the null hypothesis of no random effects using a likelihood ratio test based on residual 
pseudo-likelihood yielded a chi-square of 307.94 (p<0.0001) indicating the presence of random 
effect. Therefore, case-mix adjusted scores based on hierarchical logistic regression model with a 
random intercept are presented in Table 42a. The residual intra class correlation coefficient (ρ) 
for the random intercept model was estimated to be 0.00978 which indicates that 0.98% of the 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
 
AD Acute Measure 
Age  1.023 1.012 
Sex 
  
 Female vs. Male 0.933 0.944 
Race 
  
 Black vs. White 0.568 0.569 
 Hispanic vs. White 0.718 0.649 
 Other vs. White 0.812 0.774 
RxRisk 1.018 1.021 
 
AD Chronic Measure 
Age  1.023 1.023 
Sex 
  
 Female vs. Male 0.871 0.890 
Race 
  
 Black vs. White 0.499 0.507 
 Hispanic vs. White 0.643 0.587 
 Other vs. White 0.777 0.732 
RxRisk 1.047 1.051 
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unexplained variation after controlling for patient level variables could be attributed to variation 
between states.   
For the AD chronic measure, in the hierarchical logistic regression model with a random-
intercept, the state-level variance component was estimated to be 0.04923 (SE: 0.01259). Testing 
the null hypothesis of no random effects using a likelihood ratio test based on residual pseudo-
likelihood yielded a chi-square of 460.34 (p<0.0001) indicating the presence of a random effect. 
Therefore, case-mix adjusted scores based on hierarchical logistic regression model with a 
random intercept are presented in Table 42b. The residual intra class correlation coefficient (ρ) 
for the random intercept model was estimated to be 0.00978 which indicates that 0.98% of the 
unexplained variation after controlling for patient level variables could be attributed to variation 
between states.   
Table 42a shows the agreement between the crude and case-mix adjusted scores. The 
case-mix adjusted AD acute measure scores ranged from 40.1% to 64.4%, a slight decrease in 
range compared to the crude estimates. Case-mix adjustment ranked the states differently with 
14% (6) states ranked the same, 14% (6) states changing one rank and 72% (31) changing more 
than two positions. There was good agreement in rankings based on the crude scores and case-
mix adjusted scores based on the hierarchical logistic regression model with a random intercept 
(Kendall’s b=0.71). 
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Table 42a: Agreement in ranks: Crude and case-mix adjusted AD Acute measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 50.76 29 50.78 28 -0.03 1 
Alaska - - - - - - 
Arizona 57.12 7 57.26 5 -0.15 2 
Arkansas 50.68 31 49.92 36 0.75 -5 
California 53.96 18 55.56 9 -1.60 9 
Colorado 61.31 3 64.44 1 -3.13 2 
Connecticut 52.09 25 52.77 21 -0.68 4 
Delaware 53.99 17 55.01 13 -1.02 4 
District of Columbia 44.44 42 50.43 33 -5.99 9 
Florida 52.35 24 51.93 24 0.42 0 
Georgia 48.57 38 48.92 39 -0.35 -1 
Hawaii 40.76 43 40.08 43 0.69 0 
Idaho 58.54 5 55.83 8 2.71 -3 
Illinois 49.24 36 50.44 32 -1.20 4 
Indiana 51.72 26 50.58 31 1.14 -5 
Iowa 56.85 9 56.22 7 0.64 2 
Kansas 52.38 23 51.83 25 0.55 -2 
Kentucky 52.41 22 49.75 37 2.66 -15 
Louisiana 47.13 40 48.80 40 -1.67 0 
Maine - - - - - - 
Maryland 50.69 30 53.29 19 -2.60 11 
Massachusetts 51.53 28 50.59 30 0.94 -2 
Michigan - - - - - - 
Minnesota 49.39 34 50.36 34 -0.97 0 
Mississippi 44.71 41 46.36 42 -1.64 -1 
Missouri 52.77 21 51.02 27 1.75 -6 
Montana - - - - - - 
Nebraska 54.95 14 54.99 14 -0.04 0 
Nevada 61.45 2 58.91 4 2.55 -2 
New Hampshire 57.75 6 55.42 10 2.33 -4 
New Jersey 51.68 27 52.13 23 -0.46 4 
New Mexico 49.15 37 52.41 22 -3.26 15 
New York 54.64 16 56.53 6 -1.89 10 
North Carolina 52.88 20 53.02 20 -0.14 0 
North Dakota - - - - - - 
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Table 42a: Agreement in ranks: Crude and case-mix adjusted AD Acute measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Ohio - - - - - - 
Oklahoma 56.78 10 55.31 11 1.46 -1 
Oregon 55.71 11 55.22 12 0.49 -1 
Pennsylvania 56.96 8 54.84 15 2.12 -7 
Rhode Island 49.28 35 51.04 26 -1.76 9 
South Carolina 49.57 33 49.47 38 0.10 -5 
South Dakota - - - - - - 
Tennessee 47.49 39 46.95 41 0.54 -2 
Texas 58.81 4 60.18 2 -1.36 2 
Utah 55.38 12 53.65 17 1.73 -5 
Vermont 61.89 1 60.14 3 1.75 -2 
Virginia 50.33 32 50.71 29 -0.38 3 
Washington 55.38 13 54.15 16 1.23 -3 
West Virginia 54.94 15 50.00 35 4.93 -20 
Wisconsin 52.94 19 53.34 18 -0.40 1 
Wyoming - - - - - - 
bKendall’s b 0.71   
a
AD acute measure scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Table 42b shows the agreement between the crude and case-mix adjusted scores. The 
case-mix adjusted AD chronic measure scores ranged from 13.4% to 42.5%, a decrease in range 
compared to the crude estimates. Case-mix adjustment ranked the states differently with 14% (6) 
states ranked the same, 21% (9) states changing one rank, and 65% (28) changing more than two 
positions. There was good agreement in rankings based on the crude scores and case-mix 
adjusted scores based on the hierarchical logistic regression model with a random intercept 
(Kendall’s b=0.71). 
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Table 42b: Agreement in ranks: Crude and case-mix adjusted AD Chronic measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 33.08 17 32.20 20 0.88 -3 
Alaska - - - - - - 
Arizona 34.85 14 35.10 7 -0.25 7 
Arkansas 28.59 33 28.00 36 0.58 -3 
California 30.30 27 31.86 22 -1.56 5 
Colorado 37.87 2 42.49 1 -4.62 1 
Connecticut 35.55 8 34.08 14 1.47 -6 
Delaware 32.31 19 33.75 15 -1.44 4 
District of Columbia 24.75 40 28.60 35 -3.85 5 
Florida 31.32 24 30.10 28 1.23 -4 
Georgia 25.05 39 24.51 41 0.53 -2 
Hawaii 14.01 43 13.41 43 0.60 0 
Idaho 34.90 13 33.23 19 1.67 -6 
Illinois 27.30 36 29.32 32 -2.02 4 
Indiana 30.56 26 29.99 29 0.57 -3 
Iowa 37.41 4 38.03 3 -0.62 1 
Kansas 32.22 21 32.10 21 0.12 0 
Kentucky 30.17 28 27.49 37 2.69 -9 
Louisiana 25.63 38 27.19 38 -1.56 0 
Maine - - - - - - 
Maryland 28.44 34 30.36 27 -1.92 7 
Massachusetts 30.61 25 29.22 33 1.39 -8 
Michigan - - - - - - 
Minnesota 29.14 32 31.48 24 -2.35 8 
Mississippi 21.87 42 23.28 42 -1.40 0 
Missouri 32.35 18 30.73 26 1.62 -8 
Montana - - - - - - 
Nebraska 35.14 10 36.40 5 -1.26 5 
Nevada 37.82 3 34.10 13 3.72 -10 
New Hampshire 37.02 6 35.62 6 1.41 0 
New Jersey 29.63 30 29.73 31 -0.10 -1 
New Mexico 29.47 31 33.52 16 -4.05 15 
New York 33.10 16 34.68 9 -1.57 7 
North Carolina 31.61 23 31.50 23 0.11 0 
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Table 42b: Agreement in ranks: Crude and case-mix adjusted AD Chronic measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 35.09 12 33.41 17 1.69 -5 
Oregon 32.28 20 34.13 12 -1.85 8 
Pennsylvania 36.46 7 35.09 8 1.37 -1 
Rhode Island 28.40 35 31.10 25 -2.70 10 
South Carolina 26.35 37 26.53 39 -0.18 -2 
South Dakota - - - - - - 
Tennessee 24.60 41 24.79 40 -0.19 1 
Texas 37.08 5 37.50 4 -0.41 1 
Utah 33.72 15 33.38 18 0.34 -3 
Vermont 40.55 1 40.20 2 0.35 -1 
Virginia 29.72 29 29.89 30 -0.17 -1 
Washington 35.42 9 34.63 10 0.79 -1 
West Virginia 35.11 11 28.77 34 6.34 -23 
Wisconsin 32.17 22 34.19 11 -2.02 11 
Wyoming - - - - - - 
bKendall’s b 0.71   
a
AD chronic measure scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 43a and Table 
43b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups for the two AD measures (κ=1.00). There was 
modest agreement in classification of the states based on the crude and case-mix adjusted models 
when case-mix adjustment was conducted using both classical logistic regression (AD acute: 
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κ=0.57; AD chronic κ=0.65) and random intercept models (AD acute: κ=0.57; AD chronic 
κ=0.65).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-12. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figures 8a and 8b. Additional choropleth 
maps illustrating the distribution of AD acute and AD chronic crude scores are presented in 
Figure A-10a and A-10b (APPENDIX).  
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Table 43a: Agreement in groups: Crude and case-mix adjusted AD measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
AD Acute Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 5 3 0 5 3 0 
Medium (60%) 3 22 2 3 22 2 
Top (~20%) 0 2 6 0 2 6 
Percentage 
misclassified
a
 
37.5% 18.5% 25% 37.5% 18.5% 25% 
Cohen’s κb  0.57 0.57 
AD Chronic Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 6 2 0 
Medium (60%) 2 23 2 2 23 2 
Top (~20%) 0 2 6 0 2 6 
Percentage 
misclassified
a
 
37.5% 14.8% 25% 37.5% 14.8% 25% 
Cohen’s κb  0.65 0.65 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 43b: Agreement in groups: Case-mix adjusted AD measure scores 
Logistic Regression 
Model 
Hierarchical Logistic Regression Model 
AD Acute AD Chronic 
AD Acute Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 8 0 0 8 0 0 
Medium (60%) 0 27 0 0 27 0 
Top (~20%) 0 0 8 0 0 8 
Cohen’s κa  1.00 1.00 
a
Cohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
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Figure 8a. Interstate variations in AD Acute measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Figure 8b. Interstate variations in AD Chronic measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
   
A 
B 
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Statin use in coronary artery disease patients (CAD) 
The CAD measure was computed for 42 states and the District of Columbia. The number 
of patients eligible for the measure in each state and the proportion of patients who filled at least 
one statin prescription are shown in Table 44. The number of eligible patients with a coronary 
artery disease diagnosis in 2007 ranged from 236 in Utah to 32,568 in New York. The average 
score on the CAD measure was 62.5% across all states, ranging from only 22.0% of Medicaid 
CAD patients being prescribed a statin in Oregon to 75.0% in Vermont. States with scores above 
the national benchmark are highlighted in bold.  
Table 44: Patients meeting the CAD measure criteria by state 
State 
CAD 
#patients in the denominator %patients in the numerator 
Alabama 3,448 62.96 
Alaska - - 
Arizona  3,652 60.51 
Arkansas 1,548 52.97 
California 16,534 61.82 
Colorado 720 63.89 
Connecticut 1,015 72.51 
Delaware 581 66.61 
District of Columbia 591 57.53 
Florida 5,876 62.07 
Georgia 4,335 61.96 
Hawaii 721 49.79 
Idaho 255 68.24 
Illinois  5,890 69.47 
Indiana 2,984 64.81 
Iowa 850 70.12 
Kansas 816 63.24 
Kentucky 6,567 70.03 
Louisiana 3,901 66.55 
Maine - - 
Maryland 2,751 55.47 
Massachusetts 2,750 66.98 
Michigan - - 
Minnesota 988 67.81 
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Table 44: Patients meeting the CAD measure criteria by state (continued) 
State 
CAD 
#patients in the denominator %patients in the numerator 
Mississippi  1,944 52.67 
Missouri 3,369 68.83 
Montana - - 
Nebraska  329 70.82 
Nevada 480 59.38 
New Hampshire 275 69.82 
New Jersey 3,718 59.01 
New Mexico 783 66.92 
New York 27,387 60.19 
North Carolina 5,145 68.59 
North Dakota - - 
Ohio - - 
Oklahoma 2,263 59.13 
Oregon 817 22.03 
Pennsylvania 2,275 64.62 
Rhode Island 596 69.80 
South Carolina 2,503 64.44 
South Dakota - - 
Tennessee 6,376 57.72 
Texas 10,324 57.34 
Utah 236 64.83 
Vermont  372 75.00 
Virginia 2,560 58.83 
Washington 1,964 72.76 
West Virginia  2,885 71.58 
Wisconsin 2,017 71.69 
Wyoming - - 
Total 145,391 62.50 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 45. The mean age (± SD) of the study population was 53 ± 9 
years, and 55% were female. Medicaid beneficiaries with CAD who were prescribed a statin 
were slightly older and had more comorbidity burden than those that did not fill a statin 
prescription. A greater proportion of patients without a statin were Black compared to those with 
a statin medication.  
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Table 45: Characteristics of Medicaid patients eligible for CAD measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Statin Rx No Statin Rx 
Age  52.54 ± 8.63 54.08 ± 7.19 49.97 ± 10.09 
Sex    
 Female 55.05 53.43 57.74 
 Male 44.95 46.57 42.26 
Race    
 White 50.32 52.76 46.24 
 Black 22.07 19.52 26.32 
 Hispanic 13.99 13.65 14.57 
 Other 13.62 14.06 12.87 
RxRisk 7.76 ± 3.58 8.78 ± 3.15 6.06 ± 3.61 
RxRisk (Weighted) 9.95 ± 5.97 10.48 ± 5.79 9.05 ± 6.16 
CCI (Unweighted) 2.11 ± 1.63 2.19 ± 1.62 1.97 ± 1.64 
CCI  3.02 ± 2.52 3.12 ± 2.43 2.86 ± 2.65 
 
The results of the risk-adjusted analyses predicting statin use are presented in Table 46. 
The odds ratio estimates from the classical logistic regression model and the hierarchical logistic 
regression model with a random intercept are comparable. All parameters included in the 
models, including age, sex, race/ethnicity, and RxRisk score were found to be significant 
predictors of statin use. The c-statistic was 0.740 and 0.739 for the classical logistic and 
hierarchical logistic regression models, respectively, showing good discriminative ability for 
both models, compared to the other measures included in the study.  
Race/ethnicity, gender and RxRisk score were found to be strong predictors of statin use 
in both models. Blacks were 24% less likely to fill a statin prescription than Whites. On the 
contrary, Hispanics and other racial groups were slightly more likely to use statins compared to 
Whites. Females were 36% less likely to use statins compared to males. Age was a significant 
predictor, but with modest association with statin use in both models.  
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Table 46: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.06106 (SE: 0.01486). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 781.97 (p<0.0001) indicating the presence of a random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 47. The residual intra class correlation coefficient (ρ) for the random intercept 
model was estimated to be 0.01822 which indicates that 1.82% of the unexplained variation after 
controlling for patient level variables could be attributed to variation between states. State 
variable explained more variation in the CAD measure compared to the adherence and 
persistence measures studied. 
Table 47 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted CAD measure scores ranged from 35.47% to 73.49%, a decrease in range 
compared to the crude estimates. Case-mix adjustment ranked the states differently with 86% 
(37) changing more than two positions. There was modest agreement in rankings based on the 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  1.045 1.046 
Sex 
  
 Female vs. Male 0.633 0.644 
Race 
  
 Black vs. White 0.767 0.758 
 Hispanic vs. White 1.048 1.018 
 Other vs. White 1.086 1.028 
RxRisk 1.279 1.281 
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crude scores and case-mix adjusted scores based on the hierarchical logistic regression model 
with a random intercept (Kendall’s b=0.55). 
Table 47: Agreement in ranks: Crude and case-mix adjusted CAD measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 62.96 26 60.06 33 2.91 -7 
Alaska - - - - - - 
Arizona 60.51 30 62.84 25 -2.33 5 
Arkansas 52.97 40 59.22 35 -6.24 5 
California 61.82 29 65.14 15 -3.31 14 
Colorado 63.89 24 63.14 23 0.75 1 
Connecticut 72.51 3 67.01 8 5.50 -5 
Delaware 66.61 18 68.89 5 -2.28 13 
District of Columbia 57.53 37 62.13 29 -4.60 8 
Florida 62.07 27 57.94 41 4.13 -14 
Georgia 61.96 28 60.16 32 1.80 -4 
Hawaii 49.79 42 58.49 40 -8.69 2 
Idaho 68.24 14 63.04 24 5.20 -10 
Illinois 69.47 11 69.45 3 0.03 8 
Indiana 64.81 21 62.33 28 2.48 -7 
Iowa 70.12 7 66.46 12 3.66 -5 
Kansas 63.24 25 60.00 34 3.23 -9 
Kentucky 70.03 8 63.33 21 6.71 -13 
Louisiana 66.55 19 64.13 19 2.42 0 
Maine - - - - - - 
Maryland 55.47 39 58.86 37 -3.39 2 
Massachusetts 66.98 16 67.46 6 -0.48 10 
Michigan - - - - - - 
Minnesota 67.81 15 66.67 9 1.15 6 
Mississippi 52.67 41 60.54 31 -7.86 10 
Missouri 68.83 12 66.48 11 2.36 1 
Montana - - - - - - 
Nebraska 70.82 6 64.41 17 6.41 -11 
Nevada 59.38 32 55.82 42 3.56 -10 
New Hampshire 69.82 9 64.69 16 5.13 -7 
New Jersey 59.01 34 62.79 26 -3.78 8 
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Table 47: Agreement in ranks: Crude and case-mix adjusted CAD measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
New Mexico 66.92 17 62.33 27 4.59 -10 
New York 60.19 31 67.04 7 -6.85 24 
North Carolina 68.59 13 64.25 18 4.34 -5 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 59.13 33 58.70 39 0.43 -6 
Oregon 22.03 43 35.47 43 -13.44 0 
Pennsylvania 64.62 22 64.07 20 0.55 2 
Rhode Island 69.80 10 73.38 2 -3.58 8 
South Carolina 64.44 23 66.59 10 -2.15 13 
South Dakota - - - - - - 
Tennessee 57.72 36 61.68 30 -3.97 6 
Texas 57.34 38 59.17 36 -1.83 2 
Utah 64.83 20 65.81 14 -0.98 6 
Vermont 75.00 1 73.49 1 1.51 0 
Virginia 58.83 35 58.76 38 0.07 -3 
Washington 72.76 2 65.90 13 6.86 -11 
West Virginia 71.58 5 63.22 22 8.36 -17 
Wisconsin 71.69 4 69.28 4 2.41 0 
Wyoming - - - - - - 
bKendall’s b 0.55   
a
CAD measure scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 48a and Table 
48b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was poor agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
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adjustment was conducted using both classical logistic regression (κ=0.22) and random intercept 
models (κ=0.22).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in APPENDIX Table A-13. Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 9. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in APPENDIX Figure A-11.  
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Table 48a: Agreement in groups: Crude and case-mix adjusted CAD measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 4 4 0 4 4 0 
Medium (60%) 4 18 5 4 18 5 
Top (~20%) 0 5 3 0 5 3 
Percentage 
misclassified
a
 
50.0% 33.3% 62.5% 50.0% 33.3% 62.5% 
Cohen’s κb  0.22 0.22 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 48b: Agreement in groups: Case-mix adjusted CAD measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 9. Interstate variations in CAD measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Inhaled corticosteroid use in asthma patients (ICS) 
The ICS measure was computed for 42 states and the District of Columbia. The number 
of patients eligible for the measure in each state and the proportion of patients who filled an 
inhaled corticosteroid or similar medication are shown in Table 49. The number of patients in the 
denominator ranged from 608 in District of Columbia to 50,517 in New York. The average ICS 
score across all states was 68.1%, ranging from 57.0% of Medicaid patients filling an inhaled 
corticosteroid or similar medication prescription in Tennessee to 75.4% in Delaware. States with 
scores above the national benchmark are highlighted in bold.  
Table 49: Patients meeting the ICS measure criteria by state 
State 
ICS 
#patients in the denominator %patients in the numerator 
Alabama 4,523 69.18 
Alaska - - 
Arizona  7,279 62.01 
Arkansas 2,414 62.39 
California 30,512 70.71 
Colorado 2,000 61.35 
Connecticut 1,658 74.61 
Delaware 1,536 75.39 
District of Columbia 608 67.60 
Florida 8,043 70.87 
Georgia 4,071 62.74 
Hawaii 939 65.71 
Idaho 878 61.50 
Illinois  15,308 70.73 
Indiana 4,511 59.17 
Iowa 2,825 67.26 
Kansas 1,597 64.50 
Kentucky 8,267 61.32 
Louisiana 4,305 68.97 
Maine - - 
Maryland 4,795 65.07 
Massachusetts 7,716 62.69 
Michigan - - 
Minnesota 4,970 66.88 
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Table 49: Patients meeting the ICS measure criteria by state (continued) 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 50. The majority of the study population was comprised of 
women (76%) and the mean age (± SD) was 38 ± 12 years, younger than the population eligible 
for other measures being studied. Approximately 50% of the study population was White, with a 
greater proportion of Blacks and Hispanics being prescribed an inhaled corticosteroid or similar 
medications compared to Whites. This trend was in contrary to the race/ethnicity effect seen in 
State 
ICS 
#patients in the denominator %patients in the numerator 
Mississippi  2,333 70.90 
Missouri 6,701 65.87 
Montana - - 
Nebraska  1,243 73.61 
Nevada 748 64.71 
New Hampshire 936 67.52 
New Jersey 7,261 73.43 
New Mexico 2,388 61.89 
New York 50,517 72.50 
North Carolina 9,268 70.30 
North Dakota - - 
Ohio - - 
Oklahoma 3,174 65.00 
Oregon 887 65.73 
Pennsylvania 4,588 69.31 
Rhode Island 1,812 70.42 
South Carolina 3,098 66.24 
South Dakota - - 
Tennessee 12,424 56.99 
Texas 8,411 74.71 
Utah 1,146 66.58 
Vermont  1,628 70.52 
Virginia 5,103 67.88 
Washington 7,018 60.06 
West Virginia  3,575 67.22 
Wisconsin 9,029 66.90 
Wyoming - - 
Total 262,043 68.12 
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case of other measures being studied. Age, gender and comorbidity burden of patients included 
in the numerator for the ICS measure were similar to those not included in the numerator. 
Table 50: Characteristics of Medicaid patients eligible for ICS measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall ICS Rx No ICS Rx 
Age  37.55 ± 11.62 37.63 ± 11.68 37.36 ± 11.49 
Sex    
 Female 76.02 76.66 74.65 
 Male 23.98 23.34 25.35 
Race    
 White 50.59 48.87 54.27 
 Black 24.74 25.04 24.10 
 Hispanic 15.46 16.38 13.50 
 Other 9.21 9.71 8.14 
RxRisk 5.55 ± 3.04 5.63 ± 3.10 5.39 ± 2.91 
RxRisk (Weighted) 10.21 ± 4.46 10.25 ± 4.56 10.13 ± 4.23 
CCI (Unweighted) 0.98 ± 0.99 1.05 ± 0.98 0.84 ± 0.98 
CCI  1.30 ± 1.56 1.36 ± 1.55 1.17 ± 1.58 
*ICS – Inhaled corticosteroid or similar medications 
The results of the risk-adjusted analyses predicting inhaled corticosteroid medication use 
are presented in Table 51. All parameters included in the models, including age, sex, 
race/ethnicity, and RxRisk score were found to be significant predictors at P<0.0001 level. 
However, the c-statistic was 0.545 and 0.541 for the classical logistic and hierarchical logistic 
regression models, showing weak discriminative ability for both models. Therefore, crude 
estimates could be used to describe the ICS measure. Ranks and groups based on case-mix 
adjusted scores are expected to be similar to those based on crude estimates for the ICS measure. 
However, for uniformity in presentation of data, the case-mix adjusted estimates will be 
described for this measure. 
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The odds ratio estimates for age and RxRisk variables from the classical logistic 
regression model and the hierarchical logistic regression model with a random intercept were 
similar. The effect of gender on ICS use was different in the two models, with classical logistic 
regression estimate indicating that females were 9% more likely to use inhaled corticosteroid or 
similar medications to manage their persistent asthma compared to males. Contrarily, females 
were found to be 11% less likely to use ICS than males using the hierarchical logistic regression 
model with a random intercept. Black, Hispanic and other racial groups were observed to be 
more likely to use ICS or similar medications compared to white in the two models.  
Table 51: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.04055 (SE: 0.009211). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 2152.62 (p<0.0001) indicating the presence of random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 52. The residual intra class correlation coefficient (ρ) for the random intercept 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  0.998 0.997 
Sex 
  
 Female vs. Male 1.091 0.890 
Race 
  
 Black vs. White 1.175 1.070 
 Hispanic vs. White 1.381 1.178 
 Other vs. White 1.354 1.311 
RxRisk 1.032 1.036 
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model was estimated to be 0.01218 which indicates that 1.22% of the unexplained variation after 
controlling for patient level variables could be attributed to variation between states.   
Table 52 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted ICS measure scores ranged from 40.46% to 65.43%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 32% (14) states 
ranked the same and 37% (16) changing more than two positions. There was close to perfect 
agreement in rankings based on the crude scores and case-mix adjusted scores based on the 
hierarchical logistic regression model with a random intercept (Kendall’s b=0.93). 
Table 52: Agreement in ranks: Crude and case-mix adjusted ICS measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 69.18 15 68.70 15 0.48 0 
Alaska - - - - - - 
Arizona 62.01 36 62.10 36 -0.09 0 
Arkansas 62.39 35 63.11 33 -0.73 2 
California 70.71 10 70.38 10 0.33 0 
Colorado 61.35 39 59.37 41 1.98 -2 
Connecticut 74.61 3 73.11 4 1.49 -1 
Delaware 75.39 1 75.57 1 -0.18 0 
District of Columbia 67.60 18 67.15 22 0.45 -4 
Florida 70.87 8 69.75 13 1.12 -5 
Georgia 62.74 33 62.30 35 0.44 -2 
Hawaii 65.71 28 64.10 32 1.60 -4 
Idaho 61.50 38 61.98 37 -0.48 1 
Illinois 70.73 9 70.80 9 -0.06 0 
Indiana 59.17 42 59.33 42 -0.17 0 
Iowa 67.26 20 67.13 23 0.13 -3 
Kansas 64.50 32 64.58 31 -0.08 1 
Kentucky 61.32 40 61.04 38 0.28 2 
Louisiana 68.97 16 68.50 16 0.47 0 
Maine - - - - - - 
Maryland 65.07 29 65.36 28 -0.29 1 
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Table 52: Agreement in ranks: Crude and case-mix adjusted ICS measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Massachusetts 62.69 34 63.04 34 -0.35 0 
Michigan - - - - - - 
Minnesota 66.88 23 67.20 21 -0.32 2 
Mississippi 70.90 7 71.31 7 -0.41 0 
Missouri 65.87 26 66.09 25 -0.22 1 
Montana - - - - - - 
Nebraska 73.61 4 73.75 3 -0.14 1 
Nevada 64.71 31 64.62 30 0.08 1 
New Hampshire 67.52 19 68.12 17 -0.60 2 
New Jersey 73.43 5 73.06 5 0.37 0 
New Mexico 61.89 37 60.60 39 1.29 -2 
New York 72.50 6 72.03 6 0.47 0 
North Carolina 70.30 13 69.68 14 0.61 -1 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 65.00 30 65.23 29 -0.23 1 
Oregon 65.73 27 65.95 27 -0.22 0 
Pennsylvania 69.31 14 70.05 12 -0.74 2 
Rhode Island 70.42 12 70.18 11 0.24 1 
South Carolina 66.24 25 66.35 24 -0.11 1 
South Dakota - - - - - - 
Tennessee 56.99 43 57.55 43 -0.55 0 
Texas 74.71 2 74.14 2 0.57 0 
Utah 66.58 24 67.23 20 -0.65 4 
Vermont 70.52 11 71.18 8 -0.66 3 
Virginia 67.88 17 67.81 18 0.07 -1 
Washington 60.06 41 59.99 40 0.07 1 
West Virginia 67.22 21 67.49 19 -0.28 2 
Wisconsin 66.90 22 65.97 26 0.92 -4 
Wyoming - - - - - - 
bKendall’s b 0.93   
a
ICS measure scores could be generated for 43 states. Rankings ranged from 1-43
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
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Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 53a and Table 
53b. Results based on the two risk adjustment models showed close to perfect agreement in 
classification of states into top, medium and bottom groups (κ=0.91). There was good agreement 
in classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.83) and random intercept 
models (κ=0.91).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in Table A-14 (APPENDIX). Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the 
hierarchical logistic regression model are depicted in Figure 10. Additional choropleth maps 
illustrating the distribution of crude adherence scores are presented in Figure A-12 
(APPENDIX).  
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Table 53a: Agreement in groups: Crude and case-mix adjusted ICS measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 7 1 0 8 0 0 
Medium (60%) 1 25 1 0 26 1 
Top (~20%) 0 1 7 0 1 7 
Percentage 
misclassified
a
 
12.5% 7.4% 12.5% 0% 3.7% 12.5% 
Cohen’s κb  0.83 0.91 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 53b: Agreement in groups: Case-mix adjusted ICS measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 7 1 0 
Medium  1 26 0 
Top 0 0 8 
Percentage misclassified
a
 12.5% 3.7% 0% 
Cohen’s κb  0.91 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement 
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Figure 10. Interstate variations in ICS measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Beta-blocker use in myocardial infarction patients (MI1) 
The MI1 measure assessing the proportion of patients with an acute myocardial infarction 
who filled a beta-blocker prescription within 30 days of discharge from the hospital could be 
computed for 35 states and the District of Columbia. The number of patients eligible for the 
measure in each state and the proportion of patients who filled a beta-blocker prescription are 
shown in Table 54. The number of patients in the denominator ranged from 33 patients in New 
Mexico to 967 in California. The average MI1 measure score across all states was 49.0% across 
all states, ranging from 19.7% in Oregon to 66.7% in Wisconsin. States with scores above the 
national benchmark are highlighted in bold.  
Table 54: Patients meeting the MI1 measure criteria by state 
State 
MI1 
#patients in the denominator %patients in the numerator 
Alabama 184 63.04 
Alaska - - 
Arizona  281 58.72 
Arkansas 91 40.66 
California 967 47.57 
Colorado 54 62.96 
Connecticut 57 54.39 
Delaware - - 
District of Columbia 55 49.09 
Florida 414 51.45 
Georgia 276 57.97 
Hawaii 71 54.93 
Idaho - - 
Illinois  474 50.63 
Indiana 214 38.79 
Iowa 82 26.83 
Kansas 55 45.45 
Kentucky 325 65.23 
Louisiana 246 57.72 
Maine - - 
Maryland 134 42.54 
Massachusetts 180 68.33 
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Table 54: Patients meeting the MI1 measure criteria by state (continued) 
State 
MI1 
#patients in the denominator %patients in the numerator 
Michigan - - 
Minnesota 88 59.09 
Mississippi  137 37.96 
Missouri 243 50.21 
Montana - - 
Nebraska  - - 
Nevada 34 32.35 
New Hampshire - - 
New Jersey 141 58.87 
New Mexico 33 60.61 
New York 826 32.32 
North Carolina 430 53.26 
North Dakota - - 
Ohio - - 
Oklahoma 149 44.97 
Oregon 71 19.72 
Pennsylvania 212 42.92 
Rhode Island - - 
South Carolina 182 50.55 
South Dakota - - 
Tennessee 289 56.40 
Texas 667 34.03 
Utah - - 
Vermont  - - 
Virginia 133 52.63 
Washington 154 61.69 
West Virginia  200 63.50 
Wisconsin 144 66.67 
Wyoming - - 
Total 8,293 49.01 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 55. The majority of the study population was comprised of 
Whites (52%) and the mean age (± SD) was 53 ± 8 years. A greater proportion of the study 
population is males compared to the other medication-related measures included in the study. A 
greater proportion of the patients who did not fill a beta-blocker prescription were females, and 
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Hispanic compared to those who filled the beta-blocker prescription post discharge. The mean 
RxRisk scores were slightly higher in the MI patients who filled a beta-blocker prescription. CCI 
weighted and unweighted indices were similar across the two groups. 
Table 55: Characteristics of Medicaid patients eligible for MI1 measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Beta-blocker Rx No Beta-blocker Rx 
Age  52.65 ± 8.46 52.42 ± 8.34 52.87 ± 8.57 
Sex    
 Female 48.52 50.02 47.08 
 Male 51.48 49.98 52.92 
Race    
 White 51.69 52.98 50.46 
 Black 24.66 24.53 24.78 
 Hispanic 12.01 10.26 13.69 
 Other 11.64 12.23 11.07 
RxRisk 9.33 ± 4.09 10.39 ± 3.39 8.32 ± 4.43 
RxRisk (Weighted) 12.76 ± 7.03 13.82 ± 6.30 11.75 ± 7.53 
CCI (Unweighted) 2.49 ± 1.95 2.47 ± 1.92 2.50 ± 1.97 
CCI  3.54 ± 2.98 3.48 ± 2.89 3.60 ± 3.07 
 
The results of the risk-adjusted analyses predicting beta-blocker use post MI discharge 
are presented in Table 56. All parameters included in the models, including age, sex, 
race/ethnicity, and RxRisk score were found to be significant predictors of the TZD adherence 
measure. The c-statistic was 0.646 and 0.645 for the classical logistic and hierarchical logistic 
regression models respectively, showing modest discriminative ability for both models. The odds 
ratio estimates for age, gender and RxRisk variables from the classical logistic regression model 
and the hierarchical logistic regression model with a random intercept were similar. 
 137 
 
Female gender and Hispanic ethnicity were less likely to use beta-blockers post MI in 
both models. The effect of other two races on beta-blocker use was reversed in the two models 
with Blacks and other races being more (less) likely to be filling a beta-blocker within 30 days of 
discharge compared to whites in the classical (hierarchical) logistic regression models. An 
increase in RxRisk index by 1 was shown to increase the likelihood of beta-blocker use by 
approximately 15% in the two models. Age was a significant predictor, but with modest 
association with beta-blocker use.  
Table 56: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.0001 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.1523 (SE: 0.04533). Testing the null hypothesis of no 
random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 180.61 (p<0.0001) indicating the presence of random effect. Therefore, case-mix 
adjusted scores based on hierarchical logistic regression model with a random intercept are 
presented in Table 57. The residual intra class correlation coefficient (ρ) for the random intercept 
model was estimated to be 0.04424 which indicates that 4.42% of the unexplained variation after 
Baseline Characteristics  
Classical Logistic Regression 
Model* 
Hierarchical Logistic Regression 
Random Intercept Model* 
Point Estimate Point Estimate 
Age  0.985 0.986 
Sex 
  
 Female vs. Male 0.853 0.848 
Race 
  
 Black vs. White 1.014 0.984 
 Hispanic vs. White 0.819 0.885 
 Other vs. White 1.185 0.908 
RxRisk 1.151 1.145 
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controlling for patient level variables could be attributed to variation between states.  State level 
explained more variation in MI1 measure compared to all other measures being studied. 
Table 57 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted MI1 measure scores ranged from 25.49% to 68.44%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 14% (5) states 
ranked the same, 28% (10) states changing one position and 58% (21) changing more than two 
positions. There was good agreement in rankings based on the crude scores and case-mix 
adjusted scores based on the hierarchical logistic regression model with a random intercept 
(Kendall’s b=0.84). 
Table 57: Agreement in ranks: Crude and case-mix adjusted MI1 measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 63.04 5 59.35 7 3.69 -2 
Alaska - - - - - - 
Arizona 58.72 11 60.72 4 -2.01 7 
Arkansas 40.66 29 42.39 29 -1.73 0 
California 47.57 24 50.55 21 -2.98 3 
Colorado 62.96 6 64.15 2 -1.18 4 
Connecticut 54.39 16 50.66 20 3.73 -4 
Delaware - - - - - - 
District of Columbia 49.09 23 52.86 16 -3.77 7 
Florida 51.45 19 52.01 17 -0.56 2 
Georgia 57.97 12 55.96 12 2.01 0 
Hawaii 54.93 15 57.72 10 -2.79 5 
Idaho - - - - - - 
Illinois 50.63 20 49.49 22 1.14 -2 
Indiana 38.79 30 36.52 31 2.27 -1 
Iowa 26.83 35 25.49 36 1.34 -1 
Kansas 45.45 25 42.63 28 2.82 -3 
Kentucky 65.23 3 58.74 8 6.49 -5 
Louisiana 57.72 13 54.82 15 2.90 -2 
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Table 57: Agreement in ranks: Crude and case-mix adjusted MI1 measure scores
a
 (cont.) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Maine - - - - - - 
Maryland 42.54 28 43.85 27 -1.32 1 
Massachusetts 68.33 1 68.44 1 -0.10 0 
Michigan - - - - - - 
Minnesota 59.09 9 56.91 11 2.18 -2 
Mississippi 37.96 31 41.23 30 -3.28 1 
Missouri 50.21 22 48.15 25 2.06 -3 
Montana - - - - - - 
Nebraska - - - - - - 
Nevada 32.35 33 33.92 34 -1.57 -1 
New Hampshire - - - - - - 
New Jersey 58.87 10 55.14 14 3.73 -4 
New Mexico 60.61 8 58.33 9 2.28 -1 
New York 32.32 34 34.61 33 -2.28 1 
North Carolina 53.26 17 50.69 19 2.57 -2 
North Dakota - - - - - - 
Ohio - - - - - - 
Oklahoma 44.97 26 44.49 26 0.48 0 
Oregon 19.72 36 28.06 35 -8.34 1 
Pennsylvania 42.92 27 48.69 24 -5.76 3 
Rhode Island - - - - - - 
South Carolina 50.55 21 51.37 18 -0.82 3 
South Dakota - - - - - - 
Tennessee 56.40 14 55.95 13 0.45 1 
Texas 34.03 32 36.24 32 -2.20 0 
Utah - - - - - - 
Vermont - - - - - - 
Virginia 52.63 18 49.03 23 3.60 -5 
Washington 61.69 7 60.19 5 1.50 2 
West Virginia 63.50 4 59.66 6 3.84 -2 
Wisconsin 66.67 2 62.35 3 4.31 -1 
Wyoming - - - - - - 
bKendall’s b 0.84   
a
MI1 measure scores could be generated for 36 states. Rankings ranged from 1-36
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
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Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 58a and Table 
58b. Results based on the two risk adjustment models showed close to perfect agreement in 
classification of states into top, medium and bottom groups (κ=0.90). There was good agreement 
in classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.80) and random intercept 
models (κ=0.90).  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. The results of agreement in classification 
based on this methodology are included in Table A-15 (APPENDIX). Choropleth maps depicting 
the top, medium and bottom performing states based on the crude and case-mix adjustment 
scores estimated from the hierarchical logistic regression model are depicted in Figure 11. 
Additional choropleth maps illustrating the distribution of crude adherence scores are presented 
in Figure A-13 (APPENDIX).  
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Table 58a: Agreement in groups: Crude and case-mix adjusted MI1 measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 7 0 0 7 0 0 
Medium (60%) 0 20 2 0 21 1 
Top (~20%) 0 2 5 0 1 6 
Percentage 
misclassified
a
 
0% 9.1% 28.6% 0% 4.5% 14.2% 
Cohen’s κb  0.80 0.90 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
b
Cohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 58b: Agreement in groups: Case-mix adjusted MI1 measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 7 0 0 
Medium  0 21 1 
Top 0 1 6 
Percentage misclassified
a
 0% 4.5% 14.2% 
Cohen’s κb  0.90 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement. 
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Figure 11. Interstate variations in MI1 measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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Persistence with beta-blockers in myocardial infarction patients (MI) 
The MI measure assessing the proportion of patients persistent with beta-blockers after an 
acute myocardial infarction could be computed for 30 states. The number of patients eligible for 
the measure in each state and the proportion of patients persistent with beta-blocker therapy are 
shown in Table 59. The number of patients in the denominator ranged from 31 in Connecticut to 
460 in California. The average MI score across all states was 58.9%, ranging from 40.5% of 
Medicaid patients being persistent with beta-blocker therapy in Arkansas to 71.1% in Indiana. 
States with scores above the national benchmark are highlighted in bold.  
Table 59: Patients meeting the MI measure criteria by state 
State 
MI 
#patients in the denominator %patients in the numerator 
Alabama 116 63.79 
Alaska - - 
Arizona  165 58.18 
Arkansas 37 40.54 
California 460 65.87 
Colorado 34 50.00 
Connecticut 31 64.52 
Delaware - - 
District of Columbia - - 
Florida 213 60.56 
Georgia 160 53.13 
Hawaii 39 43.59 
Idaho - - 
Illinois  240 62.08 
Indiana 83 71.08 
Iowa - - 
Kansas - - 
Kentucky 212 58.02 
Louisiana 142 52.11 
Maine - - 
Maryland 57 50.88 
Massachusetts 123 56.91 
Michigan - - 
Minnesota 52 63.46 
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Table 59: Patients meeting the MI measure criteria by state (continued) 
State 
MI 
#patients in the denominator %patients in the numerator 
Mississippi  52 50.00 
Missouri 122 56.56 
Montana - - 
Nebraska  - - 
Nevada - - 
New Hampshire - - 
New Jersey 83 55.42 
New Mexico - - 
New York 267 65.92 
North Carolina 229 53.71 
North Dakota - - 
Ohio - - 
Oklahoma 67 50.75 
Oregon - - 
Pennsylvania 91 57.14 
Rhode Island - - 
South Carolina 92 41.30 
South Dakota - - 
Tennessee 163 53.99 
Texas 227 56.39 
Utah - - 
Vermont  - - 
Virginia 70 58.57 
Washington 95 66.32 
West Virginia  127 67.72 
Wisconsin 96 64.58 
Wyoming - - 
Total 3,945 58.94 
 
Demographic characteristics and co-morbidity measures for the eligible patient 
population are described in Table 60. The mean age (± SD) of the study population was 52 ± 8 
years and approximately 50% were females. The majority of the patients included in the MI 
measure was white (53%) followed by Black (24%), other races (12%) and Hispanic (10%). 
Non-persistent patients were slightly younger, and a greater proportion of non-persistent patients 
were male and Black compared to persistent patients. The mean comorbidity scores were slightly 
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higher in the persistent group compared to Medicaid beneficiaries’ non-persistent with beta-
blocker therapy post AMI. 
Table 60: Characteristics of Medicaid patients eligible for MI measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Persistent Non-persistent 
Age  52.41 ± 8.35 53.01 ± 7.99 51.56 ± 8.77 
Sex    
 Female 49.94 51.91 47.10 
 Male 50.06 48.09 52.90 
Race    
 White 53.21 55.27 50.25 
 Black 24.23 21.68 27.90 
 Hispanic 10.34 10.49 10.12 
 Other 12.22 12.56 11.73 
RxRisk 10.38 ± 3.39 10.75 ± 3.33 9.84 ± 3.40 
RxRisk (Weighted) 13.81 ± 6.29 14.25 ± 6.30 13.17 ± 6.23 
CCI (Unweighted) 2.47 ± 1.92 2.57 ± 1.89 2.33 ± 1.95 
CCI  3.47 ± 2.89 3.61 ± 2.84 3.28 ± 2.95 
The results of the risk-adjusted analyses predicting persistence with beta-blocker therapy 
in post-MI Medicaid patients are presented in Table 61. Age and RxRisk were significant 
predictors of persistence with beta-blocker therapy in both models. The odds ratio estimates for 
these two variables from the classical logistic regression model and the hierarchical logistic 
regression model with a random intercept were found to be similar. Black race was a significant 
predictor of beta-blocker persistence in the classical logistic regression models, and it was 
marginally significant (p=0.054) in the hierarchical logistic regression model. Also, the c-statistic 
was 0.589 and 0.590 for the classical logistic and hierarchical logistic regression models 
respectively, showing weak discriminative ability for both models.  
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Table 61: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.001; **marginally significant p=0.054 
In the hierarchical logistic regression model with a random-intercept, the state-level 
variance component was estimated to be 0.03971 (SE: 0.01987). Testing the null hypothesis of 
no random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 15.14 (p<0.0001) indicating the presence of random effect. Case-mix adjusted scores 
based on hierarchical logistic regression model with a random intercept are presented in Table 
62. The residual intra class correlation coefficient (ρ) for the random intercept model was 
estimated to be 0.01193 which indicates that 1.19% of the unexplained variation after controlling 
for patient level variables could be attributed to variation between states.   
Table 62 shows the agreement between the crude and case-mix adjusted scores. The case-
mix adjusted MI measure scores ranged from 42.05% to 66.38%, a decrease in range compared 
to the crude estimates. Case-mix adjustment ranked the states differently with 33% (10) states 
changing one position and 57% (17) changing more than two positions. There was good 
agreement in rankings based on the crude scores and case-mix adjusted scores based on the 
hierarchical logistic regression model with a random intercept (Kendall’s b=0.82). 
Baseline Characteristics  
Classical Logistic Regression 
Model 
Hierarchical Logistic Regression 
Random Intercept Model 
Point Estimate Point Estimate 
Age  1.017* 1.017* 
Sex 
  
 Female vs. Male 1.095 0.890 
Race 
  
 Black vs. White 0.744* 0.792** 
 Hispanic vs. White 0.997 0.929 
 Other vs. White 0.972 1.054 
RxRisk 1.073* 1.075* 
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Table 62: Agreement in ranks: Crude and case-mix adjusted MI measure scores
a
 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
Alabama 63.79 8 62.30 9 1.49 -1 
Alaska - - - - - - 
Arizona 58.18 13 57.90 12 0.28 1 
Arkansas 40.54 30 43.18 28 -2.64 2 
California 65.87 5 66.31 2 -0.44 3 
Colorado 50.00 26 48.48 27 1.52 -1 
Connecticut 64.52 7 60.97 10 3.54 -3 
Delaware - - - - - - 
District of Columbia - - - - - - 
Florida 60.56 11 59.54 11 1.02 0 
Georgia 53.13 22 51.78 24 1.34 -2 
Hawaii 43.59 28 42.76 29 0.83 -1 
Idaho - - - - - - 
Illinois 62.08 10 62.71 8 -0.62 2 
Indiana 71.08 1 66.38 1 4.70 0 
Iowa - - - - - - 
Kansas - - - - - - 
Kentucky 58.02 14 53.86 19 4.16 -5 
Louisiana 52.11 23 50.76 25 1.35 -2 
Maine - - - - - - 
Maryland 50.88 24 53.00 23 -2.12 1 
Massachusetts 56.91 16 56.73 14 0.18 2 
Michigan - - - - - - 
Minnesota 63.46 9 62.89 7 0.57 2 
Mississippi 50.00 26 53.92 18 -3.92 8 
Missouri 56.56 17 54.62 16 1.93 1 
Montana - - - - - - 
Nebraska - - - - - - 
Nevada - - - - - - 
New Hampshire - - - - - - 
New Jersey 55.42 19 53.42 21 2.00 -2 
New Mexico - - - - - - 
New York 65.92 4 65.75 3 0.17 1 
North Carolina 53.71 21 53.21 22 0.50 -1 
North Dakota - - - - - - 
 148 
 
Table 62: Agreement in ranks: Crude and case-mix adjusted MI measure scores
a
 
(continued) 
State 
Unadjusted Estimates 
Case-Mix Adjusted 
Estimates Score 
difference 
Rank 
difference 
Score (%) Rank Score (%) Rank 
 
Ohio - - - - - - 
Oklahoma 50.75 25 49.93 26 0.81 -1 
Oregon - - - - - - 
Pennsylvania 57.14 15 54.44 17 2.70 -2 
Rhode Island - - - - - - 
South Carolina 41.30 29 42.05 30 -0.75 -1 
South Dakota - - - - - - 
Tennessee 53.99 20 53.61 20 0.38 0 
Texas 56.39 18 57.37 13 -0.98 5 
Utah - - - - - - 
Vermont - - - - - - 
Virginia 58.57 12 56.00 15 2.57 -3 
Washington 66.32 3 63.81 5 2.50 -2 
West Virginia 67.72 2 63.01 6 4.71 -4 
Wisconsin 64.58 6 64.52 4 0.07 2 
Wyoming - - - - - - 
bKendall’s b 0.82   
a
MI measure scores could be generated for 30 states. Rankings ranged from 1-30
 
b
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores 
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 63a and Table 
63b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was good agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
adjustment was conducted using both classical logistic regression (κ=0.88) and random intercept 
models (κ=0.88).  
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An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. The results of agreement in classification 
based on this methodology are included in Table A-16 (APPENDIX). Choropleth maps depicting 
the top, medium and bottom performing states based on the crude and case-mix adjustment 
scores estimated from the hierarchical logistic regression model are depicted in Figure 12. 
Additional choropleth maps illustrating the distribution of crude adherence scores are presented 
in Figure A-14 (APPENDIX).  
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Table 63a: Agreement in groups: Crude and case-mix adjusted MI measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 5 1 0 5 1 0 
Medium (60%) 1 17 0 1 17 0 
Top (~20%) 0 0 6 0 0 6 
Percentage 
misclassified
a
 
16.7% 5.5% 0% 16.7% 5.5% 0% 
Cohen’s κb  0.88 0.88 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 63b: Agreement in groups: Case-mix adjusted MI measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Hierarchical Logistic Regression Model 
Logistic Regression Model Bottom Medium Top 
Bottom 6 0 0 
Medium  0 18 0 
Top 0 0 6 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on 
hierarchical logistic regression model as the correct classification. 
bCohen’s Kappa coefficient is a measure of 
agreement between unadjusted performance ratings and ratings based on the risk adjustment method with higher 
values indicating greater agreement. 
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Figure 12. Interstate variations in MI measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
 152 
 
Composite Measure 
A composite measure of medication use-related quality was computed for 42 states and 
the District of Columbia. Demographic characteristics and co-morbidity measures for the 
1,536,753 eligible patients are described in Table 64. The majority of the study population was 
comprised of women (68%) and the mean age (± SD) was 46.18 ± 11.94 years. Patients who did 
not receive good quality of care on any of the medication use-related quality measures were 
younger, had less comorbidity burden and a greater proportion were female, and of Black, 
Hispanic race/ethnicity compared to those receiving good quality care.  
Table 64: Characteristics of Medicaid patients eligible for the composite measure 
Patient 
Characteristics 
Prevalence(%) or Mean ± SD 
Overall Good Quality* Poor Quality** 
Age  46.18 ± 11.94 47.78 ± 11.62 43.92 ± 12.01 
Sex    
 Female 68.01 66.65 69.93 
 Male 31.99 33.35 30.07 
Race    
 White 45.06 47.84 41.12 
 Black 25.03 22.84 28.15 
 Hispanic 16.77 15.60 18.42 
 Other 13.14 13.72 12.31 
RxRisk 5.95 ± 3.00 6.46 ± 3.10 5.23 ± 2.71 
RxRisk (Weighted) 7.87 ± 5.12 8.50 ± 5.24 6.99 ± 4.82 
CCI (Unweighted) 1.0 ± 1.14 1.13 ± 1.18 0.81 ± 1.05 
CCI  1.56 ± 1.87 1.75 ± 1.91 1.30 ± 1.77 
*Good quality of care is patients qualifying for at least one of the 11 study measures (meeting the adherence 
threshold for the PDC measures, being persistent for the MI, AD measures and filling a recommended prescription 
for the CAD and ICS measures). **Poor Quality is patients not qualifying for the numerator for any of the 11 
measures included in the study. 
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The results of the risk-adjusted analyses predicting good quality of care accounting for 
patient case-mix and opportunity mix are presented in Table 65. Two hierarchical logistic 
regression models were explored, with and without accounting for nesting of observations within 
patients. In the two-level model not accounting for observations nested within patients, age, sex, 
race/ethnicity and RxRisk score were found to be significant predictors of medication utilization. 
To account for observations nested within patients and patients nested within states, a 
three-level hierarchical logistic regression model with patient and state levels modeled as random 
intercepts (G-side random effects) was explored. However, the model did not converge. 
Therefore, the patient level was modeled as a residual random effect (patient as R-side random 
effects) and the state level as a G-side random effect. All case-mix and opportunity mix variables 
were significant predictors of medication utilization behavior. Race/ethnicity was a strong 
predictor of medication use in both models, with Blacks and Females being associated with 
significantly lesser odds of receiving good quality of care compared to Whites and males, 
respectively. Hispanics were nearly 35% less likely to receive good quality of care compared to 
Whites in both models. The c-statistic was 0.637 and 0.635 for the two-level and three-level 
hierarchical logistic regression models respectively, showing modest discriminative ability for 
both models. 
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Table 65: Odds ratio estimates of patient characteristics in the risk adjustment models 
*significant at p < 0.001 
In the two-level hierarchical logistic regression model, the state-level variance 
component was estimated to be 0.02685 (SE: 0.005910). Testing the null hypothesis of no 
random effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-
square of 11689.9 (p<0.0001) indicating the presence of random effect. The residual intra class 
correlation coefficient (ρ) for the random intercept model was estimated to be 0.00810 which 
indicates that 0.81% of the unexplained variation after controlling for patient case-mix variables 
and opportunity mix could be attributed to variation between states.   
Baseline Characteristics  
Hierarchical Logistic Regression Models 
Two-level Three-level 
Point Estimate Point Estimate* 
Age  1.025* 1.023 
Sex 
  
 Female vs. Male 0.861* 0.866 
Race 
  
 White vs. Other 1.084* 1.073 
 Black vs. Other 0.704* 0.706 
 Hispanic vs. Other 0.743* 0.748 
RxRisk 1.049* 1.051 
Measure 
  
 ACEI/ARB vs. MI 1.023 0.886 
 BB vs. MI 0.888* 0.763 
 CCB vs. MI 0.972 0.838 
 BIGU vs. MI 0.751* 0.629 
 SU vs. MI 0.799* 0.667 
 TZD vs. MI 0.632* 0.519 
 STAT vs. MI 0.794* 0.632 
 AD vs. MI 0.535* 0.504 
 CAD vs. MI 1.322* 1.411 
 ICS vs. MI 2.879* 2.479 
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In the three-level hierarchical logistic regression model, the state-level variance 
component was estimated to be 0.02735 (SE: 0.006049) and the patient-level variance 
component was estimated to be 0.3972 (SE: 0.000903). Testing the null hypothesis of no random 
effects using a likelihood ratio test based on residual pseudo-likelihood yielded a chi-square of 
381589 (p<0.0001) indicating the presence of random effects. When correlation of observations 
within patients was accounted for, the residual intra class correlation coefficient (ρ) was 
estimated to be 0.00824 which indicates that 0.82% of the unexplained variation in the composite 
score could be attributed to variation between states.  A comparison of ranks and groups based 
on the case-mix adjusted scores using both the two-level and three-level models are presented in 
Tables 66, 67a and 67b.  
Table 66 shows the agreement between the crude and case-mix adjusted scores (both 
two-level and three-level models). The case-mix adjusted composite measure scores from the 
three-level model ranged from 45.99% to 63.24%, a slight decrease in range compared to the 
crude estimates. Case-mix adjustment ranked the states differently with 81% (35) states changing 
more than two positions. There was good agreement in rankings based on the crude scores and 
case-mix adjusted scores based on the two-level (Kendall’s b=0.75) and three-level (Kendall’s 
b=0.74) hierarchical logistic regression models. 
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Table 66: Agreement in ranks: Crude and case-mix adjusted composite measure scores
a
 
State 
Unadjusted 
Estimates 
Case-Mix Adjusted Estimates
b
 
Score 
difference 
Rank 
difference Score 
(%) 
Rank 
Score 
(%) 
Rank  
3 Level  
Rank 
2 Level  
Alabama 51.40 23 52.80 23 23 -1.40 0 
Alaska - - - - - - - 
Arizona 45.32 40 48.00 39 39 -2.68 1 
Arkansas 46.65 36 48.99 36 37 -2.33 0 
California 46.16 38 49.61 34 34 -3.45 4 
Colorado 45.93 39 47.18 41 41 -1.26 -2 
Connecticut 58.81 5 60.03 2 2 -1.23 3 
Delaware 50.78 26 54.16 19 20 -3.37 7 
District of 
Columbia 
47.85 34 52.51 25 25 -4.66 9 
Florida 53.37 15 53.62 22 22 -0.25 -7 
Georgia 45.13 41 46.54 42 42 -1.42 -1 
Hawaii 50.61 27 49.31 35 35 1.29 -8 
Idaho 60.61 2 59.56 3 3 1.05 -1 
Illinois 52.34 18 55.75 9 9 -3.41 9 
Indiana 49.13 32 48.49 38 38 0.64 -6 
Iowa 58.41 7 58.04 5 5 0.37 2 
Kansas 55.87 12 55.38 10 10 0.49 2 
Kentucky 57.69 8 54.28 18 18 3.41 -10 
Louisiana 48.67 33 51.61 28 29 -2.94 5 
Maine - - - - - - - 
Maryland 46.99 35 50.41 33 33 -3.42 2 
Massachusetts 51.53 22 50.87 31 32 0.66 -9 
Michigan - - - - - - - 
Minnesota 50.01 30 52.16 27 26 -2.15 3 
Mississippi 40.58 43 45.99 43 43 -5.41 0 
Missouri 55.47 14 54.93 11 11 0.55 3 
Montana - - - - - - - 
Nebraska 57.59 9 58.46 4 4 -0.87 5 
Nevada 56.12 10 54.79 12 12 1.33 -2 
New Hampshire 59.74 3 57.32 8 8 2.42 -5 
New Jersey 50.82 25 52.52 24 24 -1.71 1 
New Mexico 50.05 29 52.31 26 27 -2.26 3 
New York 51.33 24 54.30 17 21 -2.96 7 
North Carolina 51.83 19 54.14 20 19 -2.32 -1 
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Table 66: Agreement in ranks: Crude and case-mix adjusted composite measure scores
a
 
(continued) 
State 
Unadjusted 
Estimates 
Case-Mix Adjusted Estimates
b
 
Score 
difference 
Rank 
difference Score 
(%) 
Rank 
Score 
(%) 
Rank  
3 Level  
Rank 
2 Level  
 
North Dakota - - - - - - - 
Ohio - - - - - - - 
Oklahoma 49.49 31 48.93 37 36 0.56 -6 
Oregon 52.45 17 51.35 29 28 1.10 -12 
Pennsylvania 59.66 4 57.81 6 6 1.85 -2 
Rhode Island 51.82 20 54.60 14 14 -2.77 6 
South Carolina 46.58 37 50.79 32 31 -4.21 5 
South Dakota - - - - - - - 
Tennessee 45.02 42 47.19 40 40 -2.17 2 
Texas 51.66 21 54.67 13 13 -3.01 8 
Utah 50.36 28 51.18 30 30 -0.83 -2 
Vermont 64.55 1 63.24 1 1 1.32 0 
Virginia 55.77 13 57.43 7 7 -1.66 6 
Washington 55.93 11 54.57 15 15 1.36 -4 
West Virginia 58.73 6 54.46 16 16 4.27 -10 
Wisconsin 52.46 16 54.09 21 17 -1.63 -5 
Wyoming - - - - - - - 
c
Kendall’s b    0.74 0.75   
a
Composite measure measure scores were generated for 43 states. Rankings ranged from 1-43
 
b
scores are from the three-level hierarchical logistic regression model with state (G-side) and patient (R-side) 
random effects  
c
Kendall’s b is a nonparametric measure of association based on the number of concordances and discordances in 
rankings based on unadjusted and risk-adjusted scores  
Additionally, states were classified into top (20%), medium and bottom (20%) 
performers based on the crude and case-mix adjusted scores. Results of the agreement in the 
grouping based on the unadjusted and risk-adjusted groupings are shown in Table 67a and Table 
67b. Results based on the two risk adjustment models showed perfect agreement in classification 
of states into top, medium and bottom groups (κ=1.00). There was modest agreement in 
classification of the states based on the crude and case-mix adjusted models when case-mix 
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adjustment was conducted using two-level (κ=0.65) and three-level (κ=0.65) hierarchical logistic 
regression models.  
An alternate methodology was proposed for classification of states by identifying outliers 
as low (high) quality outliers if the score for a state was significantly lower (or higher) than the 
average score according to the 95% CI of the measure. However, the distribution of scores for 
the 43 states is leptokurtic i.e., concentrated about the mean, therefore not conducive to 
identifying outliers. The results of agreement in classification based on this methodology are 
included in Table A-17 (APPENDIX). Choropleth maps depicting the top, medium and bottom 
performing states based on the crude and case-mix adjustment scores estimated from the three-
level hierarchical logistic regression model are depicted in Figure 13.  
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Table 67a: Agreement in groups: Crude and case-mix adjusted composite measure scores 
Groups Based on 
Crude Estimates 
Groups Based on Case-mix Adjusted Estimates 
Hierarchical Logistic Regression 
Two-Level Model 
Hierarchical Logistic Regression 
Three-Level Model 
 
Bottom Medium Top Bottom Medium Top 
Bottom (~20%) 6 2 0 6 2 0 
Medium (60%) 2 23 2 2 23 2 
Top (~20%) 0 2 6 0 2 6 
Percentage 
misclassified
a
 
25% 14.8% 25% 25% 14.8% 25% 
Cohen’s κb  0.65 0.65 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement between 
unadjusted performance ratings and ratings based on the risk adjustment method with higher values indicating 
greater agreement 
Table 67b: Agreement in groups: Case-mix adjusted composite measure scores 
Groups Based on Case-mix 
Adjusted Estimates 
Three-Level Model 
Two-Level Model Bottom Medium Top 
Bottom 8 0 0 
Medium  0 27 0 
Top 0 0 8 
Percentage misclassified
a
 0% 0% 0% 
Cohen’s κb  1.00 
a
Percentage misclassified was calculated for each risk adjustment method using the classification based on the three-
level risk adjustment method as the correct classification. 
bCohen’s Kappa coefficient is a measure of agreement 
between unadjusted performance ratings and ratings based on the risk adjustment method with higher values 
indicating greater agreement 
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Figure 13. Interstate variations in composite measure: 
 (A) Unadjusted scores, (B) Case-mix adjusted scores 
 
 
 
 
 
   
A 
B 
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A summary of the performance measures included in the study is presented in Table 68. 
Univariate statistics and coefficient of variation describing the variation in the 13 measures and 
the composite measure are tabulated. National benchmarks for Medicaid use-related measures 
for the year 2007 ranged from 31.5% for the chronic phase persistence with antidepressants 
measure to 66.8% for the ICS measure. There was substantial variation in the 13 measures being 
studied with coefficient of variation ranging from 6.7 for the ICS measure to 20.5 for the MI1 
measure. The best performing state Medicaid programs also had significant room for 
improvement across all measures.  
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Table 68: Distribution of state performance scores by measure type 
Measure 
2007 (%) 
Mean Min 
10
th
 
percentile 
Median 
90
th
 
percentile 
Max SD CV 
PDC 
(Proportion of patients 18 years and older who met PDC threshold of 80 percent per county) 
ACEI/ARB  54.41 45.53 48.12 54.88 59.78 65.24 4.52 8.31 
BB 50.69 35.82 44.85 50.99 56.81 60.62 5.16 10.18 
CCB 53.28 40.46 48.59 52.81 58.05 65.43 4.45 8.36 
Biguanides 45.72 35.77 40.12 46.00 50.63 54.37 4.20 9.19 
Sulfonylureas 48.94 38.68 43.83 49.51 55.34 57.36 4.34 8.88 
TZDs 44.54 33.22 39.04 44.52 49.99 54.61 4.65 10.43 
Statins 51.50 42.10 45.24 50.99 58.88 64.05 5.15 10.00 
AD Acute 
(Proportion of Medicaid patients 18-65 years newly diagnosed with MDD and prescribed antidepressant therapy 
persistent with the therapy for at least 3 months) 
AD Acute 52.80 40.08 48.92 52.41 57.26 64.44 4.16 7.89 
AD Chronic 
(Proportion of Medicaid patients 18-65 years newly diagnosed with MDD and prescribed antidepressant therapy 
persistent with the therapy for at least 6 months) 
AD Chronic 31.53 13.41 26.53 31.86 36.40 42.49 4.90 15.54 
CAD 
(Percent of patients 18-65 years of age diagnosed with CAD that received at least one prescription for a statin 
medication) 
CAD 63.04 35.47 58.70 63.22 68.89 73.49 5.85 9.29 
ICS 
(Percent of asthma patients 18-50 years of age with persistent asthma that received at least one prescription for an 
inhaled corticosteroid or similar medication) 
ICS 66.81 57.55 60.60 67.15 73.06 75.57 4.46 6.67 
MI 
(Proportion of Medicaid patients 18-65 years with MI that filled a beta-blocker prescription within 30 days of 
discharge persistent with therapy for at least 6 months) 
MI 56.17 42.05 45.83 55.31 65.13 66.38 6.90 12.29 
MI1 
(Proportion of Medicaid patients 18-65 years with MI that filled a beta-blocker prescription within 30 days of 
discharge) 
MI1 50.04 25.49 34.61 51.03 60.72 68.44 10.27 20.53 
Composite 53.12 45.99 48.00 53.62 58.04 63.24 3.90 7.34 
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To assess if performance on one measure was correlated with performance on another, 
states were ranked on all measures and the correlations between the 11 medication use-related 
measures and the composite measure were assessed using Kendall’s b. Kendall’s b is a 
nonparametric rank correlation measure based on the number of concordances and discordances 
in rankings.  
A summary of state rankings based on the various performance measures and the 
correlation between rankings on these measures is provided in Table 69. There was significant 
correlation between ranks based on the seven PDC measures included in the study, with b values 
ranging from 0.54 to 0.73. However, there was no significant correlation in ranking of states 
based on the adherence/persistence measures (PDC, AD) and the standard of care measures 
(CAD, ICS). All measure based ranks except the MI measure based ranks were correlated with 
the composite measure. However, the b values indicate that there is good agreement only 
between the composite measure based ranks and the PDC measure based ranks.
  
 
1
6
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Table 69: Summary of agreement between state rankings on medication use-related performance measures 
State 
Rankings by Measure 
ACEI/ 
ARB 
BB CCB BIGU SU TZD STAT AD CAD ICS MI 
Compo
site 
Alabama 25 28 18 29 16 33 23 20 33 15 9 23 
Alaska - - - - - - - - - - - - 
Arizona  39 38 39 35 38 37 40 7 25 36 12 39 
Arkansas 21 43 27 33 33 13 34 36 35 33 28 36 
California 37 35 38 37 40 31 37 22 15 10 2 34 
Colorado 43 37 41 41 41 40 39 1 23 41 27 41 
Connecticut 4 3 4 7 4 6 3 14 8 4 10 2 
Delaware 19 21 35 24 12 23 30 15 5 1 - 19 
District of Columbia 28 32 21 11 19 42 27 35 29 22 - 25 
Florida 22 17 28 12 20 24 21 28 41 13 11 22 
Georgia 42 40 42 39 39 35 41 41 32 35 24 42 
Hawaii 41 34 36 27 32 18 15 43 40 32 29 35 
Idaho 2 2 2 3 2 2 2 19 24 37 - 3 
Illinois  16 11 17 13 7 20 19 32 3 9 8 9 
Indiana 38 33 40 40 36 39 33 29 28 42 1 38 
Iowa 7 4 10 6 14 3 4 3 12 23 - 5 
Kansas 11 9 9 18 29 8 8 21 34 31 - 10 
Kentucky 12 15 13 19 13 12 17 37 21 38 19 18 
Louisiana 29 30 24 34 28 28 32 38 19 16 25 28 
Maine - - - - - - - - - - - - 
Maryland 31 29 43 20 21 38 28 27 37 28 23 33 
Massachusetts 32 26 26 32 31 34 38 33 6 34 14 31 
Michigan - - - - - - - - - - - - 
Minnesota 33 22 37 31 34 10 24 24 9 21 7 27 
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Table 69: Summary of agreement between state rankings on medication use-related performance measures (continued) 
State 
Rankings by Measure 
ACEI/ 
ARB 
BB CCB BIGU SU TZD STAT AD CAD ICS MI 
Compo
site 
 
Mississippi  40 42 34 42 43 43 42 42 31 7 18 43 
Missouri 13 19 25 17 8 14 9 26 11 25 16 11 
Montana - - - - - - - - - - - - 
Nebraska  9 5 7 16 9 5 5 5 17 3 - 4 
Nevada 15 12 12 15 3 11 16 13 42 30 - 12 
New Hampshire 8 8 3 2 11 9 6 6 16 17 - 8 
New Jersey 26 24 29 22 24 30 35 31 26 5 21 24 
New Mexico 27 27 20 21 26 36 25 16 27 39 - 26 
New York 23 23 22 9 10 32 29 9 7 6 3 17 
North Carolina 24 18 11 26 22 16 18 23 18 14 22 20 
North Dakota - - - - - - - - - - - - 
Ohio - - - - - - - - - - - - 
Oklahoma 36 41 23 43 42 26 26 17 39 29 26 37 
Oregon 10 14 15 5 15 21 10 12 43 27 - 29 
Pennsylvania 3 6 8 10 6 4 11 8 20 12 17 6 
Rhode Island 6 20 6 28 25 19 36 25 2 11 - 14 
South Carolina 30 39 31 30 30 25 31 39 10 24 30 32 
South Dakota - - - - - - - - - - - - 
Tennessee 35 36 33 36 35 41 43 40 30 43 20 40 
Texas 18 25 14 23 27 15 12 4 36 2 13 13 
Utah 34 31 32 38 37 29 22 18 14 20 - 30 
Vermont  1 1 1 1 1 1 1 2 1 8 - 1 
Virginia 5 7 5 4 5 7 7 30 38 18 15 7 
Washington 14 16 16 8 18 22 13 10 13 40 5 15 
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Table 69: Summary of agreement between state rankings on medication use-related performance measures (continued) 
State 
Rankings by Measure 
ACEI/ 
ARB 
BB CCB BIGU SU TZD STAT AD CAD ICS MI 
Compo
site 
 
West Virginia  17 10 19 25 23 17 20 34 22 19 6 16 
Wisconsin 20 13 30 14 17 27 14 11 4 26 4 21 
Wyoming - - - - - - - - - - - - 
a
Kendall’s b 
ACEI/ARB 1.00 0.73
*
 0.73
*
 0.64
*
 0.69
*
 0.65
*
 0.64
*
 0.31
**
 0.17 0.23
**
 0.17 0.80
*
 
BB  1.00 0.59
*
 0.65
*
 0.67
*
 0.62
*
 0.67
*
 0.33
**
 0.21
**
 0.21
**
 0.33
**
 0.78
*
 
CCB   1.00 0.54
*
 0.55
*
 0.56
*
 0.60
*
 0.28
**
 0.11 0.20 0.08 0.67
*
 
BIGU    1.00 0.73
*
 0.46
*
 0.61
*
 0.30
**
 0.10 0.18 0.23 0.64
*
 
SU     1.00 0.46
*
 0.56
*
 0.25
**
 0.17 0.23
**
 0.20 0.69
*
 
TZD      1.00 0.66
*
 0.24
**
 0.13 0.19 0.01 0.65
*
 
STAT       1.00 0.34
**
 0.05 0.14 0.12 0.68
*
 
AD        1.00 0.15 0.13 0.27
**
 0.35
**
 
CAD         1.00 0.19 0.28
**
 0.23
**
 
ICS          1.00 0.14 0.33
**
 
MI           1.00 0.24 
Composite            1.00 
aKendall’s b is a nonparametric measure of association based on no. of concordances and discordances in rankings based on unadjusted and risk-adjusted scores 
*
Significant at P<0.0001level 
**
Significant at P<0.05 level
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A very small proportion of variation in the study measures was explained by the state 
level random effect. A summary of the state-level contribution to the various measures being 
studied is shown in Table 70. The intraclass correlation coefficients from the unconditional 
means models (including only state as a random effect) were very small for all measures, 
indicating that there was only a moderate degree of clustering within states, and even after 
controlling for state random effects; considerable unexplained variability in the measures exists.  
Table 70: Summary of state-level effects on performance measures 
Measure ICC
a
  Residual ICC
b
  
ACEI/ARB 0.0190 0.0110 
BB 0.0209 0.0136 
CCB 0.0193 0.0097 
BIGU 0.0153 0.0090 
SU 0.0153 0.0087 
TZD 0.0178 0.0098 
STAT 0.0228 0.0137 
AD Acute 0.0076 0.0068 
AD Chronic 0.0142 0.0147 
CAD 0.0410 0.0182 
ICS 0.0122 0.0122 
MI 0.0127 0.0119 
MI1 0.0571 0.0442 
Composite 0.0129 0.0081 
a
intraclass correlation coefficients from the unconditional means models (including only state as a random effect) 
b
residual intraclass correlation coefficients after controlling for patient-level variables 
 
The amount of variation in the performance measures explained by the state effect was 
highest for the MI1 measure, with state level explaining 5.7% of variation in the measure. 
Amount of variation in CAD measure attributable to the state level was also substantial at 4.1%. 
State level contributed to explaining approximately 1.5 – 2% of the PDC measures. Models 
adjusting for patients’ level factors including age, gender, race/ethnicity, and comorbidity burden 
decreased the amount of variation explained by the state random effect only slightly, as 
represented by the residual intraclass correlation coefficients shown in Table 70.  
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CHAPTER V – DISCUSSION AND CONCLUSIONS 
The U.S. health care system is moving towards a value-driven payment model. Value 
entails provision of high quality care at low costs. Historically, Medicaid and Medicare programs 
relied on fee-for-service payment models that did not factor in the quality of care provided. 
Today, several government agencies, private health plans and large employer groups are relying 
on pay-for-performance models that incentivize providers based on the quality of care provided. 
Some of the noted federal pay-for-performance initiatives include the bonus payments provided 
to the top performing hospitals and nursing homes by CMS as a part of the Medicare value based 
purchasing demonstration projects.
113,114
 Similar strategies can be employed by Medicaid to 
improve quality of care delivered to its enrollees.  
Public reporting of performance measures is another important method adopted by the 
Federal government to reduce variation in quality and improve overall quality of care delivered. 
Over the past decade, reports of hospital, nursing home, and health plan quality have been made 
publicly available for consumers of healthcare to make informed decisions.
1,2,3
 CMS is currently 
using public reporting in conjunction with pay-for-performance to improve quality of care 
provided by hospitals, nursing homes and Medicare Advantage plans. A few of the measures 
used by CMS to assess hospital quality and a considerable number of measures in the HEDIS 
measure set from NCQA used to determine health plan and managed care organization quality 
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are related to medication use.
1,14
 In addition, PQA has developed a comprehensive list of 
medication use-related measures that can be used to assess quality of pharmacies and health care 
plans.
10,11
 CMS currently uses some of these medication use-related quality measures (e.g., 
adherence with medications and high-risk medication use in elderly) to incentivize top 
performing Medicare Advantage plans providing drug benefits via a star rating system. These 
measures account for approximately 20% of the rating for a Medicare Advantage plan, due to 
high weightage given to the PQA medication safety and adherence measures.
115
 Moreover, data 
on several other medication safety and adherence measures are reported on a public domain to 
reinforce quality improvement of Medicare health plans.
115
 Despite an abundance of research 
directed at Medicare plans, there is sparse evidence of the quality of Medicaid programs and few 
initiatives to address quality measurement of Medicaid programs, particularly for the adult 
population.   
The Affordable Care Act mandated the Secretary of Health and Human Services (HHS) 
to establish a Medicaid adult quality measurement program by January 2012.
5
 In response to the 
mandate, AHRQ recommended an initial list of 51 measures to assess Medicaid quality for 
public comment, which included several medication use-related measures. Approximately one-
third of the public comments indicated the burden of reporting by states on 51 measures. Other 
comments alluded to aligning measures with federal measures and ensuring that the measures 
met the thresholds for evidence, validity, reliability, and feasibility.
116
 Based on the public 
feedback, the measure list was revised to 24 measures including two measures related to long-
term management of chronic conditions using medications.  
However, this does not undermine the importance of measures included in the study. In 
fact, the findings presented in this study provide evidence for the importance of inclusion of 
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these measures in sight of variations in care provided and addresses the issue of feasibility of 
computing these measures using existing data sources. Though few medication use-related 
measures are currently being considered for evaluation of Medicaid programs, we believe future 
quality measurement efforts will include more measures related to medication safety and 
adherence, as is the case with Medicare. 
In this study, Medicaid administrative claims data were demonstrated to be capable of 
providing state level performance measure scores on all proposed medication use-related quality 
measures except MI and MI1 measures. The MI measure could be assessed only for 30 states and 
the MI1 measure could be computed for only 36 states because the remaining states had less than 
30 patients eligible for the measure. There was considerable variation in average performance 
scores across the 13 study measures. The average performance score was lowest at 31.3% for the 
measure assessing persistence with antidepressant therapy over a six-month period, which is the 
measure retained in the final Medicaid adult quality measure set. The coefficient of variation was 
substantially higher for the AD chronic measure compared to all other adherence/persistence 
measures included in the study. States performed best on the standard of care CAD measure that 
assessed the use of statins in patients with coronary artery disease with 63.0% receiving the 
recommended medication. Our study results should motivate future research to focus on the 
reasons for the variation in quality of care. Identifying Medicaid plans and practitioners 
providing good medication use-related quality could help to inform other plans on strategies to 
reduce or eliminate variations in quality of care provided. 
It is also important to highlight the room for improvement on the study measures across 
all states. Direct comparisons with 2012 CMS benchmarks for Medicare Advantage plans reveal 
that even the best performing states had performance scores lower than the 3-star rated Medicare 
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Advantage plans. For instance, the 2012 PDC-ACEI/ARB and PDC-STAT thresholds for a 3-star 
plan are 70.1% and 67.4% respectively, and the corresponding measure scores for the best 
performing state Medicaid programs in 2007 are 65.2% and 64.0% respectively.
115
 The federal 
government could provide monetary incentives to Medicaid programs with high performance 
scores on these measures to encourage performance improvement. A bonus payment strategy to 
reward the top performing states may serve to motivate states to develop interventions targeted at 
quality improvement as opposed to the cost-containment strategies currently being employed by 
Medicaid programs. Rather than identifying the top performing plans relative to each other, fixed 
benchmarks should be set for Medicaid programs considering the need for substantial 
improvements in medication use-related quality across all states.  
States will start reporting on Medicaid quality measures in 2014, which includes the AD 
acute and AD chronic measures included in our study.
116
 This study concentrated only on 
chronic medication use-related measures. Future research should explore the other 23 measures 
in the AHRQ final set of Medicaid adult measures. As public reporting of Medicaid quality 
becomes a reality, it is important to assess if there is a need to adjust the performance of states 
for patient case-mix.  
Our study compares unadjusted performance scores on medication use-related measures 
with two case-mix adjusted scores based on logistic regression and hierarchical logistic 
regression models with state as a random intercept. The results from both the classical logistic 
regression model and the hierarchical logistic regression model indicate that all patient level 
predictors and the state random effect are significant predictors of the measures. Furthermore 
both models displayed modest predictive ability (c-statistic > 0.6) for all adherence measures, 
and good predictive ability for the CAD measure (c-statistic=0.74). The models performed 
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poorly in case of the ICS measure invalidating the need for case-mix adjustments using the 
proposed patient characteristics. Future studies should explore the use of additional patient 
characteristics to improve the model prediction, particularly for the ICS measure.  Comparisons 
of the c-statistics of both models revealed a lack of improvement in discriminative ability of the 
models when the state-level random effect was added. This finding was reinforced by low 
residual ICC observed for the state-level across all measures.  State level explained small but 
meaningful amount of variation in the two standard of care measures, 5.7% in case of MI1 
measure and 4.1% for the CAD measure. This was further reduced for the PDC measures, with 
state level explaining approximately between 1.5 – 2% of the variation. These findings suggest 
that state level factors may not be as important as patient factors in explaining the variation in 
medication use-related measure scores. 
States were ranked on case-mix adjusted scores and unadjusted scores and categorized 
into top (~20%), medium (60%) and bottom (~20%) performers. States were categorized 
accordingly to mimic the CMS categorization of hospitals and nursing homes for pay-for-
performance demonstration projects.
113,114
 Results of the agreement in ranks based on the 
unadjusted and case-mix adjusted scores showed that case-mix adjustment ranked the states very 
differently with the majority of states (>50%) changing more than two ranks across all measures 
except ICS. The validity of the risk adjustment model for the ICS measure was questionable 
because of the poor discriminative ability of the model.  Moreover, there was a lack of agreement 
in grouping of states into top and bottom performers based on crude and case-mix adjusted 
methods for majority of the measures (κ=0.22 – 0.74), except for the ICS measure (κ=0.91). The 
lack of agreement in crude and case-mix adjusted scores was also observed in case of the 
composite measure (κ=0.65). Mehta et al (2008) assessed the agreement in grouping of hospitals 
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based on unadjusted and risk adjusted rankings of a composite measure score and observed 
similar changes in hospital performance rankings.
80
  
The two risk adjustment methods used in the study showed high level of agreement 
across all measures. For the composite measure, there was perfect agreement in groups based on 
the two-level and the three-level hierarchical regression models (κ=1.00). Overall, these findings 
reinforce the importance of case-mix adjustment using either classical logistic regression models 
or hierarchical logistic regression models in providing performance scores for state Medicaid 
programs. The importance of case-mix adjusting of performance scores for public reporting or 
pay-for-performance purposes has been reported in several studies. Several researchers have 
found that adjusting for patient demographics, disease severity and comorbidity burden changes 
providers’, facilities’ or healthcare systems’ performance profiles.78-83 Hofer et al.6 demonstrated 
that physicians can improve their performance profile by preferential patient selection. Similarly, 
a recent study found that adjusting for patient characteristics and treatment opportunities 
improved hospital rankings on indicators assessing adherence to treatment guidelines for acute 
MI.
80
 The importance of case-mix adjustment was also demonstrated in evaluating health plan 
performance on chronic care provided to Medicaid enrollees.
82
 Similarly, this study emphasizes 
the importance of risk-adjustment methodologies to adjust for patient differences in assessing the 
quality provided by state Medicaid programs. 
Study findings also demonstrate that racial disparities predominantly drive the need for 
case-mix adjustment of medication-use related quality measures. Blacks were significantly less 
likely to receive good quality of care (measured as adherence, persistence with therapy and 
receiving standard of care medications) compared to Whites on 11 of the 13 measures studied, 
after controlling for demographic characteristics and comorbidity burden. Hispanics were also 
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less likely to receive standard of care medications, and be adherent/persistent to the 
recommended therapy compared to Whites. On the contrary, Blacks and Hispanics were more 
likely to fill an inhaled corticosteroid or similar medication to manage persistent asthma 
compared to Whites. The racial disparities were substantial and consistent across the measures 
included in the study. However, the magnitude of the disparity varies across the quality 
measures. The disparity was smallest for the MI1 measure and largest for the AD measures. This 
study’s findings reinforce the existing evidence of disparities in adherence and persistence with 
medication therapy.
40,67,68
 
This study did not control for socioeconomic characteristics like education and income. 
Despite the population being Medicaid enrollees, states have different enrollment criteria and 
socioeconomic variables may be useful in explaining some of the racial disparity in quality of 
care observed. In addition, future studies should explore the effect of provider and payer 
characteristics in quality of care provided to different racial groups. Racial minorities may be 
disproportionately enrolled in poorly performing plans and receiving care from low quality 
providers. Medicaid programs need to identify the quality of care being provided by various 
practitioners and payers serving Medicaid beneficiaries and incentivize top performers to provide 
better quality of care.  
This widespread disparity in the medication use-related quality of care received by 
different racial/ethnic groups is formidable. Health plans and practitioners have an important role 
to play in improvement of medication utilization patterns among Blacks and Hispanics. Existing 
evidence emphasizes the positive impact of practitioner-led initiatives in closing the racial 
disparities in care provision.
117
 Additionally, payers are taking various medication therapy 
management initiatives to monitor and improve patient safety and adherence with medication 
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regimen. Medicaid data is a useful data source to identify underserved populations, and Medicaid 
plans can use the results of this study to provide targeted medication management interventions 
to racial minority beneficiaries. 
An objective of this study was to assess if states performed consistently across all the 
medication use-related measures. While there was some degree of correlation between the state 
rankings on the seven adherence measures, states were ranked differently on the standard of care 
measures. Considering the substantial differences in performance of states on measures related to 
the management of chronic conditions using medication therapy, it becomes crucial to construct 
one unique measure of medication quality for each state that can be used for public reporting and 
pay-for-performance.  
A composite measure of chronic medication use-related quality was constructed adjusting 
both for patient case-mix and opportunity mix. The average composite score across states was 
53.1%, with values ranging from 46.0% for Mississippi to 63.2% for Vermont. Though some 
states are performing relatively poorer than others, all Medicaid programs demonstrated a need 
for improvement on medication use-related measures. Medicaid programs can achieve quality 
improvements by diverting its patients to better quality providers in the state and by incentivizing 
providers providing good quality care. Medicaid can also employ quality bonus payments similar 
to Medicare to motivate providers to improve performance. However, the budget shortfalls that 
most states are experiencing present challenges in adopting a pay-for-performance strategy. 
Therefore, before financial incentives are considered, public reporting of performance is 
recommended.  
 176 
 
The results of this study should be viewed in the light of a few limitations. Inherent 
limitations of administrative claims data research apply to this study. It is not possible to assess 
the reasons for discontinuation of medications using administrative claims data. For example, 
change in therapy by the physician due to lack of efficacy or adequate control through alternative 
methods may be the reason for discontinuation of medications. Another limitation of using 
administrative claims database is that, factors explaining adherence and persistence measures 
like self-efficacy, patient-provider communication, health literacy, or readiness to change cannot 
be measured using claims data. Also, it is not possible to capture medication refills not paid for 
by Medicaid using Medicaid data. These inadequacies in administrative claims data may have 
biased our study results. Another limitation is the inability to concretely judge the need for risk 
adjustment methods. Since we do not know the true rankings of quality, it is challenging to 
ascertain rankings based on one method as being more “right” than the other. However, since 
there is evidence of difference in patient case-mix across states and because these patient 
characteristics are significantly associated with medication utilization patterns, one can postulate 
that case-mix adjusted scores are more appropriate indicators of Medicaid quality than the 
unadjusted scores.  
This study has several strengths. To our knowledge, this is the first study to examine 
interstate variations in quality of care provided using a comprehensive list of medication use-
related measures spanning several chronic conditions. This study provides evidence for the 
feasibility of assessing medication use-related quality measures for Medicaid programs using 
administrative claims data. This study highlights the need for including medication use-related 
measures in the Medicaid adult quality measure set, considering the variations in performance of 
states on these measures and the substantial room for improvement across all measures. National 
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benchmarks on medication use-related measures for the year 2007 are computed. Eventually, 
when states start voluntarily reporting on medication use measures, the study findings provide a 
baseline against which to compare changes in medication use-related quality. Additionally, I 
created a composite measure of medication use-related quality adjusting for patient case-mix and 
opportunity-mix. States could use a similar approach to report on medication use-related quality 
if they find it too burdensome to report on multiple measures. Moreover, the importance of case-
mix adjustment of performance scores when comparing state Medicaid programs is 
demonstrated. The study showcased the lack of agreement in rankings and reimbursement 
grouping of states based on crude and case-mix adjusted scores. Medicaid programs should 
consider the findings of this study before publicly reporting on crude performance scores.  
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FIGURE A-1: Conceptual Framework Underlying the Study. 
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FIGURE A-2: The Aday-Andersen Model for Determinants of Healthcare Utilization
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TABLE A-1: Definitions of Study Measures 
Indicator Definition 
MI – Persistence of beta-blocker 
treatment after a heart attack 
Measure: Proportion of patients who had a myocardial infarction 
that are persistent to beta-blocker therapy 
Numerator: # patients with continuous (gap of less than 51 days or 
less) use of beta-blockers for at least 6 months during the 
measurement period.  
Denominator: # of patient who had a myocardial infarction 
between April 1, 2006 and March 31, 2007 and filled a beta-
blocker prescription within 30 days of discharge. 
CAD – Statin therapy in patients 
with coronary artery disease 
Measure: Proportion of patients with coronary artery disease who 
received at least one prescription for a statin. 
Numerator: # patients with at least one prescription fill for a statin 
medication during the measurement period. 
Denominator: # patients with a diagnosis for coronary artery 
disease during the measurement year. 
ICS – Use of appropriate 
medications for people with 
asthma 
Measure: Proportion of patients with persistent asthma who were 
dispensed an inhaled corticosteroid or similar medication during 
the measurement period. 
Numerator: # patients with at least one prescription for inhaled 
corticosteroid, nedocromil, cromolyn sodium, leukotriene 
modifiers or methylxanthines during the measurement period. 
Denominator: # patients with persistent asthma, ages 18-56 years. 
AD – Persistence with 
antidepressant medications 
Measure: Proportion of patients on antidepressant therapy that are 
persistent with therapy for at least 6 months. 
Numerator: # patients with continuous use of antidepressants for at 
least 6 months during the measurement period (total gap of 51 
days or less). 
Denominator: # patients with at least two prescriptions for an 
antidepressant medication filled on two unique service dates, with 
the first prescription filled between May 1, 2006 and April 30, 
2007 and no prior use of antidepressants for at least three months. 
PDC - Adherence with 
medications 
Measure: Proportion of patients who met the PDC threshold of 
80% for 
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Beta-blockers (BB), 
ACEI/ARBs (ACEI), 
Calcium channel blockers (CCB), 
Statins (LLD), 
Biguanides (BU), 
Sulfonylureas (SU), 
Thiazolidinedione (TZD). 
Numerator: # patients who met the 80% PDC threshold 
Denominator: # patients with at least two prescription fills for 
medications in the particular therapeutic class during the 
measurement period. 
 Additionally, patients should be of age 18-<65 years, except for asthma, and continuously 
enrolled in Medicaid during the measurement year. 
 Patients with a non acute stay during the measurement year will be excluded for all measures.  
 Dual-eligible patients will be excluded. 
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TABLE A-2: List of medications used in the study 
ICS MEASURE - ASTHMA – A 
Short-Acting Inhaled Beta Agonists 
 Albuterol 
 levalbuterol 
 pirbuterol 
 
Long-Acting Inhaled Beta Agonists and 
Combinations 
 salmeterol 
 formoterol 
 budesonide & formoterol 
 fluticasone & salmeterol 
 
Inhaled Corticosteroids and Combinations 
 beclomethasone 
 budesonide 
 flunisolide 
 fluticasone 
 fluticasone & salmeterol 
 mometasone 
 triamcinolone 
 budesonide & formoterol 
 
Leukotriene Inhibitors 
 zafirlukast 
 montelukast 
 zileuton 
 
Xanthines 
 long acting theophylline 
 
Mast Cell Stabilizers 
 nedocromil  
 cromolyn 
 
ICS MEASURE - ASTHMA – B 
 tiotropium 
 ipratropium & albuterol 
 ipratropium 
 pulmozyme 
 beclomethasone  
 budesonide  
 ciclesonide 
 flunisolide 
 fluticasone 
 mometasone 
 triamcinolone 
BB, MI, MI1 MEASURES 
Beta-Blocker Medications 
 acebutolol HCL 
 atenolol 
 betaxolol HCL 
 bisoprolol fumarate 
 carteolol HCL 
 carvedilol 
 labetalol HCL 
 metoprolol succinate 
 metoprolol tartrate 
 nadolol 
 nebivolol HCL 
 penbutolol sulfate 
 pindolol 
 propranolol HCL 
 timolol maleate 
 
BB Combination Products 
 atenolol & chlorthalidone 
 bisoprolol & HCTZ 
 nadolol & bendroflumethiazide 
 metoprolol & HCTZ 
 propranolol & HCTZ 
 timolol & HCTZ 
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ACEI/ARB MEASURE 
ARB Medications 
 candesartan 
 eprosartan 
 irbesartan 
 losartan 
 olmesartan  
 telmisartan 
 valsartan 
 
ACE Inhibitor Medications 
 benazepril 
 captopril  
 enalapril 
 fosinopril  
 lisinopril 
 moexipril 
 perindopril 
 quinapril  
 ramipril  
 trandolopril  
 
ACE Inhibitor Combination Products 
 amlodipine & benazepril 
 benazepril & HCTZ  
 captopril & HCTZ  
 enalapril & HCTZ  
 enalapril & felodipine 
 fosinopril & HCTZ 
 lisinopril & HCTZ 
 moexipril & HCTZ 
 lisinopril & nutritional supplement 
 quinapril & HCTZ  
 trandolopril-verapamil HCL 
 
ARB Combination Products 
 candesartan & HCTZ  
 eprosartan & HCTZ 
 telmisartan & amlodipine 
 irbesartan & HCTZ  
 losartan & HCTZ  
 amlodipine & olmesartan 
 olmesartan & HCTZ 
 telmisartan & HCTZ 
 aliskiren & valsartan 
 valsartan & HCTZ 
 amlodipine & valsartan 
 amlodipine  & valsartan & HCTZ 
CCB MEASURE 
CCB Medications 
 amlodipine besylate 
 diltiazem HCL 
 felodipine 
 isradipine 
 nicardipine HCL 
 nifedipine (long acting only) 
 verapamil HCL 
 nisoldipine  
CCB Combination Products 
 amlodipine besylate & benazepril HCL  
 amlodipine & valsartan 
 amlodipine & valsartan & HCTZ 
 enalapril maleate & felodipine 
 telmisartan & amlodipine 
 amlodipine & olmesartan 
 trandolopril & verapamil HCL 
 amlodipine & atorvastatin 
BIGU MEASURE 
Biguanides 
 metformin 
 
Biguanide Combination Products 
 glipizide & metformin 
 
 glyburide & metformin 
 rosiglitazone & metformin 
 pioglitazone & metformin 
 repaglinide & metformin 
 sitagliptin & metformin 
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SU MEASURE 
Sulfonylureas 
 acetohexamide 
 chlorpropamide  
 glimepiride 
 glipizide  
 glyburide 
 tolazamide 
 tolbutamide 
 
Sulfonylurea Combination Products 
 glipizide & metformin 
 glyburide & metformin 
 rosiglitazone & glimepiride 
 pioglitazone & glimepiride 
TZD MEASURE 
Thiazolidinediones 
 pioglitazone  
 rosiglitazone  
Thiazolinedione Combination Products 
 rosiglitazone & metformin 
 pioglitazone & metformin 
 rosiglitazone & glimepiride 
 pioglitazone & glimepiride 
STAT & CAD MEASURE 
Statin Medications 
 lovastatin 
 rosuvastatin  
 fluvastatin 
 atorvastatin 
 pravastatin 
 simvastatin 
Statin Combination Products 
 niacin & lovastatin 
 atorvastatin & amlodipine 
 niacin & simvastatin 
 pravastatin & aspirin 
 ezetimibe & simvastatin 
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TABLE A-3: List of UB Revenue Codes for Identifying Non Acute Stays 
 
Description UB Revenue 
Hospice 0115, 0125, 0135, 0145, 0155, 0650, 0656, 0658, 
0659 
SNF 019x 
Rehabilitation 0118, 0128, 0138, 0148, 0158 
Respite 0655 
Residential substance abuse treatment 
facility 
1002 
Psychiatric residential treatment center 1001 
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TABLE A-4: RxRisk Score Categories  
 
Chronic Disease Medication Class(es) 
Anxiety and tension Salicylate combinations, Barbiturates, Benzodiazepines, 
Meprobamate, Miscellaneous hypnotics, Paraldehyde 
Asthma Anti‐inflammatory glucocorticoids, Isoproterenol, 
Bronchodilators, Cromolyn, Xanthines 
Bipolar disorder Lithium 
Cardiac disease Beta adrenergic blockers, Dopamine, Calcium channel 
blockers, Class I a antiarrhythmic, Class I c 
antiarrhythmics, Class III antiarrhythmic, 
Procainamide, Disopyramide, Quinidine, Vasodilator 
nitrates, Diuretic loops 
Coronary/peripheral vascular disease Antiplatelet, Oral anticoagulants, Trental 
Cystic fibrosis Anti-inflammatory Glucocorticoids, Enzymes 
Depression Monoamine oxidase inhibitors, Phenothiazine 
combinations, Tricyclic anti-depressants, SSRIs 
Diabetes Biguanides, Insulins, Sulfonylureas 
Epilepsy Anticonvulsants 
End Stage Renal Disease Marrow stimulants, Human erythropoietin 
Gastric acid disorder Histamine H2 blockers, Prostaglandins, Proton pump 
inhibitor 
Gout Colchicine, Uric acid inhibitors 
HIV Miscellaneous antiprotozoal, antivirals, pentamidine 
Hyperlipidemia Antilipemic clofibrate, Antilipidemic exchange resins, 
HMG coagulant reductase 
Inhibitors 
Hypertension Angiotensin Converting Enzyme (ACE) inhibitors, Beta 
adrenergic blockers, Dopamine, Calcium channel blockers, 
Antihypertensive vasodilators, Clonidine, Ganglionic 
blockers, 
Guanethidine, Methyldopa, Rauwolfia alkaloids, 
Alpha/Beta blockers, Diuretic 
combinations, Diuretic k depleting agents, Diuretic k 
sparing agents 
Irritable bowel syndrome Sulfonamides 
Liver disease Ammonia detoxicants 
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Malignancies Leucovorin,  Monoclonal, Miscellaneous antinauseants, 
Antineoplastic alkylating, 
Antineoplastic antibiotics, Antineoplastic MAO inhibitors, 
Antineoplastic progesterones, 
Antineoplastic pyrimidines, Antineoplastics misc, Bladder 
protectant, Methotrexate, 
Purine antimetabolites, Colony stimulating factors 
Pain Nonsteroidal anti-inflammatory agents 
Pain and Inflammation Opiates 
Parkinsons disease Dopamine, MAO b inhibitors 
Psychotic illness Miscellaneous antipsychotics, Butyrophenones, 
Phenothiazines, Thiothixenes 
Renal disease Potassium removing resins 
Rheumatoid arthritis Antiinflammatory Glucocorticoids, Gold salts-injectable, 
Gold salts-oral 
Thyroid disorder Thyroid replacement 
Transplant Immunosuppressive agents 
Tuberculosis Anti-tuberculosis antibiotics, Isoniazide 
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TABLE A-5: Agreement in outliers: Crude and case-mix adjusted ACEI/ARB adherence 
scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  11 6 6 14 7 2 
Medium  2 0 1 2 1 0 
High  0 0 17 0 2 15 
Percentage 
misclassified
a
 
15.4% 100.0% 29.2% 12.5% 90.0% 11.8% 
Cohen’s κb  0.43 0.52 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
FIGURE A-3: Interstate variations in ACEI/ARB crude estimates 
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TABLE A-6: Agreement in outliers: Crude and case-mix adjusted BB adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  11 4 2 13 3 1 
Medium  1 5 2 2 5 1 
High  0 1 17 0 1 17 
Percentage 
misclassified
a
 
8.3% 50.0% 19.0% 13.3% 44.4% 10.5% 
Cohen’s κb  0.64 0.71 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
FIGURE A-4: Interstate variations in BB crude estimates 
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TABLE A-7: Agreement in outliers: Crude and case-mix adjusted CCB adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  10 7 2 15 3 1 
Medium  0 5 2 1 4 2 
High  0 2 15 0 4 13 
Percentage 
misclassified
a
 
0.0% 64.3% 21.1% 6.3% 63.6% 18.8% 
Cohen’s κb  0.55 0.60 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
 
FIGURE A-5: Interstate variations in CCB crude estimates 
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TABLE A-8: Agreement in outliers: Crude and case-mix adjusted BIGU adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  14 5 0 14 5 0 
Medium  1 5 3 1 5 3 
High  0 2 13 0 2        13 
Percentage 
misclassified
a
 
6.7% 58.3% 18.8% 6.7% 58.3% 18.8% 
Cohen’s κb  0.61 0.61 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
FIGURE A-6: Interstate variations in BIGU crude estimates 
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TABLE A-9: Agreement in outliers: Crude and case-mix adjusted SU adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  11 4 0 13 2 0 
Medium  2 8 4 2 10 2 
High  0 4 10 0 5 9 
Percentage 
misclassified
a
 
15.4% 50.0% 28.6% 13.3% 41.2% 18.2% 
Cohen’s κb  0.51 0.62 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
FIGURE A-7: Interstate variations in SU crude estimates 
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TABLE A-10: Agreement in outliers: Crude and case-mix adjusted TZD adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  11 4 2 13 3 1 
Medium  1 9 2 1 10 1 
High  0 2 12 0 2 12 
Percentage 
misclassified
a
 
8.3% 40.0% 25.0% 7.1% 33.3% 14.3% 
Cohen’s κb  0.62 0.72 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
FIGURE A-8: Interstate variations in TZD crude estimates 
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TABLE A-11: Agreement in outliers: Crude and case-mix adjusted STAT adherence scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  13 5 2 16 3 1 
Medium  0 3 4 0 6 1 
High  0 0 16 0 3 13 
Percentage 
misclassified
a
 
0.0% 62.5% 27.3% 0.0% 50.0% 13.3% 
Cohen’s κb  0.60 0.71 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
 
FIGURE A-9: Interstate variations in STAT crude estimates  
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TABLE A-12: Agreement in outliers: Crude and case-mix adjusted AD measure scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
AD Acute Low Medium High Low Medium High 
Low  8 4 0 8 4 0 
Medium  4 13 0 4 13 0 
High  0 4 10 0 5 9 
Percentage 
misclassified
a
 
33.3% 38.1% 0.0% 33.3% 40.9% 0.0% 
Cohen’s κb  0.57 0.54 
AD Chronic Low Medium High Low Medium High 
Low  8 4 0 8 4 0 
Medium  2 14 2 2 13 3 
High  1 3 9 1 3 9 
Percentage 
misclassified
a
 
27.3% 33.3% 18.2% 27.3% 35.0% 25.0% 
Cohen’s κb  0.57 0.53 
 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
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FIGURE A-10a: Interstate variations in AD Acute crude estimates 
  
 
FIGURE A-11b: Interstate variations in AD Chronic crude estimates   
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TABLE A-13: Agreement in outliers: Crude and case-mix adjusted CAD measure scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  9 3 2 9 3 2 
Medium  5 5 2 5 5 2 
High  0 7 10 0 7 10 
Percentage 
misclassified
a
 
35.7% 66.7% 28.6% 35.7% 66.7% 28.6% 
Cohen’s κb  0.34 0.34 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
FIGURE A-12: Interstate variations in CAD crude estimates 
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TABLE A-14: Agreement in outliers: Crude and case-mix adjusted ICS measure scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  14 0 0 14 0 0 
Medium  2 11 0 1 12 0 
High  0 2 14 0 0 16 
Percentage 
misclassified
a
 
12.5% 15.4% 0.0% 6.7% 0.0% 0.0% 
Cohen’s κb  0.86 0.97 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
  
FIGURE A-13: Interstate variations in ICS crude estimates 
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TABLE A-15: Agreement in outliers: Crude and case-mix adjusted MI1 measure scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  5 3 0 6 2 0 
Medium  0 16 1 0 16 1 
High  0 2 9 0 3 8 
Percentage 
misclassified
a
 
0.0% 23.8% 10.0% 0.0% 23.8% 11.1% 
Cohen’s κb  0.73 0.73 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
 
 
 
FIGURE A-14: Interstate variations in MI1 crude estimates 
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TABLE A-16: Agreement in outliers: Crude and case-mix adjusted MI measure scores 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted Estimates 
Classical Logistic Regression Model 
Hierarchical Logistic Regression 
Random Intercept Model 
 
Low Medium High Low Medium High 
Low  1 1 0 1 1 0 
Medium  1 23 0 0 24 0 
High  0 2 2 0 2 2 
Percentage 
misclassified
a
 
50.0% 11.5% 0.0% 0.0% 11.1% 0.0% 
Cohen’s κb  0.55 0.63 
a
Percentage misclassified was calculated assuming risk adjustment method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
 
 
 
  
FIGURE A-14: Interstate variations in MI crude estimates 
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TABLE A-17: Agreement in outliers: Crude and case-mix adjusted  
composite measure scores 
 
Groups Based 
on Crude 
Estimates 
Groups Based on Case-mix Adjusted 
Estimates 
Hierarchical Logistic Regression 
Three-Level Model 
 
Low Medium High 
Low  15 3 6 
Medium  0 1 3 
High  0 0 15 
Percentage 
misclassified
a
 
0.0% 75.0% 37.5% 
Cohen’s κb  0.54 
a
Percentage misclassified was calculated assuming risk adjustment  
method as the correct classification.  
bCohen’s Kappa coefficient is a measure of agreement between unadjusted  
performance ratings and ratings based on the risk adjustment method  
with higher values indicating greater agreement. 
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